**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 58158

**Manuscript Type:** REVIEW

**Autophagy in liver diseases**

Kouroumalis E *et al*. Autophagy and liver

Elias Kouroumalis, Argryro Voumvouraki, Aikaterini Augoustaki, Dimitrios N Samonakis

**Elias Kouroumalis,** Liver Research Laboratory, University of Crete Medical School, Heraklion 71110, Greece

**Argryro Voumvouraki,** 1st Department of Internal Medicine, AHEPA University Hospital, Thessaloniki 54636, Greece

**Aikaterini Augoustaki, Dimitrios N Samonakis,** Department of Gastroenterology and Hepatology, University Hospital of Crete, Heraklion 71110, Greece

**Author contributions:** Kouroumalis Econtributed to the review idea and design, manuscript drafting and final revision of the article; Voumvouraki Acontributed to literature search, final revision of the article; Augoustaki A contributed to literature search; Samonakis DNcontributed to literature research and final revision of the article.

**Corresponding author: Dimitrios N Samonakis, FAASLD, MD, Chief Physician, Doctor,** Department of Gastroenterology and Hepatology, University Hospital of Crete, Voutes, Heraklion 71110, Greece. dsamonakis@gmail.com

**Received:** July 9, 2020

**Revised:** December 10, 2020

**Accepted:** December 26, 2020

**Published online:**

**Abstract**

Autophagy is the liver cell energy recycling system regulating a variety of homeostatic mechanisms. Damaged organelles, lipids and proteins are degraded in the lysosomes and their elements are re-used by the cell. Investigations on autophagy have led to the award of two Nobel Prizes and a health of important reports. In this review we describe the fundamental functions of autophagy in the liver including new data on the regulation of autophagy. Moreover we emphasize the fact that autophagy acts like a two edge sword in many occasions with the most prominent paradigm being its involvement in the initiation and progress of hepatocellular carcinoma. We also focused to the implication of autophagy and its specialized forms of lipophagy and mitophagy in the pathogenesis of various liver diseases. We analyzed autophagy not only in well studied diseases, like alcoholic and nonalcoholic fatty liver and liver fibrosis but also in viral hepatitis, biliary diseases, autoimmune hepatitis and rare diseases including inherited metabolic diseases and also acetaminophene hepatotoxicity. We also stressed the different consequences that activation or impairment of autophagy may have in hepatocytes as opposed to Kupffer cells, sinusoidal endothelial cells or hepatic stellate cells. Finally, we analyzed the limited clinical data compared to the extensive experimental evidence and the possible future therapeutic interventions based on autophagy manipulation.

**Key Words:** Autophagy; Lipophagy; Mitophagy; Fatty liver disease; Fibrosis; Liver sinusoidal cells

Kouroumalis E, Voumvouraki A, Augoustaki A, Samonakis DN. Autophagy in liver diseases. *World J Hepatol* 2020; In press

**Core Tip:** Extensive investigation of autophagy is mostly based on experimental data. However there is now enough evidence to support the notion that autophagy is not only the waste recycling mechanism of the hepatocyte, but is strongly involved in the pathogenesis of almost all liver diseases. It can be either a defensive mechanism against various insults or a detrimental machinery aggravating the underlying disease. Modulation of autophagy has different consequences in the hepatocyte than in the liver macrophages, the sinusoidal endothelium or the hepatic stellate cells. There is also an opportunity for future treatment applications of autophagy manipulation.

**INTRODUCTION**

***Autophagy in the liver***

Autophagy (from the Greek self-eating) is a process crucial for cell survival[1,2]. Autophagy is a lysosomal degradation pathway that controls the disposition of intracellular waste including damaged organelles or invading pathogens. It can be characterized as the recycling energy system of the cell.

Under basal conditions autophagy degrades 1.5% of total hepatic protein per hour but in starvation, protein degradation increases to 4.5% of liver protein per hour[3]. When rodents are starved for 48 h, autophagy degrades up to 40% of liver protein[4].

Although It is accepted that the term “autophagy” was introduced in 1963 by the Belgian researcher Christian René de Duve, in fact the term autophagy was used almost a century earlier by Anselmier in a French journal[5].

However the modern era of autophagy started with the pioneer work of de Duve and Novicoff in the 1950s when acid phosphatase positive lysosomes were described in the rat liver[6-9] and the term lysosome was used for the first time[10].Later de Duve introduced the term autophagosome and Arstila and Trump proved that the autophagosomes originate from the endoplasmic reticulum (ER)[11]. The next important progress came when Takeshige *et al*[12] identified approximately fifteen Autophagy related genes (Atgs) involved in Saccharomyces cerevisiae autophagy[12-14]. Today, more than 40 Atgs in various animal and human cells have been identified and unified[15-17]. The importance of autophagy was recognized by the award of two Nobel Prizes for Physiology or Medicine, the first to Cristian De Duve in 1974 and the second to Yoshinori Ohsumi in 2016[18,19]. Landmarks of autophagy were recently described[20]. During the period 2008-2018 more than 33000 papers related to autophagy were published[21,22].

Autophagy has certain discrete stages including induction, phagophore formation, autophagosome formation, autolysosome formation and degradation[23-25]. Atg molecules are involved in various complexes essential for autophagy induction and autophagosome formation[26]. Initiation starts with activation of the unc-51-like kinase 1 complex (ULK1, Atg1 in yeast) followed by beclin 1 (Atg6 in yeast) and a subsequent cascade of Atg proteins leading to autophagosome formation where LC3 (Atg8 in yeast) is implicated[27]. LC3 is further processed to form initially LC3-I and then LC3-II[28]. Once the autophagosome is formed, a blockage of autophagic flux at late steps will downregulate the clearance of autophagosomes. A blockage of autophagic flux finally results in autophagy dependent cell death[29]. Detailed descriptions of the complex molecular steps of each stage of autophagy were recently published[20,28,30].

A commonly used marker for estimating autophagosome formation is the fusion protein green fluorescent protein-LC3 (GFP-LC3)[31]. Of the three members LC3A, LC3B, and LC3C of the human LC3 gene family, LC3B and LC3-II are mostly used for autophagy assays[32-34]. Autophagic flux into the lysosomes is estimated by measuring p62/SQSTM1 degradation. p62/SQSTM1 is a protein complex that binds to LC3 and is efficiently degraded by autophagy[35]. The total cellular level of p62/SQSTM1 inversely correlates with autophagic activity. Thus in autophagy-deficient cells, p62/SQSTM1 levels are increased after starvation in contrast to cells with normal autophagy[36].

It should be stressed that he level of LC3 is related to the induction of autophagy but might not reflect the final stages of autophagy and should not be used as a general marker of autophagy[34-36]. Further progress of autophagy is detected by a low level of p62 since p62 degradation depends on the function of the autophagosome-lysosome fusion[37]. Therefore an increase of both LC3 and p62 indicates formation of autophagosomes without lysosomal degradation[38].

As mentioned before, a major breakthrough in autophagy was the identification of Atgs. Evidence for the importance of autophagy in liver homeostasis was provided by the generation of of Atgs-knockout mice models[39]. Livers of mice with deletion of the autophagy gene Atg7 were markedly enlarged, up to 30% of the body weight of the animal and hepatocytes were characterized by structural alterations of mitochondria and peroxisomes and aggregation of ubiquitinated proteins. These aggregates disappeared when the ATg7- knockout mouse was bred to a mouse null for SQSTM1/p62indicating that SQSTM1 is important to direct damaged cytosolic proteins into the autophagic pathway[40,41].

To date, three major types of autophagy, namely, macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), have been described[22,42,43].

Macroautophagy is the classical pathway that engulfs the cytosolic components targeted for lysosomal degradation. Initiation of autophagy is controlled by two metabolic sensors the mammalian target of rapamycin complex 1 (mTORC1) and the AMP-activated protein kinase (AMPK). mTORC1 negatively regulates autophagy by direct phosphorylation of ULK1 thus inhibiting ULK1. AMPK suppresses mTORC1 activity by phosphorylation of tuberous sclerosis 2 and raptor, two essential regulators of mTORC1[44,45]. Recently it was reported that the final step in this activation process of mTOR is dependent on Rheb, a small GTPase that binds to mTOR and allosterically activates its kinase activity[46]. The long-term regulation of autophagy is carried out by transcription factor EB (TFEB)[47], the main regulator of lysosomal biogenesis and autophagy. Under nutrient-rich conditions, mTORC1 phosphorylates TFEB and retains TFEB in the cytosol[48-50]. Nutrient deprivation on the other hand leads to mTORC1 inhibition, dephosphorylation of TFEB and its translocation to the nucleus to initiate the rapid transcription of autophagy genes[51,52]. All subsequent series of complex events leading to the final degradation in lysosomes have elegantly been described[2,24,53].

A simplified scheme of macroautophagy is presented in Figure 1.

Microautophagy is the least studied type of autophagy where compounds or membranous vesicles are directly taken up by lysosomes[54]. Microautophagy is important during amino acid starvation[55,56] and possibly three different types can be recognized[57].

Chaperone Mediated Autophagy (CMA) is a selective engulfment process of substrates containing the pentapeptide “Lys-Phe-Glu-Arg-Gln” (KFERQ) motifs. They are recognized by, the cytosolic chaperone heat-shock cognate protein of 70 kDa (HSC70), and transported into the lysosomes through the lysosomal membrane protein 2A (LAMP2A)[58,59]. CMA is induced by DNA damage, hypoxia and oxidative stress, among others[60-65].

Today macroautophagy is also divided into non selective autophagy and selective macroautophagy targeting special organelles or specific compounds for degradation[43,66,67]. Thus new names have appeared according to the coumpounds involved: ribophagy (ribosomes)[68], pexophagy (peroxisomes)[69], ferritinophagy (iron-based compounds)[70] and most importantly reticulophagy (ER)[71] lipophagy (lipids)[72]and mitophagy (mitochondria)[73]. The last two are practically involved in every form of fatty liver.

**Reticulophagy:** Multiple receptors directly interact with LC3 and form autophagosomesduring reticulophagy, a very important form of macroautophagy thatpreserves the size and function of the ER in different conditions like starvation, non-alcoholic fatty liver disease (NAFLD), viral infections and fibrosis[74-79].

**Lipophagy:** Lipophagy is implicated in lipid homeostasis and metabolism in liver diseases. It is usually down-regulated in steatosis of either alcoholic or non-alcoholic liver disease[80-84], but it is up-regulated when fibrosis, cirrhosis or hepatocellular carcinoma are evolving[85-87]. Comprehensive reviews of lipophagy in liver disease were recently presented[88-91].

**Mitophagy:** The first step of mitophagy in mammals requires the induction of canonic Atg-dependentautophagy with either mTOR suppression induced by mitochondrial generated reactive oxygen species (ROS), or AMPK activation induced by adenosine triphosphate (ATP) depletion. The second step is the priming of the mitochondria involving molecular modifications leading to their recognition by the autophagosomes[92,93]. Even in the healthy liver, worn out mitochondria with a half-life of 10 to 25 d are removed by mitophagy[94,95]. Elimination of aged or damaged mitochondria protect cells from release of pro-apoptotic proteins, generation of toxic ROS and non proper hydrolysis of ATP[96-99]. When oxidative stress appears, autophagy rapidly acts to remove oxidized proteins or damaged mitochondria that generate more ROS. Recent data show that in autophagy deficiency there is acummulation of ROS and p62 probably mediated by the loss ofFOXO1/3. It has been reported that the p62-FOXO1/3 axis is the molecular basis for the reduction of antioxidant defense in autophagy deficiency[100]. Three different types of mitophagy have been described based in the different molecular pathways involved[101,102]. An extensive review of molecular mechanisms of mitophagy in liver diseases has been recently published[103].

**New players in liver autophagy:** It is clear today that apart from the known pathways regulating liver autophagy, there are additional mechanisms involved. The most important are the long non-coding RNAs (lncRNAs), microRNAs (miRNAs) and exosomes. Many recent studies have presented strong evidence that ncRNAs influence autophagy by regulating various autophagy pathways[104-110]. Equally, miRNAs regulate autophagy influencing the core autophagy pathways[111].

Evidence from experimental animals with liver specific deletions of Atgs has demonstrated the role of High mobility group box 1 (HMGB1)[112] and Yes-associated protein (YAP)[113] in the pathological changes induced by autophagy. Nuclear receptors were also reported to control autophagy. Activation of the farnesoid X receptor (FXR), occurs during feeding and suppresses Atgs expression. On the other hand during starvation, fasting-activated nuclear receptors, the peroxisome proliferator-activated receptor alpha (PPAR), and the cAMP response element-binding protein (CREB), induce expression of Atgs and therefore increase autophagy[114-116].

An association of autophagy with the formation and function of exosomes has also been described. Exosomes are extracellular vesicles originating from late endosomes, which do not fuse with lysosomes but are released extracellularly by exocytosis. Exosomes can either activate autophagy pathways or transfer extracellular vesicles to the lysosomes[117].The interplay between autophagy and exosome biogenesis has been recently described[118].

Most researchers have studied either the early or the late stages of autophagy. However equally important is the final stage, namely the lysosome reformation (ALR), leading to regeneration of functional lysosomes from autolysosomes. A series of proteins including clathrin, the motor protein KIF5B, and dynamin 2 are sequentially involved up to the maturation of functional lysosomes. Early lysosomes are pH-neutral but eventually they gain acidity and luminal proteins[119-122]. Accumulating evidence suggests that most, if not all, components of the molecular machinery for autophagy also mediate autophagy-independent functions. Autophagy is involved in various cell functions like endocytosis, phagocytosis, DNA repair, centrosome function, cell proliferation, cell death and immunological response including memory. Details were recently reported[123].

**Autophagy and immunity:** The implication of autophagy with the immune system has been investigated in the last few years[124-131]. Non-canonical forms of macroautophagy were described, resulting in the formation of autophagosomes that fuse with the lysosomes[132]. Only a subset of the Atgs machinery is used. Among these, LC3-associated phagocytosis (LAP) has been extensively studied because of its implication in immune regulation. LAP recruits LC3-II to the phagosomal membrane[133-135] and is taken up by macrophages through innate immune receptors such as Toll-like receptors. In contrast to autophagy the LAPasome is a single membrane vacuole. In contrast to autophagy, ULK1 is not required for LAP[133]. Chaperone-mediated autophagy has also attracted attention because of its central role in antigen presentation and aging[136,137]. Autophagy is also implicated in the function of innate immunity interfering with macrophage autophagy. There is interplay between autophagy and innate immunity as interferon (IFN)-γpromotes autophagy in macrophages[138]. Mice fed with high fat diet had impaired autophagy in bone marrow-derived macrophages and peritoneal macrophages[139]. Mice with Atg5 deficient macrophages, developed hepatic inflammation when stimulated with lipopolysaccharide (LPS) after a high fat diet feeding. Acquired immunity is primarily a defense function against specific pathogens and is brought about by the different subsets of T cells and B cells. Interestingly there is evidence that high autophagic activity maintains the differentiation and function of important T-cell subsets such as regulatory T (Treg)-cells[140] and γ δ T-cells[141].

**Autophagy and cell death:** It has been proven that autophagy can be either a protective mechanism or a contributor to cellular death in certain instances[142-144]. Autophagy is involved in cellular death mostly by its effects on apoptosis. Autophagy is connected to apoptosis and these two cellular destructive phenomena are affecting each other[145-148].This is particularly important in hepatic cell death[149].

Generally autophagy blocks the induction of caspase-dependent apoptosis, and apoptosis-associated caspase activation stops the autophagic process. Yet, in special cases, autophagy may induce apoptosis or necrosis, and autophagy has been shown to degrade the cytoplasm, leading to ‘autophagic cell death’[150-152].

Autophagy is also implicated in caspase-independent cell death, leading to necrosis and necroptosis[153]. Induction of apoptosis eliminates cells damaged through the action of the tumor suppressor gene p53[154]. Apoptosis is counteracted, among others, by the mTOR/AKT pathway also involved in autophagy. The balance between p53 and AKT/mTOR is crucial for the fate of injured cells[155,156]. In addition, autophagy induces a particular mechanism of cell death named ferroptosis. It was initially reported as a specific iron-dependent form of malignant cell death. It soon became clear that ferroptosis is a more general form of cell death[157,158]. Many proteins implicated in autophagy (like Atgs and BECN1) were also involved in ferroptosis. Moreover activators of ferroptosis, like erastin, induced autophagosome accumulation and activation of autophagy led to ferroptotic cell death possibly by the turnover of ferritin through ferritinophagy[159-161].

A recent study has shown that ferroptosis is also interconnected with lipophagy. Lipids released during lipophagy and subsequent peroxidized increase ferroptosis. Therefore it might be that ferroptosis is a mechanism of cellular death in NAFLD[162].

**Autophagy and inflammation:** Autophagy is also closely associated with the inflammatory response in the liver. Inflammasome and autophagy regulate each other by the same inhibitory mechanisms which however are controlled by different input pathways. The NLRP3 inflammasome activation, usually through the stimulation by pathogen- and/or danger-associated molecular patterns[163,164], induces procaspase-1 activation which promotes interleukin interleukin (IL)-1β and IL-18 production leading to pyroptotic cell death. These events are counteracted by caspase-1-mediated activation of autophagy. In addition autophagy reduces inflammasome activation degrading the inflammasomes in the autophagosomes but also eliminating damaged cytoplasmic organelles that otherwise would produce DAMPS increasing activation of inflammasomes[165,166].

On the other hand, the negative correlation between inflammasomes and autophagy[167-169] leads to an increased production of the pro-inflammatory IL-1β[170] when autophagy is decreased[128].However, the relationship between NLRP3 and autophagy has not been fully clarified, and recent studies have reported that nuclear factor-κappa beta (NF-κB) activation can modulate the NLRP3 and autophagy towards the same direction[171].

In view of the above is not surprising that many reviews on autophagy use the term “double-edged sword” stressing the fact that autophagy may have opposite effects on the same biological phenomenon[172]. Prominent general paradigms are cancer[173,174] and viral infections[175].

Another characterization pertinent to the liver is that autophagy behaves like Jekyll and Hyde depending on the cells involved. In hepatocytes, macroautophagy [in NAFLD and alcoholic liver disease (ALD)] and CMA (in NAFLD) is protective. It reduces fat accumulation and oxidative stress, it removes damaged mitochondria and favors regeneration. In macrophages, macroautophagy inhibits liver inflammation and fibrosis but it enhances fibrosis activated stellate cells. It is protective in early phases of hepatocellular carcinoma, but may be detrimental in late phases[176,177].

Autophagy in hepatocytes but also in the non-parenchymal sinusoidal cells of the liver is a key for liver physiology[178,179] and defects of autophagy are implicated in the pathophysiology of most liver diseases[180]. Both common diseases like alcoholic and non-alcoholic fatty liver or viral hepatitis and rare entities like Wilson’s disease and a1 antitrypsin deficiency are related to autophagy defects[30,41,57,181-184]. Defective autophagy also leads to accumulation of detrimental hepatocyte byproducts due to the fact that hepatocytes have a long half life of 6-12 mo [143]. Moreover, the liver is responsible for handling of a large number of xenobiotics and autophagy is a cytoprotective mechanism[99,185] (Figure 2).

**OBESITY, STEATOSIS AND NAFLD**

NAFLD is the commonest liver disease worldwide. Recently it was suggested that it should be renamed as metabolic dysfunction-associated fatty liver disease (MAFLD)[186,187]. Pathological lesions in the liver vary from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. Current pathogenesis of NASH is mainly focused on the effects of insulin resistance and lipotoxicity in hepatocytes[188]. The abnormalities reported in Kupffer cells, stellate cells and endothelial cells are regarded as secondary events[189,190].

Obesity and insulin resistance are well documented risk factors for NAFLD development. Defects in liver autophagy have been established as fundamental abnormalities in both conditions.

***Hepatic autophagy in obesity and insulin resistance***

In the hepatocyte, lipids are catabolized by two major pathways. The first involves cytoplasmic neutral lipases and the second is lipophagy and acid lipases and hydrolases of the lysosomes. The end result is the production of free fatty acids that are further broken down by βI-oxidase in the mitochondria[191].

Lipid droplets have a core of lipids enwrapped in a phospholipid layer characterized by proteins called perilipins directing them to the autophagosome[72]. A crucial protein mediating lipolysis and autophagy is the adipose triglyceride lipase (ATGL). Cytoplasmic lipolysis and lipophagy are interconnected. The degradation of perilipins by autophagy facilitates actions of ATGL which in turn induces autophagy *via* sirtuin1 deacetylation of certain Atgs and activation of the transcription factors FoxO1 and FoxO3 thus promoting autophagy[192-194].

Lipophagy can prevent lipid accumulation in hepatocytes, while the inhibition of lipophagy promotes lipid droplets (LDs) accumulation, resulting in hepatocellular steatosis[195].

Characteristic changes of the metabolic syndrome like obesity, hyperglycemia, and dyslipidemia have been shown to exert a negative effect on autophagy because the regulatory control of forkhead box O1 (FoxO1) on the expression of *Atg* genes is lost leading to autophagy malfunction[196].Macroautophagy and CMA are also down-regulated by increased intracellulal lipids due to either interference with the lysosomal stability of the CMA receptor or to the reduction of the ability of autophagosomes to fuse with lysosomes leading to the reduction of macroautophagic flux[196-198].

The severity of steatosis is related to the expression of three proteins, the damage regulated autophagy modulator (DRAM), BAX and p53. In mice livers, p53 expression increased in mild and severe steatosis. A DRAM expression increase was observed in mild hepatosteatosis, whereas high BAX expression was identified in severe hepatosteatosis[199].

A clinical study has confirmed the link between induction of autophagy and liver steatosis[200]. Autophagy-related genes (Atg5, LC3A, and LC3B) were overexpressed in obese patients compared with non obese patients.

Experimental evidence also suggests that defective autophagy is crucial in the development of obesity, oxidative stress, and the metabolic syndrome[201-203].

Insulin is intimately involved in autophagy regulation as the mTOR inhibitor of the FoxO and TFEB controllers of the transcription of autophagic genes is insulin-inducible[204]. Overactivation of mTOR in turn leads to insulin resistance[205,206]. Several mechanisms might explain this defect in obesity. Obesity increases calpain-2 by a still unknown signal pathway. Calpain is a protease that degrades Atg7 and modulates autophagy[201]. Autophagosome-lysosome fusion is also defective in livers of obese mice due to alterations of the lipids in cellular membranes induced by the high-fat diet[198]. A defective liver autophagy and the associated decrease of lysosomal degradation contribute to an additional increase in the ER stress which leads to insulin resistance and a vicious circle is completed[201,207,208]. Hyper-insulinemia decreases liver autophagy and reduced hepatic autophagy aggravates ER stress and insulin resistance.

An additional mechanism is a defect in acidification of lysosomes. Impaired substrate degradation in autolysosomes has also been reported for obese ob/ob mice. Activities of lysomal cathepsins were implicated in obesity. Cathepsin L was decreased in obese adipose tissue, while Cathepsin B was significantly elevated. Interestingly in obese adipose tissue inflammasomes were activated and further upregulation of cathepsin B resulted in additional activation of inflammasomes[209-212].

A study of the expression of 322 lysosomal/autophagic genes was recently reported in adipose tissue of lean and obese patients. Among 35 significantly expressed genes, 34 were upregulated. In isolated murine cells, tumor necrosis factor alpha (TNFα) stimulation resulted in upregulation of lysosomal/autophagic genes accompanied by upregulation of the autophagy associated SQSTM1/p62 receptor leading to increased degradation of perilipin 1. It seems that local inflammatory cytokines may impair lipid storage *via* autophagy induction[213].

An extensive review of lysosomal enzyme abnormalities in both adipose and liver tissue was recently published[214]. A recent report suggests an additional mechanism contributing to obesity-associated abnormalities. Obesity increases lysosomal iNOS and NO production leading to exacerbation of lysosomal nitrosative stress, impairment of lysosomal function, defective autophagy and insulin resistance[215].

There is also evidence that mitophagy is negatively regulated by liver insulin resistance. Mitophagy can promote mitochondrial fatty acid oxidation to inhibit hepatic fatty acid accumulation and improve hepatic insulin resistance. Fundc1 is a recently characterized mitophagy receptor and mice lacking this receptor develop severe obesity and insulin resistance when maintained in a high-fat diet[216,217].

However, when autophagy is defective an alternative mechanism protects the liver from steatosis. An induction of fibroblast growth factor 21 (FGF21) was reported in mice with subsequent amelioration of insulin resistance and decreased diet-induced obesity[218,219]. This has been corroborated in a clinical study of overweight NAFLD patients, where increased FGF21 levels were correlated with steatosis grade, fibrosis and lobular inflammation. NASH patients had the highest levels[220]. An analogue of FGF21 has been tested in experimental animals and obese diabetic patients with promising results[221-223]. Nevertheless, the control of adipose tissue biology is very complex and is elegantly described in a recent publication[224].

**NAFLD-NASH**

Not surprisingly autophagy is strongly associated with NAFLD pathogenesis[179]. Diet-induced NAFLD in mice blocks hepatic autophagy and leads to oxidative stress and mitochondrial dysfunction[225], also reducing thyroid hormone-induced mitophagy[226]. The potential molecular pathways and possible therapeutic implications of thyroid hormones in NAFLD have been recently reviewed[227].

Mitophagy abnormalities are strongly implicated in NAFLD[228-230]. In particular an impairment of mitophagy seems to activate the NLRP3 inflammasome favoring the progression of NAFLD to NASH[38]. Accordingly, recent evidence indicates that restoration of mitophagy may improve NAFLD[231-234].

In addition to mitophagy, reticulophagy is also implicated in NAFLD. An extensive reticulophagic response is evident in hepatocytes after induction of NAFLD by oleic acid[228,235]. It is suggested that reticulophagy and mitophagy are independent, events involved in NAFLD progression[228].

Impaired lipophagy and lipotoxicity are also strongly involved in NAFLD[72,192,236,237]. Lipid accumulation in hepatocytes blocks autophagic flux and impaired autophagic flux favors the progress of NAFLD[30].

This impaired flux and the subsequent ER stress can be improved by inhibition of the sterol regulatory element-binding protein 2 (SREBP-2) whose activation promotes accumulation of cholesterol in NAFLD. This improvement is associated with upregulation of autophagy genes[238].

Intracellular lipid trafficking is also regulated by store operated calcium entry and enhanced lipophagy is observed in cells defective in this system[239]. Moreover, the detrimental effects of diets rich in saturated FFA were increased bysirtuin-3, which enhanced lipotoxicity, reducing the autophagic flux[240]. The effect of lipophagy in liver steatosis is further supported by experimental evidence that various chemicals are involved in steatosis by interfering with autophagy. Caffeine reduces lipid content and stimulates beta-oxidation in hepatocytes through autophagy in mammalian liver cells in NAFLD[17]. In essence caffeine protects against fatty liver through the co-ordination of the induced lipophagy and mitochondrial β-oxidation[241,242]. Epidemiologic studies demonstrated that coffee consumption reduced the development of fatty liver, fibrosis, and hepatocellular carcinoma in NAFLD patients[243,244] supporting thus the experimental evidence.

Methionine is a well known inactivator of autophagy and lipophagy. The correlation between lipophagy and methionine in the liver from patients with liver steatosis has been studied. Increased levels of methionine inhibit autophagic catabolism of lipids and contribute to liver steatosis in NAFLD[83]. Mice fed with a methionine/choline deficient diet developed steatosis, inflammation, fibrosis and ER stress associated with mitochondrial dysfunction. The administration of the autophagy enhancer rapamycin ameliorated these lesions while chloroquine, a well established autophagy inhibitor, aggravated the liver injury[245]. Resveratrol, another autophagy activator, also attenuated liver lesions induced by a similar diet[246,247]. Consistent with these findings is a recent report that a traditional Chinese herb increased autophagy and considerably improved steatohepatitis induced by methionine/choline deficient diet in rats[248].

Other diet-supplied molecules affect autophagy and are possibly beneficial in NAFLD including the purple sweet potato color[249]. Likewise, the caffeic acid of vegetables has been reported to ameliorate hepatic steatosis[250] while curcumin, an antioxidant polyphenol of Curcuma longa, has been shown to inhibit apoptosis and induce autophagy with a potential protective effect on hepatocellular carcinoma[251].

A finding that might be useful in future treatment of NAFLD was recently reported. Celecoxib, a COX-2 inhibitor, attenuated steatosis and restored autophagic flux in cells treated with palmitate and rats fed a high fat diet[252].

Other lipids like the sphingolipid ceramide may be implicated in NAFLD as it is increased in Atg7 knockout mouse liver in parallel with the impaired autophagy[253]. Autophagy increased when sphingolipid de novo synthesis was upregulated, indicating that lipid degradation was activated to prevent excessive sphingolipid accumulation.

Interestingly, autophagic activity seems to be upregulated when the renin angiotensin system is overexpressed. The underlying mechanisms and its role in NAFLD have yet to be clarified as there are many controversial issues to be solved[254]. Overall there is extensive evidence that inhibition of lipophagy is detrimental for the liver in NAFLD[198,222,238,255].

Summarizing the above studies, a therapeutic approach against NAFLD would be the activation of lipophagy[90]. However, it is noteworthy that there is one study indicating the opposite, as suppression of autophagy through inhibition of c-Jun N-terminal Kinase (JNK) ameliorates insulin resistance in a rat NAFLD model[256].

Extensive reviews on the mechanisms of autophagy deregulation in NAFLD were recently published[183,257,258]. Not only impaired macroautophagy but also reduced liver chaperon mediated autophagy (CMA) favors steatosis due to failure in the timely removal of perilipins[259,260] and therefore an increase in lipogenic enzymes. When oxidative stress is increased in the liver, an upregulation of CMA occurs to selectively remove damaged proteins[62]. Loss of CMA leads to impairment of proteostasis and accumulation of oxidized protein aggregates perpetuating thus chronic oxidative stress[261].

***Autophagy and NASH***

Involvement of autophagy in the progression of NAFLD to NASH has not yet been clarified and molecular mechanisms are not fully understood.

One of the histological characteristics of NASH used in diagnosis and scoring systems is the formation of Mallory-Denk bodies (MDB)[262-264]. There is experimental evidence that inhibition of autophagy and accumulation of p62 is related to their formation while autophagy activation with rapamycin leads to their resolution[265]. Further support of the involvement of autophagy in NAFLD evolution to NASH was reported in a clinical and experimental study where a decrease of autophagic flux in parallel with an increase in ER stress was demonstrated both in the livers from NAFLD patients and mice models of NAFLD, and in lipid-overloaded human hepatocytes[266]. However tests for measurements of autophagic flux used in this paper are not full-proof as they can be influenced by autophagy independent factors. Therefore these findings should be corroborated in a different set up.

Patients with NASH and murine models of steatotic inflammation had reduced expression of Atg7 and TFEB while the autophagy inhibitor rubicon was increased[139,177,255].

In contrast, steatosis and liver injury were improved in parallel with restoration of autophagy and reduction of ER stress in mice with a deletion of the Rubicon or adenoviral delivery of Atg7[202,251]. Recent evidence also indicates that impaired mitophagy may contribute to liver injury during progression of NAFLD and formation of megamitochondria[229].

Transition of NAFLD to NASH also implicates Kupffer cells. These cells, constitute 80%-90% of tissue macrophages in the body and are critical cells in liver inflammation[20]. They are the main site of NLRP3 inflammasome activation and production of the pro-inflammatory cytokines compared to hepatocytes and stellate cells[267,268]. Activation of the NLRP3 inflammasome plays an important role in the transition from NAFLD to NASH[269].

An earlier report demonstrated that cathepsin B, a lysosomalcysteine protease, is released in the cytosol in response to FFAs and that this redistribution of cathepsin B is present in the liver of patients with NAFLD related to disease severity. Importantly in a dietary mouse model of NAFLD, inhibition of Cath B significantly decreased steatosis, liver inflammation and insulin resistance[270].

These findings were recently elaborated in more detail as it was reported that cathepsin B and activation of the NLRP3 inflammasome are interconnected in a murine model of NASH but also in isolated Kupffer cells stimulated with palmitate. Expression of cathepsin B and activation of NLRP3 inflammasome were increase in NASH animals. Moreover, an inhibition of Cathepsin B decreased liver inflammation, ballooning, and the pro-inflammatory cytokines IL-1β and IL-18. *In vitro* stimulation of Kupffer cells showed identical results in inflammasome activation, expression of Cath.B and cytokine production before and after Cath.B inhibition. These results indicate that NASH pathogenesis probably depends in part to inflammasome activation which in turn is regulated by the activity of aprotease tightly connected to autophagy[271].

Additional supporting evidence for the role of autophagy in NASH pathogenesis is the fact that impaired autophagy in obese mice is critical for macrophage polarization. M2 macrophage polarization relies on energy provided by FFA oxidation, suggesting a potential implication of autophagy in this process. Macrophages change to a pro-inflammatory phenotype due to both increased M1 and decreased M2 polarization[132] with a resultant upregulation of liver inflammation, a prominent feature of NASH.

The situation is controversial when adipose tissue macrophages from obese mice are concerned. Increased rather than decreased autophagy of macrophages has been demonstrated in adipose tissue[272,273]. Another cathepsin mostly found in Kupffer cells seems to be implicated in NASH. Lysosomal cholesterol accumulation inside murine Kupffer cells leads to increased liver Cathepsin D activity which is related to liver inflammation[274]. Kupffer cell cathepsin D may therefore be an additional key player in hepatic inflammation of NASH[275]. The impairment of macrophage autophagy with aging may explain in part the increased prevalence of the metabolic syndrome and steatohepatitis of older age in humans[276,277].

The oxidative stress is also involved in the progression to NASH. Hepatocytes exposed to palmitate concentrations similar to those found in patients with the metabolic syndrome and NAFLD showed mitochondrial membrane permeabilization and production of ROS. Similarly, an inhibition of Cathepsin B ameliorated mitochondrial dysfunction and oxidative stress, indicating an additional mechanism of NASH progression[229,278].

Under normal conditions, damaged mitochondria are removed through mitophagy. In certain cases of NAFLD however mitophagy is defective and the oxidation of biomolecules by mitochondrial ROS starts a vicious cycle of increasing mitochondrial dysfunction and aggravation of hepatocellular oxidative damage. This ultimately leads to hepatic inflammation and liver failure[279,280], since impaired mitophagy triggers liver NLRP3 inflammasome activation *in vivo* and *in vitro* in isolated murine hepatocytes[38].

Impairment of autophagy in other liver sinusoidal cells may also participate in the progression of NAFLD to NASH. Decreased autophagy has been observed in the liver endothelial cells of patients with NASH or in mice with endothelial deletion of Atg5 and features of inflammation[180,190,281]. A very recent study has convincingly shown that impaired autophagy of liver endothelial cells (LSECs) occurs in NASH patients but not in simple steatosis. Deficiency in autophagy in LSECs induces endothelial inflammation ultimately leading to liver inflammation and fibrosis. This defective autophagy, in part due to inflammatory mediators of the portal blood, might well be one of the missing links of the progression of simple steatosis to NASH and cirrhosis[282].

A further mechanisms leading to NASH involves multivesicular bodies (MVBs), a form of endosomes, whose contents are transported into lysosomes[283]. The MVB-lysosomal pathway was shown to participate in the development of steatohepatitis through lysosomal degradation of Toll-like receptor 4 reported to be critical for the progression of NASH[284].

Finally a role of the chemokine CXCL10 in the development of steatohepatitis has been proposed. Upregulation of CXCL10 impairs autophagic flux decreasing thus autolysosome formation. Autophagic protein degradation is inhibited followed by the accumulation of ubiquitinated proteins with ultimate development of steatohepatitis[285].

**ALD**

The liver is the organ mostly responsible for ethanol metabolism. Oxidation of ethanol happens through three pathways namely alcohol dehydrogenase in the cytosol, cytochrome P450 (CYP2E1) in the ER and microsomes and the enzyme catalase in peroxisomes[286]. Ethanol oxidation also produces ROS, including superoxide anion, and hydroxyl radicals that may damage hepatocytes[287].

Ethanol induces autophagosome formation in the liver. Reduction of autophagy results in the accumulation of lipid droplets and apoptosis of hepatocytes[288]. On the other hand activation of autophagy by rapamycin attenuates steatosis and injury induced by a combination of ethanol and lipopolysaccharide[289].

Induction of autophagy by acute ethanol exposure is mediated through many mechanisms Ethanol-induced autophagy requires ethanol oxidation to acetaldehyde and ROS generation[290,291]. ROS activates autophagy by suppressing mTOR and proteasome activity[292,293] and inactivation of Atg4[294].

Oxidants differentially influence the activities of the proteasome (the other major pathway of protein degradation.) Proteasomes are reduced when autophagosomes are increased[295]. Proteasome inhibition further triggers ER stress activates autophagy through JNK activation. Ethanol may also suppress Akt and mTOR through the upregulation of PTEN[296,297]. Metals, like zinc, are also implicated in autophagy alterations after ethanol treatment[298].

A caution should be exercised on CYP2E1 ethanol oxidation as oxidative products resulting from the expression of CYP2E1 may in fact impair autophagy leading to lipid accumulation in the liver. In cells expressing CYP2E1, hepatocyte lipids and generation of ROS were increased by an inhibitor of autophagy and decreased when a stimulator of autophagy was used[299]. Similar results were found after acute alcohol in CYP2E1 knockout mice[291]. These findings also support the idea that autophagy protects against ethanol/CYP2E1-dependent hepatic injury.

It has also been shown that hepatic autophagy depends on the level of acetaldehyde produced during ethanol metabolism. Mice expressing the ALDH2 isoenzyme, clear acetaldehyde more rapidly and have increased autophagy and lower levels of hepatic triglycerides[300]. Cannabinoid receptor 2 can also induce macrophage autophagy to protect from alcoholic liver damage[301].

It should be stresses however that acute and chronic ethanol exposure may have different effects in liver autophagy[302]. Increased autophagosome formation and autophagy flux were shown in cultured hepatocytes after short term incubation with ethanol or in livers of mice after acute alcohol administration[288,302]. Enhanced autophagy parallel a higher hepatocyte nuclear content of TFEB, the main transcriptional regulator of genes involved in lysosome biogenesis[49,50].

Alcohol also has an effect on the transcription factor forkhead box O3a (FoxO3a) that modulates liver autophagy[303]. The activity of FoxO3a is largely controlled by multiple post-transcriptional modifications, including phosphorylation and acetylation[304]. Acute ethanol exposure increases nuclear translocation of FoxO3a inducing its dephosphorylation and acetylation.

However, results are not uniform for the chronic ethanol effect. Chronic ethanol administration (Lieber-DeCarli model) for 4 wk or 10 wk increased autophagosome numbers in murine livers, suggesting the induction of autophagy[305]. In another similar murine model, mice were given gradually increasing ethanol ethanol concentrations for 10 d and autophagic flux was reduced[302].

The discrepancy seems to be solved by the report that autophagy response was dependent on the alcohol concentration used. In a murine model on Lieber-DeCarli diet with different levels of alcohol for 4 wk, autophagy is increased by a lower dose of alcohol (29% of the caloric need), but decreased by a higher dose (36% of the caloric need). Liver injury was aggravated by further reduction of autophagy and attenuated by autophagy activation[306].

Earlier studies have also demonstrated that chronic alcohol exposure disrupts lysosome function[307]. Overall results have demonstrated that autophagy is suppressed in chronic alcohol consumption due to either the defect of lysosomal function and biogenesis from TFEB suppression[302,308] or to a reduction in AMPK activity and inhibition of autophagosome formation[309,310].

After ethanol-induced reduction of autophagy, there is accumulation of aggregated proteins and SQSTM1/p62, leading to activation of nuclear factor erythroid 2-related factor 2 (Nrf2) and damage to the mitochondria and cell death[309,311].

How the other autophagy-related transcriptional factors, such as TFEB and farnesoid X receptor (FXR) are interconnected with FoxO3a in the expression of autophagy genes is unknown. Moreover, how ROS generation in acute or chronic alcoholic condition systematically affects the mTORC1 activation or TFEB translocation is unclear.

Autophagy is also protective against CYP2E1-dependent liver lesions in a chronically ethanol-fed murine model[312]. Autophagy in ALD can be further affected by additional factors identified in various experimental models. Augmenter of liver regeneration (ALR) is a factor that can promote liver growth. It was reported to protect mice from ethanol-induced liver injury through inhibition of mTOR and therefore activation of autophagy[313]. Moreover an interesting recent study used many genetic models of autophagy impairment, with different functional levels and different alcohol regimens. Deficiencies of either Atg7 or Atg5 demonstrated variable responses to ethanol feeding according to the timing of autophagy dysfunction, the gene being affected, and the alcohol scheme used[314].

It should be stressed that in acute alcohol administration, ethanol-induced autophagy may protect the liver by three basic mechanisms namely mitophagy[80,102,315,316], lipophagy[72,293,317] and clearance of Mallory-Denk bodies by proteophagy[265,318,319].

However, chronic alcohol exposure impairs autophagy and lipophagy[308,320] most likely due to the activation of mTOR signaling and a decrease in lysosomal biogenesis. Administration of the mTOR inhibitor Torin- 1 restores lysosomal biogenesis and attenuates liver lesions[308]. An additional pathway through which chronic alcohol exposure could reduce liver autophagy is the inactivation of the guanosine triphosphateRab7 and reduction of dynamin 2 activity leading to depletion of lysosomes and inhibition of hepatocyte lipophagy[320,321].

Ethanol Induced steatosis activates mitophagy by elevating PINK1 expression on mitochondria[305]. PINK1-dependent mitophagy was correlated with the mitochondrial expression of Parkin and the level of an indicator of oxidative mtDNA damage[322-325]. Mitophagy has a dominant role in protection of the hepatocyte from alcohol-induced hepatic injury as evidenced by a report that enhancement of mitophagy by quercetin, a natural flavonoid, attenuated ethanol-induced mitochondrial damage[326].

Regulation of mitophagy is related to three receptors namelyFUN14 domain containing 1 (FUNDC1), BCL2 interacting protein 3 (Bnip3), and Parkin[327].

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a newly described housekeeper of liver mitochondrial fission. DNA-PKcs is overexpressed in murine livers after exposure to ethanol and was positively correlated with steatosis, mitochondrial damage andfibrosis. On the other hand this over expression repressed FUNDC1-required mitophagy[328].

An additional significant point is the effect that ethanol might have on the different sinusoidal cell subpopulations. There is strong evidence that autophagy in macrophages is crucial to protect the liver from ethanol-induced damage. Investigations were mostly performed in macrophage specific deletions of either Atg7 or Atg5. The cannabinoid CB2 receptors of macrophages were found to have a protective rolein ALD, which was abrogated by Atg5-deletion in macrophages[301]. Increased mortality in Atg5 deleted mice was also demonstrated after chronic ethanol feeding plus LPS challenge[329]. Similar findings were reported after Atg7 deletion[330]. Both studies demonstrated an activation of the inflammasome and an augmented IL-1 production.

In contrast to hepatocytes and macrophages the effect of autophagy in hepatic stellate cells after ethanol exposure has not been clarified. A recent study in immortalized rat stellate cells demonstrated that autophagy could contribute to ethanol-induced stellate cell activation[331]. Induction of fibrosis by alcohol in current murine models is not feasible unless accompanied by steatosis induced by a high-fat diet[332].

Most autophagy studies in ALD are focused on the involvement of macroautophagy. Recent evidence however indicates that CMA is also important in alcoholic liver disease through the CMA negative regulator sorting nexin 10 (snx10). Snx10 knockout mice fed with Lieber-DeCarli diet were resistant to alcohol-induced liver injury associated with an increase of lysosome-associated membrane protein 2A (LAMP2A) and CMA activation through inhibition of the enzyme Cathepsin A which is responsible for LAMP2A degradation[333]. Deficiency therefore of a CMA negative regulator, protects animals from ALD. Deficiency of another CMA negative regulator, Lipocaline-2 (LCN2), also maintains hepatic CMA activity in murine livers after chronic alcohol administration[334] verifying the idea that impaired CMA may be responsible at least in part in alcohol-induced liver injury.

Involvement of miRNAs is an additional factor in the regulation of autophagy in ALD that has emerged from recent evidence. Several miRNAs were reported to alter autophagy and alcoholic steatosis[335]. miR-26a ameliorates alcohol-induced acute liver injury by two MAPKs inhibitors thus inducing Beclin-1 expression and autophagy[335]. Another report provided evidence that miR-155 is a mediator of alcohol-related exosome production and autophagy impairment in both hepatocytes and macrophages[336]. Deletion of miR-155 protected mice from alcoholic steatosis and inflammation. Interestingly in this study serum levels of exosomes were increased in ALD patients and alcohol exposed mice, whereas miR-155 deficient mice had significantly reduced exosome release from both hepatocytes and Kupffer cells. It was suggested therefore that autophagy is an atypical promoter of exosome release in ALD.

Clinically important observations indicate that withdrawal of ethanol from ethanol-fed rats resolves steatosis[337] suggesting that removal of ethanol oxidation and restoration of lipophagy may be the mechanism of steatosis resolution observed in humans after ethanol abstinence[338,339]. Informative reviews of autophagy in ALD were recently published[90,181,182,340-342].

In view of the fundamental role of lipophagy in the pathogenesis of ALD, it is not surprising that pharmacological inducers of lipophagy like carvamazepine, rapamycin, resveratrol and simvastatin were tested in alcohol-fed animals with a resultant attenuation of liver lesions. By contrast chloroquine exacerbated hepatic steatosis[312,343,344]. Recently plant-derived agents were also used to activate lipophagy. Thus, corosolic acid[345], quercetin[346] and Salvianolic acid A[347] all had a favorable result on alcohol-induced liver lesions activating lipophagy through different pathways.

Summarizing, it is evident that whether ethanol causes an increase or decrease of autophagy depends on the duration of ethanol consumption/exposure, the amount of alcohol given, and the manner in which it is administered[290,302]. Moreover, lipophagy and mitophagy cannot act as defensive mechanisms in the long term as they do in acute ethanol consumption as they are inhibited by chronic alcohol exposure[102,348].

**VIRAL HEPATITIS**

In the past decade, hepatic autophagy has been implicated in viral infection with either hepatitis B (HBV) or hepatitis C (HCV).

***HBV***

Recent studies have shown that autophagy is involved in the life cycle of Hepatitis B. Inhibition of autophagosome formation could reduce HBV production, while stimulation of autophagy could significantly contribute to HBV production[349,350].

However, the mechanism by which HBV activates autophagy is not clear. Previous reports have implicated either the HBx[351,352] the large HBsAg protein[353] or a mutant with a deletion in the preS2 region[354,355] as inducers of ER stress which in turn increases autophagy.

In contrast it was shown that HBx does not play a significant role in the induction of autophagy compared to the small HBsAg protein also increasing autophagy *via* the induction of ER stress. An HBV genome unable to express small HBsAg does not activate autophagy[356]. To reconcile the discrepancy, it has been suggested that autophagy can be stimulated both by HBx and the small surface HBsAg protein through upregulation of beclin-1 expression[357,358]. In addition HBx induces autophagy through its effect on the cytoplasmic high-mobility group box 1 (HMGB1), identified as a a positive regulator of autophagy. HBx binds to HMGB1 and triggers autophagy in hepatocytes[359]. This observation may be clinically relevant. Spontaneous and induced autophagy of peripheral Treg cells from 98 patients with chronic hepatitis B were assessed[360]. No difference of spontaneous autophagy was found between patients and normal controls but induced autophagy was significantly higher in patients. It was also related to HMGB1 as it was significantly decreased when HMGB1 was blocked with a neutralizing antibody.

HBx further impairs lysosomal acidification with a final result the accumulation of immature lysosomes. Moreover immature lysosomal hydrolase cathepsin D was shown in human liver tissues with chronic HBV infection suggesting that a repressive effect of HBx on lysosomes may be responsible for the inhibition of autophagic degradation[350]. Interestingly, although HBV could impair lysosomal acidification it was unable to induce autophagic protein degradation, due to the inability of HBV to increase the sequestration of proteins destined for degradation by autophagy[350]. Therefore, it is usually stated that HBV induces incomplete autophagy. In addition, it was clearly shown that HBV specifically targets damaged mitochondria and mitophagy. Either the whole HBV genome or HBx alone were able to induce Parkin-mediated mitophagy[361,362]. In addition, HBx-induced autophagy inhibited mitochondrial apoptosis increasing the survival of HBV DNA-transfected cells[349]. Another clinically important observation is that different HBV genotypes have a variant effect on autophagy. HBV genotype C was a more potent inducer of autophagy than HBV genotype B. HBV-C is associated with more severe disease than HBV-B but however attractive such an association between autophagy and severity of liver disease may be, it has to be verified[363,364].

It is important to realize that many viruses, including HBV, have developed strategies to hijack autophagy to benefit their replication and dissemination[356,3365,366]. So far, HBV is the only DNA virus known to exploit autophagy for its own replication as it is RNA, but not DNA viruses, that commonly use autophagic function to promote replication[367].

HBV infection induced the early-stage formation of autophagic vacuoles increasing the PI(3)K enzyme activity to promote HBV DNA replication. HBx can directly bind and activate the PI3KC3 complex[368,369]. Ablation of Atg5 has been shown to inhibit autophagy and impair nuclear localization of the HBV core protein. HBV DNA level in sera was decreased by more than 90% accompanied by practically undetectable levels of the HBV DNA replicative intermediate in the liver[370].

Autophagy was responsible for the degradation of an oncogenic microRNA-224 in the liver of HBV patients with hepatocellular carcinoma (HCC) and HBx-transgenic mice. In HCC patients, the combination of low-Atg5 expression and high miR-224, was significantly correlated with a poor overall survival rate[371]. The list of the mechanisms used by HBV to subvert autophagy and the detrimental consequences in the liver is by no means complete as new factors are constantly reported including release of pro-inflammatory cytokines and chemokines and inhibition of neutrophil extracellular trap[372-375].

Further evidence of autophagy subversion by HBV was recently reported. In HBV-replicating hepatocyte cultures, the silencing of Atg5, Atg12, and Atg16L1, interfered with viral core/nucleocapsid (NC) formation/stability and significantly reduced virus yields. It was further demonstrated that a covalent conjugation of Atg12 to Atg5 was essential for HBV replication. In addition the virus required Atg10 and Atg3 which are necessary for Atg5-12 conjugation. Deletion of Atg10 and Atg3 decreased HBV yields, while Atg3 overexpression increased virus production. HBV was associated with the Atg5-12/16L1 *via* interaction of HBV core protein with the Atg12 unit of the complex. Subsequent autophagosome maturation events were not necessary for HBV replication. These data indicate that HBV subverts early, non degradative autophagy components avoiding thus autophagosomal destruction[178,376,377].

Death receptors of TNFSF10 (tumor necrosis factor superfamily member 10) participate in the immune defense against several viruses by promoting apoptosis. HBx impairs TNFSF10 receptor signaling through autophagy mediated lysosomal and not proteasomal degradation. Importantly a significant reduction of the protein TNFRSF10B was demonstrated not only in cell lines but also in the liver of chronic HBV patients[378].

It was very recently reported that the hepatitis D virus also utilizes autophagy to assist its life cycle as it increases autophagosome accumulation and impairs autophagic flux. Both the small HDAg and large HDAg proteins are capable to disturb the autophagy machinery, in particular the proteins Atg7, Atg5, and LC3 involved in the early elongation stage of autophagy. Unexpectedly, deletion of Atg5 and Atg7 reduced the intracellular HDV RNA level in hepatocyte cell lines without an effect on HDV secretion[379]. Reviews of autophagy in HBV have recently been published[366,380].

***HCV***

Reported data have shown that HCV could induce autophagy to support its own replication[381,382].Several mechanisms for HCV induction of autophagy have been investigated using hepatocyte cell lines[383,384]. HCV infection initiates the formation of phagophores after induction of the localization of Atg5 to the ER. Phagophores fuse to form autophagosomes. HCV-induced autophagosomes were further reported to be required for viral RNA replication as the autophagosomal membrane provided a platform containing HCV NS5A, NS5B, and viral RNA for replication[385-387] but subsequently HCV blocks the fusion of autophagosomes and lysosomes through Rubicon overexpression. As a result autophagosomes accumulate and HCV RNA replication and assembly of infectious virions[385,388,389,390,391] are supported.

However, several studies have contradicted the need for co-localization of viral proteins in the autophagosomal membrane suggesting that this is not a necessity for viral replication[392-395].

Autophagy favors HCV replication with an additional mechanism. The entire autophagic process may be manipulated leading to the suppression of the HCV associated innate antiviral response[393,396]. After silencing different Atgs, HCV viral infectivity was suppressed in parallel with an upregulation of interferon-stimulated gene expression[390]. Moreover, HCV seems to activate autophagy to degrade the tumor necrosis factor receptor -associated factor 6 (TRAF6), thus subverting innate host immunity[389,397-399]. HCV induced unfolded protein response strongly activates autophagy to sustain viral replication through inhibition of cellular apoptosis[396]. Different HCV genotypes may have variable influence on autophagy[391,400].

HCV was also found to selectively activate lipophagy to counteract the HCV induced lipid abnormalities. This may be clinically important as the levels of autophagy in the liver of chronic HCV patients were inversely correlated to steatosis[401]. Inhibition of autophagic degradation of lipophagy may account for the characteristic occurrence of hepatic steatosis in chronic HCV infection. Mitophagy is also selectively activated *via* the PINK1–Parkin axis in infected cells, thereby promoting HCV viral RNA replication[361,402]. Virus-activated mitophagy further attenuates apoptosis and favors persistent viral infection[403]. In agreement with this finding, the viral non-structural protein 5A (NS5A) was shown to disrupt mitochondrial dynamics, thus increasing ROS production and mitophagy[404].

On the other hand, the viral core protein interacts with Parkin inhibiting its translocation to mitochondria. Mitophagy is suppressed and mitochondrial injury of infected hepatocytes is sustained and viral persistence is maintained[405].

Syntaxin 17 is an autophagosomal protein required for the fusion of autophagosomes with lysosomes and also the release of HCV. The amount of syntaxin 17 was reduced in HCV-replicating cells indicating that HCV impairs the late stages of autophagy affecting the equilibrium between the release and the lysososomal degradation of viral particles[406].

Recently CMA was also demonstrated to be activated by HCV leading to degradation of IFN-alpha receptor-1[407]. Moreover the HCV NS5A was found to interact with Hsc70, recruiting Hsc70 to hepatocyte nuclear factor 1 alpha thus targeting HNF-1α for CMA degradation[408]. Taken together these studies indicate that HCV induced CMA also facilitate HCV replication.

However, an opposite less permissive effect of the manipulation of autophagy by HCV has been suggested as a result of recent studies. Atg10 is critical for autophagy as it promotes the Atg5-Atg12 complex formation. Two isoforms of the Atg10 protein were described, namely Atg10 (a longer one) and Atg10S. They have a similar amino acid sequence except for an absence of a 36-amino acid fragment in Atg10S. Yet they differ in their effects on HCV genome replication. Atg10 with deleted or mutated two cysteins, (Cys44 and Cys135) could trigger the expression of anti-HCV immunological genes combating the HCV replication[409,410].

Taken together these results indicate that autophagy is required for initiation of the HCV replicative phase but not for further replication[393]. However this might not be entirely true, as chloroquine an inhibitor of lysosomal acidification inhibits HCV replication offering an additional evidence for the permissive role of autophagy in HCV infectivity in the late phase[411].

Autophagy may additionaly be involved in HCV replication through the regulation of the exosomal pathway[390] and apolipoprotein transport[412], both critical steps in the egress of the HCV virion. The virion is associated to apolipoprotein E (ApoE) and its infectivity is enhanced. Autophagy has a central role in the trafficking of ApoE in HCV-infected cells leading to partial autophagic degradation of ApoE, but also to the interaction between ApoE and the viral protein E2 to increase the production of infectious viral particles[412].Molecular details of how HCV is using autophagy to its own advantage were recently published[380,413].

In summary,the life cycles of HBV and HCV in liver cells can be subdivided into 7 steps: endocytosis, uncoating, genome replication, translation, envelopment, assembly and release. Both HBV and HCV drive autophagy largely by the ER stress response resulting from uncontrolled translation of viral proteins[414-416]. In addition HBx modulates autophagy for the benefit of HBV replication[357], while multiple HCV proteins including p7, NS3/4A and NS4B, modulate autophagy by direct or indirect association with moieties of the early autophagy machinery in favor of its replication[417-419]. Pharmacological or genetic manipulation of autophagy may limit the viral yield[183,369,420], making autophagy a feasible target for HBV and HCV treatment.

**FIBROSIS-CIRRHOSIS**

The liver responds to practically any insult with only a limited number of pathological lesions: Hepatitis (hepatocyte death), cholestasis, fibrosis-cirrhosis or a combination of the three. Autophagy participates in all liver pathological responses.

Liver fibrosis is a complex and dynamic cellular process implicated in the evolution of the majority of chronic liver disease towards cirrhosis. Most review articles have broadly concentrated on the role of autophagy in liver diseases, with restricted information on cell types implicated in liver fibrosis. Not unexpectedly, most research has focused on hepatic stellate cells (HSCs) and myofibroblasts, because they are the central elements in extracellular matrix production[421]. However, other liver cells, including hepatocytes, macrophages, sinusoidal endothelial cells (LSECs), infiltrating immune cells and the so-called ductular reaction (DR) are also important[422,423]. DR significantly correlates with the degree of fibrosis and involves cholangiocyte-like cells that dominate an interplay of extracellular matrix and inflammatory infiltrate[424-427].

***HSC and autophagy***

The fundamental event in fibrosis is the transformation of hepatic stellate cells into myofibroblasts and this is closely related to autophagy. Typical autophagosomes that contained LDs were found in cultured HSCs indicating a connection of liver fibrosis and lipid autophagy[428]. Increasing evidence supports the notion that inhibition of lipophagy in hepatocytes reduces HSC activation and fibrosis progression[429,430]. Inhibition of the activation of HSCs and the formation of autophagosomes have been reported and these seem to be connected with the downregulation of transforming growth factor beta 1/Smads pathway as an increase in TGFb/Smad3 Leads the transcription of Beclin-1, which is a critical player in the autophagy process[431-433].

In rat-derived HSCs, cytoplasmic LDs are degraded followed by fibrogenic genes expression. Moreover induced lipid accumulation by an alkaloid, was associated with quiescent HSCs due to autophagy blockade[434].Inhibition of autophagy by chloroquine improved CCl4-induced liver fibrosis affecting the activation of hepatic stellate cells as expected[435]. On the other hand, dihydroceramide an inhibitor of autophagy promoted the progression of liver steatosis to fibrosis[436]. Similarly, inhibition of YAP degradation also led to liver fibrosis[113].

In addition, it has been suggested that the IL-17A/STAT3 signaling pathway is important in the evolution of liver fibrosis through suppression of hepatocellular autophagy since neutralization of IL-17A promotes the resolution of experimental fibrosis[437].

Based therefore on current evidence, it has been stated that autophagy at least in murine hepatocytes is a selective survival mechanism through clearance of excessive fat leading to attenuation of lipotoxicity[438]. This is certainly not the case for HSCs autophagy where lipid droplets are digested to supply energy for the activation of HSCs, promoting thus liver fibrosis. Non specific inhibition of stellate cell autophagy or specific inhibition of Atg5 or Atg7, blocked HSCs activation[439-441]. Lipophagy in HSCs is induced by ER stress[442] and is mediated through Rab25 in a ROS dependent manner as antioxidants were effective in stopping autophagy[87]. In agreement with experimental data, clinical research found that cirrhotic patients had significantly increased levels of several autophagy- related genes compared with non cirrhotics accompanied by increased maturation of lysosomal cathepsin D[85]. Furthermore, serum lipids were evaluated in patients with cirrhosis of viral etiology and compared to non cirrhotics. Low serum lipids were found in HCV and HBV cirrhosis which were negatively correlated with lipophagy[443].

Micro-RNAs interfere with the activation of stellate cells. miR-16 inhibits the expression of guanine nucleotide-binding -subunit 12 (G12) which is overexpressed during fibrogenesis and facilitates Atg12-5 formation, thus activating stellate cells[444]. Also miR-181-5p transferred to mouse HSCs *via* exosomes from engineered adipose derived stem cells led to inhibition of fibrosis[445].

Several signals can induce autophagy in HSCs[180], including hypoxia-inducible factor-1alpha[446], transforming growth factor 1[447], as well as the danger-associated pattern molecule high-mobility group box-1 (HMGB-1)[448]. Additional signals like ROS-JNK1/2 and the XBP1 arm of the Unfolded Protein Response have also been identified as necessary requirements of HSCs activation through autophagy[449,450]. TGF-β1 has also been reported to mediate autophagy[440]. Similarly, HSCs in cell culture with depleted Atg2A fail to spontaneously trans-differentiate[451]. Quercetin attenuated hepatic fibrosis in mice through inhibition of hepatic HSC activation and autophagy[452].

Selective activation of mitophagy in HSCs also favors fibrosis. PM2.5 is an air pollutant that activates HSCs and initiates liver fibrosis. This is due to increased ROS production and induction of mitophagy through activation of the Pink1/Parkin pathway[453]. In contrast, inhibition of mitophagy was shown to promote inflammation[454] due to dissemination of inflammatory signals from HSCs production of inflammatory cytokines[455]. However very recently it was reported that selective inhibition of mitophagy in macrophages attenuates fibrosis. Mice Kupffer cells from CCL4-induced acute injury showed increased ROS production, activated mitophagy and increased TGF-β1 secretion. T-cell immunoglobulin domain and mucin domain-4 (TIM-4) interference in Kupffer cells inhibited Akt1-mediated ROS production and decreased mitophagy and TGF-β1 secretion through suppression of PINK1/Parkin, to ameliorate CCl4-induced hepatic fibrosis[456]. Seemingly in disagreement with this notion, is the finding that the autophagic proteinp62/SQSTM1, a negative controller of HSC activation is downregulated in trans-differentiating HSCs associated with hepatocellular carcinoma. P62 ablation increases fibrogenesis but this is not related to autophagy but rather to the reduction of p62-dependent activation of the vitamin D receptor (VDR) and the resultant loss of repression of HSC by VDR agonists[457,458].

Even in HSCs the characterization of autophagy as a double-edged sword has been justified. A novel molecular mechanism of selective autophagy in HSCs indicates that autophagy may also protect from liver fibrosis. The RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. ELAV1 enhances ferritinophagy leading to ferroptosis of HSCs and attenuation of liver fibrosis[459]. Despite this report, most existing evidence indicate that activation of HSCs autophagy is pro-fibrogenic, therefore a selective block of autophagy in fibrogenic cells might be an attractive future anti-fibrotic therapy[90].

The opposite seems to happen in hepatic macrophages[55] where activation of autophagy is anti-fibrogenic[460]. Mice macrophages with specific deletion of atg5, secreted increased levels of ROS-induced IL-1A and IL-1B. In addition, liver myofibroblasts incubated with the conditioned medium of Atg5(-/-) macrophages expressed increased pro-fibrogenic genes. Attenuation of fibrosis was achieved after IL-1 neutralization indicating that IL1A/B are critical mediators of the profibrotic effects of autophagy inhibition in macrophages[461-463]. Autophagy in Kupffer cells is counteracted by the enzyme monoacylglycerol lipase catalyzing the production of arachidonic acid leading to inflammatory macrophage activation and fibrosis[464].

On the other hand deletion of Atg7 in sinusoidal endothelial cells (LSECs) demonstrated that the selective loss of their autophagy led to cellular dysfunction and decreased intrahepatic nitric oxide. Impairment of autophagy after CCL4-induced acute liver injury in rats, also impaired handling of oxidative stress by LSECs and amplified liver fibrosis[465].

Similarly, autophagy defective sinusoidal endothelial cells (LSECs) as demonstrated in patients with NASH favor advancement of fibrosis[282]. At the same time, even excessive autophagy activation may lead to caveolin-1 degradation, thus worsening the LSECs defenestration and ultimately promoting fibrosis[466]. Therefore, any dysregulation of autophagy in LSECs may aggravate liver fibrosis[467].

An elegant immunofluorescence study of cirrhotic livers linked autophagy with an additional population of fibrogenic cells other than HSCs, the reactive ductular cells (RDC) which were characterized as cholangiocyte-like epithelial cells positive for cytokeratin 19[85]. They are responsible for ductular reaction (DR), a common response to various insults of the liver implicated in the pathogenesis of cirrhosis[432]. Administration of chloroquine, reduced the expression of CK19 positive RDC and blunted liver fibrosis[86]. DR parallels HSC activation in many liver diseases[430]. Reactive ductular cells secrete soluble pro-fibrogenic factors targeting HSCs and myofibroblasts[468]. Recently it was demonstrated that in cirrhotic human livers, RDCs with activated autophagy also had upregulated expression of TGF and fibroblast specific protein-1[469] making autophagy a necessary requirement during the DR process. The role of autophagy in liver fibrosis is therefore complex and the end result depends on the cell population involved. In general, HSCs and RDCs have a pro-fibrogenic effect. On the contrary, autophagy counteracts fibrogenesis acting in hepatocytes, macrophages and LSECs[470].

**HCC**

The role of autophagy in tumor cell biology has not been fully elucidated. Autophagy has both pro-and anti-tumorigenic roles. For example, it can either inhibit inflammation acting as an anti-oncogen or protect tumor cells from ROS damage acting as a pro-oncogen[471,472].

Opposing effects have been reported. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis[473]. On the other hand, Ras-induced expression of two proteins Noxa and Beclin-1 promotes autophagic cell death, limiting thus the oncogenic potential of deregulated Ras signals[474]. Drugs like ursodexocycholic acid can efficiently eliminate resistant to other drugs cancer cells through induction of autophagic death[475].

HCC is one of the most common types of liver cancer[476]. Most of the HCC cases are accompanied by cirrhosis that results from long-standing chronic inflammation due to viral hepatitis or non-viral etiologies including heavy alcohol intake, NAFLD, autoimmune hepatitis, primary biliary cholangitis, and hemochromatosis[477].

Mice with impaired autophagy are unable to develop HCC even after of strong challenge. This was related to the induction of tumor suppressors like p53[478]. However, after initiation of HCC, the presence of autophagy is required to degrade tumor suppressors promoting thus the development of HCC[86]. Both macroautophagy and CMA are implicated as a double edge sword in liver tumorigenesis[479].

Autophagy has a dual role in hepatocellular carcinoma (HCC). It is an anti-cancer mechanism in the dysplastic stage of HCC initiation, while it favors HCC development and confers resistance to treatment[480,481]. This is possibly due to the maintenance of mitochondrial integrity and protection of cells against oxidative stress during HCC initiation, followed by the downregulation of tumor suppressors to promote the development of HCC[86,482].

In a study of 156 HCC patients increased levels of the autophagy marker LC3B are associated with a dismal prognosis[483]. Higher levels of LC3-II were associated with lymph nodes metastasis, higher vascular invasion and reduced 5-year survival[484].

Macroautophagy may also have an anti-oncogenic function, as reduction of either Atg5 or Atg7 Levels lead to appearance of multiple liver tumors[485]. Similarly, low levels of autophagic proteins and activity are associated with bad prognosis of human HCC[486,487]. Beclin-1 Levels are lower in HCC tissue samples compared to normal tissue from the same patient. Beclin-1 expression was studied in 300 HCC patients. A correlation with disease-free survival and overall survival was found only in the Bcl-xL+ve patients. It was suggested therefore that a synergy of defective autophagy and altered apoptotic activity lead to tumor progression and reduced survival[488].

Inhibition of autophagy leads to the accumulation of SQTSM1/p62. Accumulation of p62 on the one hand may protect from HCC initiation as it blocks the antioxidant functions of nuclear factor erythroid-2- related factor 2 (Nrf2)[489-492]. On the other hand, accumulation of p62 also contributes to carcinogenesis through persistent activation of Nrf2[493]. Nrf2 expression promotes the development of HCC[493]. Deletion of p62 in autophagy defective livers counteracts tumorigenesis. Therefore an accumulation of p62 is partly responsible for the increase in hepatic tumors, *via* the activation of Nrf2[492-494]. The activation of Nrf2 turns glucose and glutamine into anabolic pathways supporting tumor cell proliferation[176,495]. In addition, autophagy inhibits malignant transformation in the liver through Yes associated protein 1 (YAP1) degradation, a protein with a crucial role in hepatic oncogenesis[113,496].

Aberrant activation of the Wnt/β-catenin signaling is another critical pathway in the onset and development of HCC. A recent study reported that the Wnt/β-catenin inhibitors exert anti-tumor effects on HCC cells by regulating autophagy[497]. However this is in disagreement with a previous report where interfering with Wnt secretion in HCC cell lines does not affect autophagy or the level of β-catenin signaling despite cell growth suppression indicating that other mechanisms might underlie the growth-suppressive effect[498].

Furthermore, the activation of autophagy was shown to mediate inhibition of proliferation and induction of apoptosis of hepatoma cell through several mechanisms[499-506]. The induction of autophagy by concanavalin A or different chemotherapeutic drugs in murine livers inhibit hepatoma cell growth and prolongs survival[507-519]. On the other hand suppression of autophagy was reported to enhance the susceptibility of hepatocellular cancer cells towards a variety of chemotherapeutic agents[108,520-529].

Several microRNAs (mirRNAs) have been implicated in HCC tumorigenesis. miR-204 reduces tumor autophagy in HCC[530]. Moreover autophagy degradation of miRNA-224 suppressed the growth of HBV-related HCC[371], while miR-375 which is downregulated in HCC was reported to inhibit autophagy by decreasing the expression of Atg7 and autophagic flux. Up-regulation of miR-375 inhibits mitophagy of HCC cells, reduces the elimination of damaged mitochondria, and decreases cell viability[99]. miR-26 could inhibit autophagy and enhance chemosensitivity of HCC cells[531].

LncRNAs are another set of ncRNAs with a length exceeding 200 nucleotides without translation into proteins[109]. Several lncRNAs, like Hnf1a-as1, Hotair and Hulc promote autophagy and function as oncogenes in HCC[106-109].

The role of mitophagy and lipophagy is also important in HCC growth acting as a double edge sword. Increased mitophagy by concanavalin A, adriamycin or curcumin was shown to suppress hepatoma cell growth[507,510,517,530] while melatonin increased the sensitivity of human hepatoma cells to sorafenib by triggering mitophagy[532]. A recent study also demonstrated that inhibition of inflammasome activation and induction of mitophagy suppressed HCC growth[533]. On the other hand it has been demonstrated that increased mitophagy may facilitate HCC cell survival either through ROS production or attenuation of p53 activity[534,535].

Lipophagy can also act both ways. On the one hand, it can allow tumor cells to have access to a supply of energy critical to their growth[536] and on the other hand, lysosomal acid lipase, the lipase that facilitates lipophagy, exhibits tumor suppressor activity[537]. Lipophagy was also reported to induce apoptosis *in vitro*, *via* induction of ER and mitochondrial stress[538]. CCAAT enhancer binding protein a, a protein that is upregulated in HCC patients, increases resistance to energy starvation and favors carcinogenesis through lipophagy[539].

In addition to the general characteristics of autophagy implication in HCC, there are certain points to be mentioned in specific liver disease associated HCC. As mentioned before, autophagy is activated by the HBx protein[357,369] and this may be related to HBV carcinogenesis. Increased autophagosome formation by HBx was accompanied by decreased degradation of LC3 and SQSTM1/p62 and greatly impaired lysosomal acidification and accumulation of immature Cathepsin D. These data may indicate that repression of lysosomal function by HBx could be important for the initiation and progress of HBV-associated HCC[350].

CMA and cancer metabolism are also interconnected. Once malignant transformation occurs, CMA activity is significantly increased in cancer cells so that the new metabolic requirements are maintained[64]. Blockade of CMA which is upregulated in several cancers reduces progression and metastatic potential of solid tumors because the characteristic increased rates of aerobic glycolysis are reduced in a p53-dependent manner[540]. Macroautophagy and CMA seems to be interconnected and often substitute for one another as in the case of HCC. Under physiological conditions there is no expression of p62 in normal livers pointing to macroautophagy as the main mechanism facilitating cell survival. However in a recent study of 46 cirrhotic livers it was shown that p62 was increased indicating an impairment of macroautophagy, but LAMP-2A and heat shock protein 70 were uniformly increased indicating that an upregulated CMA was trying to compensate for the reduced macroautophagy and therefore promote HCC survival. Moreover, hydroxychloroquine inhibition of lysosomal degradation led to induction of the tumor suppressor p53 and promotion of apoptosis[541]. HCV is also an inducer of HCC. During HCV infection, increased cellular stress has been reported. Severe stress promotes Nrf2 transcription which in turn is responsible for CMA activation resulting in the suppression of hepatic innate immunity and possible degradation of tumor suppressors. The subsequent oncogenic cell programming initiated by a cytoplasmic virus like HCV, has been recently described in detail[542].

Defective autophagy is linked to MAFLD-related HCC, because the accumulated p62/SQSTM1, induces the oncogenic NF-κB activity while retained damaged mitochondria and produced ROS to damage cellular DNA[543]. A novel mechanism was recently reported in ethanol induced liver disease and HCC. Tumor necrosis factor-α-induced protein 8 (TNFAIP8) has been associated with tumor progression in several cancer types including the initiation of HCC. TNFAIP8 induced autophagy in liver cancer cells through blocking of AKT/mTOR signaling and direct interaction with ATtg3-Atg7 proteins. This mechanism is operative in alcohol related liver disease in mice and humans but not in high-fat-fed obese mice or patients with MAFLD[544]. Details of the molecular mechanisms of autophagy in both protection and promotion of HCC were recently published[545-547].

An additional aspect of HCC biology where autophagy plays an important role is the involvement of tumor-associated macrophages and tumor microenvironment. They are polarized after implication of sensing factors from tumor environment and autophagy[130,548]. Deficiency of TLR2 decreased the liver production of TNFα, IFN gamma and IL1a/b accompanied by reduction of autophagy flux and increase in oxidative stress and p62 aggregates in liver tissue. These changes were associated with increased carcinogenesis and progression of HCC[549]. Enhancement of autophagy in tumor-associated macrophages leads to M1 polarization which reduces tumor progression while M2 polarization is permissive for tumorigenesis[550]. The mTOR-TSC2 pathway, a key negative regulator of autophagy, is crucial for macrophage polarization since its activation leads to M2 phenotype. It was recently shown that the coagulants tissue factor (TF) and factor VII (FVII) produced in tumor microenvironment, are implicated in HCC growth promotion by suppression of autophagy mediated through mTOR activation and Atg7[551].

In view of the variable functions of autophagy, there should be an individualized approach of autophagy manipulations for HCC treatment. Thus, various lysosomal inhibitors including chloroquine and hydroxychloroquine have been used as treatment either as sole agents or in combinations with other treatment modalities in a variety of murine HCC models[523,552,553]. Interference with autophagy may be a sound therapeutic option for the treatment of HCC[554,555]. Based on the fact that autophagy is upregulated in metastatic HCC[556] use of autophagy inhibitors like chloroquine and hydrochloroquine in combination with other drugs may be a better option for treating metastatic HCC in humans. A combination of a number of drugs with autophagy inducers have been used to target cancer cells. A combination of percutaneous transarterial chemoembolization with chloroquine, was associated with increased tumor cell necrosis and apoptosis[557] and might counteract the presence of residual hepatocellular carcinoma cells[558,559]. Sorafenib, a multikinase inhibitor approved for HCC treatment, induces autophagy[560] and data show that a combination with autophagy inhibitors increase tumor response[537,561].

***Cholangiocarcinoma***

Xenografts in nude mice are widely used models of cholangiocarcinoma (CCA). Activated autophagy has been reported in tumor cells from such a model and in specimens from CCA patients[562]. LC3B, Beclin 1, and p62/SQSTM1 expressions were additionally found to be increased at the initial stage of the multistep cholangiocarcinogenesis[563]. However, a lower Beclin 1 expression was associated with metastatic lymph node disease and poor survival of patients with intrahepatic CCA[564,565]. Apoptosis was induced in cholangiocellular cell lines and tumor development was suppressed in a mice xenograft model after interference with autophagy[562]. Similarly, suppression of autophagy by chloroquine increased the chemosensitivity of cisplatin-treated CCA cells[566] and increased apoptosis of CCA cells through ER stress[567]. Chloroquine blockade of autophagy inhibited the tumor growth in Kras/p53 intrahepatic CCA[568,569]. CCA is extremely resistant to chemotherapy. 5-fluorouracil (5-FU) induced autophagy in CCA cells[570] while autophagy inhibition by capsaicin was followed by repression of malignant cell growth[570], indicating that autophagy may be implicated in the multidrug resistance of this tumor. Autophagy was also induced after incubation of CCA cells with the sphingosine kinase 2 inhibitor, ABC294640. Inhibition of autophagy by chloroquine potentiated ABC294640-induced apoptosis[571]. Modulation of autophagy therefore may be helpful in CCA treatment.

**INHERITED METABOLIC DISEASES**

***A1 antitrypsin deficiency and fibrinogen storage disease***

Autophagy is also implicated in other types of liver injury like the inherited metabolic diseases. Alpha 1-antitrypsin deficiency is the most extensively studied. Alpha 1-AT is a glycoprotein inhibitor of destructive neutrophil proteases[572,573]. Several naturally occurring mutants of alpha1-AT, have been shown to participate in the pathogenesis of human diseases, such as chronic liver-associated diseases[574-576]. The Z mutation resulting from a single G->A transition in codon 342, generates a mutant protein that forms aggregates in the hepatocytes[577]. Liver injury is caused by the retention of this polymerized mutant alpha1-ATZ molecule in the ER of hepatocytes followed by an induction of autophagic response. Removal of the insoluble alpha-1 anti-trypsin by the autophagosome is the mechanism by which the activation of autophagy protects the liver in alpha1-antitrypsin deficiency[578-581]. In earlier studies, liver injury was associated with mitophagy indicating that the ER retention of alpha(1)-ATZ led to involvement of the mitochondria, with specific patterns of mitochondrial dysfunction and mitochondrial injury[582,583].

Genetic studies in mice have shown that deletion of Atg5 led to an increased retention of alpha 1-ATZ[584] and that deficiency of Atg6 and Atg14 in yeasts inhibited alpha1-ATZ degradation[585]. Similarly, the induction of autophagy in mice by rapamycin reduced liver alpha1-ATZ aggregation and liver injury[582,586-589]. These findings have been repeated and verified when enhancement of autophagy[590] with either carbamazepine[591], gene transfer of the autophagy regulator TFEB[592] or an analog of glibenclamide[593] reduced the toxic protein. Recent preclinical studies have also demonstrated that an exogenous bile acid like norursodeoxycholicacid may be clinically useful in this condition[594,595].

Fibrinogen storage disease is a very rare autosomal-dominant ER storage disease presented with hypofibrinogenemia, elevated transaminases, accumulation of fibrinogen aggregates in the ER of hepatocytes and several fold increase of autophagocytic vacuoles. Some patients progress to cirrhosis similar to alpha-1-AT deficiency. A clinical study of eight patients has showed that administration of carbamazepine at low anticonvulsive dosage led to rapid normalization of alanine-aminotransferase indicating a critical role of autophagy in this disease[596].

***Wilson’s disease***

Wilson disease is an inherited disease of copper metabolism linked to hundreds of mutations in the ATP7B gene[597]. Recent evidence based on studies from hepatocytes of patients and ATP7b deleted mice has shown the presence of an increased number of autophagosomes, indicating the activation of an autophagic response to prevent copper associated cell death[598]. Moreover, inhibition of autophagy accelerated hepatocyte death whereas increased autophagy by either starvation or TFEB overexpression had a cytoprotective effects[598]. Autophagy therefore seems to be a major protective mechanism for hepatocytes in copper accumulation. These findings may lead to the use of autophagy inducers like carbamazepine as a future potential treatment of Wilson’s disease.

***Glycogen storage disease***

Glycogen storage disease type 1a (GSD1a) is an inherited hepatic disease associated with decreased autophagic flux as a consequence of defects in the glucose-6-phosphatase a, that converts glucose-6-phosphate into glucose. These abnormalities lead to glycogen and lipid accumulation in hepatocytes[599]. GSD1a is associated with the down regulation of several components of the autophagy machinery[600].

GSD1a has also been associated with defective sirtuin 1 (SIRT1) signaling leading to impairment of TFEB activity. As in other storage diseases, pharmacological or genetic activation of autophagy reduces the accumulation of glycogen and lipids in cellular and animal models[601].

**VARIOUS DISEASES**

Autophagy in the liver is implicated in other diseases as well. An important point that should always be remembered is that the liver is the site of almost 80% of body macrophages and therefore innate immunity can be deeply involved in liver and other organ abnormalities through impaired autophagy of Kupffer cells. Sepsis is the main paradigm of this notion.

***Sepsis and liver autophagy***

Infection can lead to a systemic multi-organ inflammatory response. Macrophages, play a critical role as they are the most important cells of the innate immunity. Autophagy induction is protective in sepsis through regulation of macrophage polarization. Negative regulation of macrophage activation inhibits inflammasome activation[602]. Autophagy also interferes with macrophage apoptosis. Uncontrolled autophagy however may lead to autophagy death of macrophages with additional aggravation of inflammation and the so called cytokine storm[603].A current example is possibly the SARS-Cov-2 pandemic[604]. Interestingly, autophagy-deficient macrophages after LPS stimulation over-secrete macrophage migration inhibitory factor and aggravate inflammation[605]. Other mechanisms are also involved including signaling pathways such as NF-κB, mTOR, and PI3K/AKT[603].

Mitophagy and mitochondrial dysfunction seem to be also a fundamental factor in multiple organ failure caused by sepsis[606]. It has been shown that mtDNA liberated from damaged mitochondria, induces a cascade of inflammatory responses[607-609]. Mitophagy therefore is of great importance for the protection against oxidative stress during sepsis. It should be noted however that mitophagy defects in the liver, are not the only cause of organ or cell damage during sepsis[610]. Nonetheless, the liver is the main organ responsible for sepsis-induced damage[611]. Autophagy is an important protective mechanism in septic liver injury. Increased autophagy can play a protective role in liver function in septic conditions where the activation of autophagy is mediated through activating transcription factor 4 (ATF4). ATF4 is inhibited 48 h after LPS-induced acute liver injury and reversed after obeticholic acid treatment[612]. Autophagy inhibitors or AMPK inhibitors administration reduced the protective mitochondrial function in LPS-induced human hepatocyte injury[613,614]. Mitophagy is also involved in apoptosis of CD4+ve T cells which is the main mechanism of immune inhibition during sepsis. Mitofusin 2 (Mfn2) is a mitochondrial outer membrane protein and a negative regulator of autophagy which is increased in sepsis leading to inhibition of autophagy and increase in apoptosis of CD4ve+ T cells[615]. Autophagy defects can affect antigen presentation by T cells leading to immunosuppression as in the case of Atg5 deficiency[616]. The role of autophagy in sepsis has been recently reviewed[617].

***Acetaminophen liver damage***

Autophagy is also implicated in acetaminophen induced liver disease. There is evidence that increased autophagy is protective against acetaminophen (APAP)-induced liver damage[618,619].Pathogenetically, APAP was reported to form APAP-protein adducts in hepatocytes of mice and humans[620]. Adducts localized in mitochondria contribute to APAP-induced mitochondrial dysfunction and subsequent oxidant stress[621,622]. Therefore, it is plausible that removal of APAP-adducts will help to ameliorate APAP-induced mitochondrial damage and maintain hepatocyte integrity[41,623,624]. Experimental evidence indicates that autophagy is mostly responsible for the removal of APAP-adducts[625]. Moreover administration of adiponectin was found to attenuate APAP-induced injury activating AMPK mediated autophagy[626]. Activation of autophagy by rapamycin also attenuates APAP-induced liver injury, whereas inhibition of autophagy by chloroquine or deletion of Atg7 in hepatocytes deteriorates liver damage[153,627]. There is also evidence that autophagy is activated after APAP overdose in specific liver zones[53].

Somewhat different results were recently presented. Unc-51-like autophagy activating kinase 1 and 2 (Ulk1/2) are important autophagy initiation regulators. Unexpectedly, Ulk1/2 double knockout mice have normal autophagic activity after fasting, but are exceptionally resistant to APAP-induced liver injury possibly indicating that autophagy-dependent and independent ULK1/2 pathways have opposing effects in APAP-induced liver injury[628].

Reduction of ROS and repression of apoptosis by autophagy is also essential for hepatic regeneration after APAP-induced acute liver failure[520,627]. A very recent report confirmed that increased autophagy by rapamycin protects mice against APAP hepatotoxicity while chloroquine enhanced liver injury. Importantly it was demonstrated that APAP overdose activated PINK1/Parkin-mediated mitophagy and increased the expression of NF-kB and NLRP3 inflammasome signaling. These findings were reversed by rapamycin and augmented by chloroquine indicating the critical role of mitophagy in APAP hepatotoxicity[629].

Interestingly it was reported that infusion of human amniotic mesenchymal stromal cells ameliorated the APAP liver injury through promotion of Kupffer cell M2 polarization and reduction of Kupffer cell autophagy. These results suggest that Kupffer cell autophagy has an opposite effect on APAP hepatotoxicity compared to hepatocytes. This last observation may be useful for future therapeutic exploitation[630].

***Acute liver failure***

Acute liver failure (ALF) is a serious syndrome of different etiologies with high mortality[631]. HSCs implication is significant in ALF. Temporarily increased fibrosis in ALF is probably beneficial serving as scaffolding that maintains regenerating hepatocytes and hepatic integrity[437,632,633]. Data from a murine APAP induced ALF model have demonstrated that mortality was significantly increased in HSCs depleted animals[633]. HSCs cannot usually regenerate during ALF due to the submassive necrosis. Autophagy seems to be implicated[634]. The significance of HSCs survival has been verified in a study of patients with HBV induced acute liver failure. ALF was accompanied by fibrosis and HSCs activation and autophagy induction. It was shown for the first time that the High Mobility Group Box 1 (HMGB1) protein is a powerful inducer of autophagy responsible for HSCs survival[635].

As mentioned before, autophagy is crucial for HSCs activation which in turn maintains the liver architecture thus preventing the liver scaffold collapse during ALF.

Nitric oxide induces HSCs apoptosis through generation of ROS[636]. There is evidence however that nitric oxide is also involved in the regulation of autophagy in ALF. Observations in human liver tissue showed an inhibition of autophagy in HSCs while further *in vitro* experiments demonstrated that nitric oxide inhibited autophagy and increased apoptosis of HSCs. These findings were reproduced by chloroquine and reversed by the autophagy inducer rapamycin. Therefore, nitric oxide impairment of HSCs survival may be a decisive factor for the devastating effects of ALF[637].

An additional clinical and experimental study verified the significance of intact mitophagy in ALF. One of the measurements of oxidative stress is the level of superoxide dismutase (SOD). The serum superoxide dismutase was significantly increased in ALF patients, correlating with the MELD-Na score. SOD levels returned to normal in the remission stage of ALF. In liver tissue from ALF patients and mice models, manganese-dependent SOD was overexpressed and mitophagy in HSCs was inhibited by ROS. Inhibition of mitophagy promoted inflammation in HSCs which was reversed by a mitophagy inducer[454].

***Acute liver damage***

Autophagy also protects hepatocytes from acute liver injury, a characteristic of viral hepatitis and acute alcoholic and non-alcoholic steatohepatitis. Mechanisms and cells involved are different as both direct and indirect effects on hepatocytes and macrophages are implicated. Direct effects include autophagy dependent inhibition of caspase 8 in hepatocytes[638], while indirect effects on macrophages involve limitation of NF-kB-mediated inflammation and inflammasome-dependent IL-1b production through p62-dependent mitophagy[462,639]. Reduced macrophage autophagy can induce pro-inflammatory macrophage polarization and increase the immune mediated acute damage in obese mice[131]. The TAM family of RTKs (receptor tyrosine kinases), which is expressed in macrophages, has been reported to alleviate inflammation. AXL is the only member of the TAM family that induces autophagy in macrophages and ameliorates hepatic inflammatory responses inhibiting the NLRP3 inflammasome activation in murine macrophages[640].

The role of Kupffer cells (Kcs) is significant in the pathogenesis of acute liver injury. In a murine model of thioacetamide induced acute liver injury it was shown that hyperglycemia aggravated the liver lesions activating the NLRP3 inflammasome of Kupffer cells *via* inhibition of AMPK/mTOR-mediated autophagy. Interestingly, AMPK activation or mTOR signaling deletion restored autophagy and subsequently inhibited inflammasome activation in Kupffer cells[641]. Spermine is an anti-oxidative polyamine with autophagy induction properties. In a model of acute liver injury, spermine pre-treatment ameliorated liver injury and intrahepatic inflammation by promoting M2 polarization of Kupffer cells.

Furthermore, spermine increased autophagy in KCs. Deletion of Atg5 in spermine treated KCs greatly increased pro-inflammatory cytokines and reduced the anti-inflammatory cytokine IL-10[642].

LSECs are also involved in acute liver injury. Selective impairment of autophagy in liver endothelial cells increases oxidative stress, thus leading to fibrosis in acute injury[465].

***Ischemia/reperfusion injury***

The central role of autophagy in ischemia/reperfusion injury (I/R) injury has been verified by the fact that pharmacological or genetic stimulation of autophagy ameliorate the liver reperfusion injury[643-645].

I/R impairs hepatocellular autophagy[646] through I/R-induced ATP depletion leading to energy shortage and malfunction of the autophagic machinery. Moreover Ca2+ overloading during I/R results in calpain overproduction and ultimate loss of key autophagy proteins like Atg7. Interestingly the autophagy suppressor chloroquine attenuated liver injury when administered in early phases of I/R but aggravated the lesions, as expected, when given in late phases[647].

***Hepatic encephalopathy***

Ammonia is an important mediator of hepatic encephalopathy. Increased ammonia levels rapidly induce an autophagic response that preferentially targets mitophagy[648-650]. Ammonia induced autophagy may in fact be a protective mechanism against encephalopathy as suggested by a recent report. Deletion of Atg7 or loss of functional TFEB deteriorated ammonia detoxification in mice. By contrast activation of liver autophagy either by rapamycin administration or genetic TFEB expression reduced ammonia levels in acquired hyperammonaemia[651].

***Autoimmune hepatitis***

The role of autophagy in autoimmune hepatitis (AIH) has not been adequately studied. It is suggested that autophagy is implicated in AIH through its involvement in antigen processing and presentation to T cells[652] and its well proven role in liver fibrosis[653], but the exact pathways have not been delineated.

Concanavalin A-induced hepatitis is an extensively used model for immune-mediated liver injury. Comparative proteomic results in this model have shown that the activation of immune system resulted in hepatitis with deregulation of autophagy as indicated by an increase in p62 and LC3B. Arctigenin is a biologically active lignan with antioxidant and anti-inflammatory properties. Pretreatment with arctigenin alleviated autophagy as well as apoptosis verifying that immunity and autophagy are interconnected in AIH pathogenesis[654].

A group of researchers recently used the same model of concanavalin (conA) induced experimental hepatitis to clarify the role of autophagy in AIH. Methyl prednisolone (MP) treatment significantly decreased inflammation in the liver and activated the Akt/mTOR pathway to inhibit hepatocyte apoptosis and autophagy. Reduced numbers of autophagosomes were present in the MP treated group compared to the conA group. It was further shown that MP attenuated the mitochondria-mediated autophagy and apoptosis[655]. In a second report on the same experimental model, accumulation of mature conventional dendritic cells (cDCs) was observed in the liver. *In vitro*, ConA treatment induced the expression of autophagy proteins and the formation of autophagosomes in dendritic cells. A further blockade of autophagy flux inhibited the maturation of DCs and the proliferation and differentiation of CD4+ T cells when ConA-induced DCs were co-cultured with CD4+ T cells. Taken together these studies elegantly showed that autophagy is critically implicated in AIH and aberrant autophagy and defective maturation of cDCs are involved in AIH immunopathogenesis[656].

A recent clinical study using immunohistochemistry in liver biopsy samples from chronic HCV and AIH patients confirmed the central role of autophagy in AIH. Activated but impaired autophagy and less efficient elimination of damaged mitochondria were demonstrated in AIH as compared with HCV. Increased p62 levels significantly correlated with necroinflammation in AIH[657].

***Biliary disease***

The mechanisms of liver damage in cholestasis are incompletely understood. Autophagy and protein degradation were shown to be impaired in cholestasis induced in bile duct ligated mice[658-660]. Moreover, defective autophagy after chloroquine inhibition or deletion of Atg7 and Atg5 led to increased cholestatic liver injury[661,662].

Accumulated toxic bile acids lead to ER stress, mitochondrial dysfunction with increased oxidative stress, inflammasome activation and apoptosis leading to liver fibrosis[663]. These events should in fact activate autophagy in cholestasis but instead, at least in mice, it appears that autophagy is inhibited in cholestasis[664,665]. Bile acids can inhibit autophagy in mice either *via* the farnesoid X receptor (FXR) during the feeding-fasting cycle[114,115] or independently of FXR[666]. How autophagy is affected in human cholestasis is under investigation.

In human disease autophagy was initially associated with the pathogenesis of primary biliary cholangitis (PBC)[667-669]. As mentioned before autophagy is also involved in the processing and presentation of various antigens. It is only logical therefore that an interesting hypothesis implicating deregulated cholangiocyte autophagy connected to cholangiocyte senescence has been proposed to explain not only the pathogenesis of PBC but of the other fibrosing cholangiopathies including primary sclerosing cholangitis (PSC) and biliary atresia as well[670].

An upregulation of autophagy was reported along with senescence in PBC[668,671]. LC3B and p62 proteins were accumulated in damaged bile ductular cells in association with senescence markers[68,125] suggesting that autophagy could induce and facilitate cholangiocyte senescence[664,665,671-674]. Mitophagy may be specifically involved in PBC as granular expression of the mitochondrial protein PDC-E2 was co-localized with LC3[667].

Autophagy has also been implicated in the treatment of PBC. Ursodeoxycholic acid (UDCA) is still the first line treatment of PBC while obeticholic acid (OCA) is a second-line treatment[675-677]. Hydrophobic bile acids, such as glycochenodeoxycholic acid impair autophagy *in vitro* and induce abnormal expression of mitochondrial antigens and cellular senescence in cholangiocytes, possibly through induction of ER stress. Pretreatment with UDCA reduced ER stress and partially restored deregulated autophagy and cellular senescence[678]. It is not clear how UDCA stimulates autophagy. UDCA has been reported to be an FXR antagonist[679] but this may not be the explanation[680]. On the contrary, OCA is a semi-synthetic FXR agonist with anti-cholestatic functions including the suppression of endogenous bile acid synthesis and interference with hepatocellular bile acid transporter systems[681]. OCA impairs autophagic flux *in vitro* and also *in vivo*. A favorable effect of treatment with OCA in a cholestatic disease like PBC would be incompatible with data, indicating that cholestasis progresses when autophagy is blocked[661,662]. However, the other potent, anti-cholestatic properties of OCA can overcome the negative effects of reduced autophagy.

A recent paper offers an interesting explanation. Autophagy seems to be also impaired in human cholestatic conditions where accumulated bile acids induce Rubicon in an FXR-dependent fashion. Rubicon induction suppresses autophagosome-lysosome fusion and inhibits proper autophagolytic breakdown. Rubicon was also induced after treatment with the FXR agonist OCA. Genetic inhibition of Rubicon reversed the impairment of autophagic flux. In contrast, UDCA reduced Rubicon levels, enhanced autophagic flux and autophagolysosome formation independently of FXR [680].

An overview of autophagy abnormalities is presented in Table 1.

**CONCLUSION**

Autophagy is an important process through which intracellular parts are degraded in the lysosomes. It is a fine example of effective cellular recycling mechanism, connecting cellular quality control with energy saves. There are three types of autophagy with various pathways of delivery to the lysosomes: macroautophagy (which is further divided into non selective autophagy and selective macroautophagy targeting special organelles or specific compounds for degradation), microautophagy and chaperon-mediated autophagy. Autophagy is related to major physiologic processes as cell death, inflammation and immunity. It is increasingly recognized that it is implicated in almost every aspect of liver diseases, and this can be the basis for future pathophysiologically based and targeted management.

**REFERENCES**

1 **Choi AM**, Ryter SW, Levine B. Autophagy in human health and disease. *N Engl J Med* 2013; **368**: 651-662 [PMID: 23406030 DOI: 10.1056/NEJMra1205406]

2 **Levine B**, Kroemer G. Biological Functions of Autophagy Genes: A Disease Perspective. *Cell* 2019; **176**: 11-42 [PMID: 30633901 DOI: 10.1016/j.cell.2018.09.048]

3 **Schworer CM**, Shiffer KA, Mortimore GE. Quantitative relationship between autophagy and proteolysis during graded amino acid deprivation in perfused rat liver. *J Biol Chem* 1981; **256**: 7652-7658 [PMID: 7019210]

4 **Mortimore GE**, Hutson NJ, Surmacz CA. Quantitative correlation between proteolysis and macro- and microautophagy in mouse hepatocytes during starvation and refeeding. *Proc Natl Acad Sci U S A* 1983; **80**: 2179-2183 [PMID: 6340116 DOI: 10.1073/pnas.80.8.2179]

5 **Ktistakis NT**. In praise of M. Anselmier who first used the term "autophagie" in 1859. *Autophagy* 2017; **13**: 2015-2017 [PMID: 28837378 DOI: 10.1080/15548627.2017.1367473]

6 **De Duve C**, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem J* 1955; **60**: 604-617 [PMID: 13249955 DOI: 10.1042/bj0600604]

7 **Novikoff AB**, Beaufay H, De Duve C. Electron microscopy of lysosomerich fractions from rat liver. *J Biophys Biochem Cytol* 1956; **2**: 179-184 [PMID: 13357540]

8 **Appelmans F**, Wattiaux R, De Duve C. Tissue fractionation studies. 5. The association of acid phosphatase with a special class of cytoplasmic granules in rat liver. *Biochem J* 1955; **59**: 438-445 [PMID: 14363114 DOI: 10.1042/bj0590438]

9 **Essner E**, Novikoff AB. Human hepatocellular pigments and lysosomes. *J Ultrastruct Res* 1960; **3**: 374-391 [PMID: 13820842 DOI: 10.1016/s0022-5320(60)90016-2]

10 **De Duve C**. The lysosome turns fifty. *Nat Cell Biol* 2005; **7**: 847-849 [PMID: 16136179 DOI: 10.1038/ncb0905-847]

11 **Arstila AU**, Trump BF. Studies on cellular autophagocytosis. The formation of autophagic vacuoles in the liver after glucagon administration. *Am J Pathol* 1968; **53**: 687-733 [PMID: 4300890]

12 **Takeshige K**, Baba M, Tsuboi S, Noda T, Ohsumi Y. Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction. *J Cell Biol* 1992; **119**: 301-311 [PMID: 1400575 DOI: 10.1083/jcb.119.2.301]

13 **Tsukada M**, Ohsumi Y. Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. *FEBS Lett* 1993; **333**: 169-174 [PMID: 8224160 DOI: 10.1016/0014-5793(93)80398-e]

14 **Noda T**, Matsuura A, Wada Y, Ohsumi Y. Novel system for monitoring autophagy in the yeast Saccharomyces cerevisiae. *Biochem Biophys Res Commun* 1995; **210**: 126-132 [PMID: 7741731 DOI: 10.1006/bbrc.1995.1636]

15 **Klionsky DJ**, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, Sandoval IV, Sibirny A, Subramani S, Thumm M, Veenhuis M, Ohsumi Y. A unified nomenclature for yeast autophagy-related genes. *Dev Cell* 2003; **5**: 539-545 [PMID: 14536056 DOI: 10.1016/s1534-5807(03)00296-x]

16 **Klionsky DJ**, Codogno P, Cuervo AM, Deretic V, Elazar Z, Fueyo-Margareto J, Gewirtz DA, Kroemer G, Levine B, Mizushima N, Rubinsztein DC, Thumm M, Tooze SA. A comprehensive glossary of autophagy-related molecules and processes. *Autophagy* 2010; **6**: 438-448 [PMID: 20484971 DOI: 10.4161/auto.6.4.12244]

17 **Klionsky DJ**, Baehrecke EH, Brumell JH, Chu CT, Codogno P, Cuervo AM, Debnath J, Deretic V, Elazar Z, Eskelinen EL, Finkbeiner S, Fueyo-Margareto J, Gewirtz D, Jäättelä M, Kroemer G, Levine B, Melia TJ, Mizushima N, Rubinsztein DC, Simonsen A, Thorburn A, Thumm M, Tooze SA. A comprehensive glossary of autophagy-related molecules and processes (2nd edition). *Autophagy* 2011; **7**: 1273-1294 [PMID: 21997368 DOI: 10.4161/auto.7.11.17661]

18 **Sheng R**, Qin ZH. History and Current Status of Autophagy Research. *Adv Exp Med Biol* 2019; **1206**: 3-37 [PMID: 31776978 DOI: 10.1007/978-981-15-0602-4\_1]

19 **Harnett MM**, Pineda MA, Latré de Laté P, Eason RJ, Besteiro S, Harnett W, Langsley G. From Christian de Duve to Yoshinori Ohsumi: More to autophagy than just dining at home. *Biomed J* 2017; **40**: 9-22 [PMID: 28411887 DOI: 10.1016/j.bj.2016.12.004]

20 **Ohsumi Y**. Historical landmarks of autophagy research. *Cell Res* 2014; **24**: 9-23 [PMID: 24366340 DOI: 10.1038/cr.2013.169]

21 **Levine B**, Klionsky DJ. Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker's yeast fuel advances in biomedical research. *Proc Natl Acad Sci U S A* 2017; **114**: 201-205 [PMID: 28039434 DOI: 10.1073/pnas.1619876114]

22 **Mizushima N**. A brief history of autophagy from cell biology to physiology and disease. *Nat Cell Biol* 2018; **20**: 521-527 [PMID: 29686264 DOI: 10.1038/s41556-018-0092-5]

23 **Tooze SA**, Yoshimori T. The origin of the autophagosomal membrane. *Nat Cell Biol* 2010; **12**: 831-835 [PMID: 20811355 DOI: 10.1038/ncb0910-831]

24 **Li Y**, Ding WX. Adipose tissue autophagy and homeostasis in alcohol-induced liver injury. *Liver Res* 2017; **1**: 54-62 [PMID: 29109891 DOI: 10.1016/j.livres.2017.03.004]

25 **Yu L**, Chen Y, Tooze SA. Autophagy pathway: Cellular and molecular mechanisms. *Autophagy* 2018; **14**: 207-215 [PMID: 28933638 DOI: 10.1080/15548627.2017.1378838]

26 **Dikic I**, Elazar Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol* 2018; **19**: 349-364 [PMID: 29618831 DOI: 10.1038/s41580-018-0003-4]

27 **Tanida I**. Autophagosome formation and molecular mechanism of autophagy. *Antioxid Redox Signal* 2011; **14**: 2201-2214 [PMID: 20712405 DOI: 10.1089/ars.2010.3482]

28 **Nakamura S**, Yoshimori T. New insights into autophagosome-lysosome fusion. *J Cell Sci* 2017; **130**: 1209-1216 [PMID: 28302910 DOI: 10.1242/jcs.196352]

29 **Sarkar C**, Zhao Z, Aungst S, Sabirzhanov B, Faden AI, Lipinski MM. Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury. *Autophagy* 2014; **10**: 2208-2222 [PMID: 25484084 DOI: 10.4161/15548627.2014.981787]

30 **Madrigal-Matute J**, Cuervo AM. Regulation of Liver Metabolism by Autophagy. *Gastroenterology* 2016; **150**: 328-339 [PMID: 26453774 DOI: 10.1053/j.gastro.2015.09.042]

31 **Mizushima N**, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. *Mol Biol Cell* 2004; **15**: 1101-1111 [PMID: 14699058 DOI: 10.1091/mbc.e03-09-0704]

32 **Tanida I**, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. *Autophagy* 2005; **1**: 84-91 [PMID: 16874052 DOI: 10.4161/auto.1.2.1697]

33 **Mizushima N**, Yoshimori T, Levine B. Methods in mammalian autophagy research. *Cell* 2010; **140**: 313-326 [PMID: 20144757 DOI: 10.1016/j.cell.2010.01.028]

34 **Klionsky DJ**, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, Ghosh P, Giammarioli AM, Giatromanolaki AN, Gibson SB, Gilkerson RW, Ginger ML, Ginsberg HN, Golab J, Goligorsky MS, Golstein P, Gomez-Manzano C, Goncu E, Gongora C, Gonzalez CD, Gonzalez R, González-Estévez C, González-Polo RA, Gonzalez-Rey E, Gorbunov NV, Gorski S, Goruppi S, Gottlieb RA, Gozuacik D, Granato GE, Grant GD, Green KN, Gregorc A, Gros F, Grose C, Grunt TW, Gual P, Guan JL, Guan KL, Guichard SM, Gukovskaya AS, Gukovsky I, Gunst J, Gustafsson AB, Halayko AJ, Hale AN, Halonen SK, Hamasaki M, Han F, Han T, Hancock MK, Hansen M, Harada H, Harada M, Hardt SE, Harper JW, Harris AL, Harris J, Harris SD, Hashimoto M, Haspel JA, Hayashi S, Hazelhurst LA, He C, He YW, Hébert MJ, Heidenreich KA, Helfrich MH, Helgason GV, Henske EP, Herman B, Herman PK, Hetz C, Hilfiker S, Hill JA, Hocking LJ, Hofman P, Hofmann TG, Höhfeld J, Holyoake TL, Hong MH, Hood DA, Hotamisligil GS, Houwerzijl EJ, Høyer-Hansen M, Hu B, Hu CA, Hu HM, Hua Y, Huang C, Huang J, Huang S, Huang WP, Huber TB, Huh WK, Hung TH, Hupp TR, Hur GM, Hurley JB, Hussain SN, Hussey PJ, Hwang JJ, Hwang S, Ichihara A, Ilkhanizadeh S, Inoki K, Into T, Iovane V, Iovanna JL, Ip NY, Isaka Y, Ishida H, Isidoro C, Isobe K, Iwasaki A, Izquierdo M, Izumi Y, Jaakkola PM, Jäättelä M, Jackson GR, Jackson WT, Janji B, Jendrach M, Jeon JH, Jeung EB, Jiang H, Jiang H, Jiang JX, Jiang M, Jiang Q, Jiang X, Jiang X, Jiménez A, Jin M, Jin S, Joe CO, Johansen T, Johnson DE, Johnson GV, Jones NL, Joseph B, Joseph SK, Joubert AM, Juhász G, Juillerat-Jeanneret L, Jung CH, Jung YK, Kaarniranta K, Kaasik A, Kabuta T, Kadowaki M, Kagedal K, Kamada Y, Kaminskyy VO, Kampinga HH, Kanamori H, Kang C, Kang KB, Kang KI, Kang R, Kang YA, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar A, Kerkhoff C, Kessel DH, Khalil H, Kiel JA, Kiger AA, Kihara A, Kim DR, Kim DH, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, Kitamoto K, Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BC, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Kouri Flores JB, Kovács AL, Kraft C, Krainc D, Krämer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Krüger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, La Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, László L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, Le W, Le Cam L, Ledbetter DJ, Lee AJ, Lee BW, Lee GM, Lee J, Lee JH, Lee M, Lee MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, Lonial S, Loos B, Lopez-Berestein G, López-Otín C, Lossi L, Lotze MT, Lőw P, Lu B, Lu B, Lu B, Lu Z, Luciano F, Lukacs NW, Lund AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MC, Malorni W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Mariño G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin B, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, Meisler MH, Meléndez A, Melia TJ, Melino G, Mena MA, Menendez JA, Menna-Barreto RF, Menon MB, Menzies FM, Mercer CA, Merighi A, Merry DE, Meschini S, Meyer CG, Meyer TF, Miao CY, Miao JY, Michels PA, Michiels C, Mijaljica D, Milojkovic A, Minucci S, Miracco C, Miranti CK, Mitroulis I, Miyazawa K, Mizushima N, Mograbi B, Mohseni S, Molero X, Mollereau B, Mollinedo F, Momoi T, Monastyrska I, Monick MM, Monteiro MJ, Moore MN, Mora R, Moreau K, Moreira PI, Moriyasu Y, Moscat J, Mostowy S, Mottram JC, Motyl T, Moussa CE, Müller S, Muller S, Münger K, Münz C, Murphy LO, Murphy ME, Musarò A, Mysorekar I, Nagata E, Nagata K, Nahimana A, Nair U, Nakagawa T, Nakahira K, Nakano H, Nakatogawa H, Nanjundan M, Naqvi NI, Narendra DP, Narita M, Navarro M, Nawrocki ST, Nazarko TY, Nemchenko A, Netea MG, Neufeld TP, Ney PA, Nezis IP, Nguyen HP, Nie D, Nishino I, Nislow C, Nixon RA, Noda T, Noegel AA, Nogalska A, Noguchi S, Notterpek L, Novak I, Nozaki T, Nukina N, Nürnberger T, Nyfeler B, Obara K, Oberley TD, Oddo S, Ogawa M, Ohashi T, Okamoto K, Oleinick NL, Oliver FJ, Olsen LJ, Olsson S, Opota O, Osborne TF, Ostrander GK, Otsu K, Ou JH, Ouimet M, Overholtzer M, Ozpolat B, Paganetti P, Pagnini U, Pallet N, Palmer GE, Palumbo C, Pan T, Panaretakis T, Pandey UB, Papackova Z, Papassideri I, Paris I, Park J, Park OK, Parys JB, Parzych KR, Patschan S, Patterson C, Pattingre S, Pawelek JM, Peng J, Perlmutter DH, Perrotta I, Perry G, Pervaiz S, Peter M, Peters GJ, Petersen M, Petrovski G, Phang JM, Piacentini M, Pierre P, Pierrefite-Carle V, Pierron G, Pinkas-Kramarski R, Piras A, Piri N, Platanias LC, Pöggeler S, Poirot M, Poletti A, Poüs C, Pozuelo-Rubio M, Prætorius-Ibba M, Prasad A, Prescott M, Priault M, Produit-Zengaffinen N, Progulske-Fox A, Proikas-Cezanne T, Przedborski S, Przyklenk K, Puertollano R, Puyal J, Qian SB, Qin L, Qin ZH, Quaggin SE, Raben N, Rabinowich H, Rabkin SW, Rahman I, Rami A, Ramm G, Randall G, Randow F, Rao VA, Rathmell JC, Ravikumar B, Ray SK, Reed BH, Reed JC, Reggiori F, Régnier-Vigouroux A, Reichert AS, Reiners JJ Jr, Reiter RJ, Ren J, Revuelta JL, Rhodes CJ, Ritis K, Rizzo E, Robbins J, Roberge M, Roca H, Roccheri MC, Rocchi S, Rodemann HP, Rodríguez de Córdoba S, Rohrer B, Roninson IB, Rosen K, Rost-Roszkowska MM, Rouis M, Rouschop KM, Rovetta F, Rubin BP, Rubinsztein DC, Ruckdeschel K, Rucker EB 3rd, Rudich A, Rudolf E, Ruiz-Opazo N, Russo R, Rusten TE, Ryan KM, Ryter SW, Sabatini DM, Sadoshima J, Saha T, Saitoh T, Sakagami H, Sakai Y, Salekdeh GH, Salomoni P, Salvaterra PM, Salvesen G, Salvioli R, Sanchez AM, Sánchez-Alcázar JA, Sánchez-Prieto R, Sandri M, Sankar U, Sansanwal P, Santambrogio L, Saran S, Sarkar S, Sarwal M, Sasakawa C, Sasnauskiene A, Sass M, Sato K, Sato M, Schapira AH, Scharl M, Schätzl HM, Scheper W, Schiaffino S, Schneider C, Schneider ME, Schneider-Stock R, Schoenlein PV, Schorderet DF, Schüller C, Schwartz GK, Scorrano L, Sealy L, Seglen PO, Segura-Aguilar J, Seiliez I, Seleverstov O, Sell C, Seo JB, Separovic D, Setaluri V, Setoguchi T, Settembre C, Shacka JJ, Shanmugam M, Shapiro IM, Shaulian E, Shaw RJ, Shelhamer JH, Shen HM, Shen WC, Sheng ZH, Shi Y, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shintani T, Shirihai OS, Shore GC, Sibirny AA, Sidhu SB, Sikorska B, Silva-Zacarin EC, Simmons A, Simon AK, Simon HU, Simone C, Simonsen A, Sinclair DA, Singh R, Sinha D, Sinicrope FA, Sirko A, Siu PM, Sivridis E, Skop V, Skulachev VP, Slack RS, Smaili SS, Smith DR, Soengas MS, Soldati T, Song X, Sood AK, Soong TW, Sotgia F, Spector SA, Spies CD, Springer W, Srinivasula SM, Stefanis L, Steffan JS, Stendel R, Stenmark H, Stephanou A, Stern ST, Sternberg C, Stork B, Strålfors P, Subauste CS, Sui X, Sulzer D, Sun J, Sun SY, Sun ZJ, Sung JJ, Suzuki K, Suzuki T, Swanson MS, Swanton C, Sweeney ST, Sy LK, Szabadkai G, Tabas I, Taegtmeyer H, Tafani M, Takács-Vellai K, Takano Y, Takegawa K, Takemura G, Takeshita F, Talbot NJ, Tan KS, Tanaka K, Tanaka K, Tang D, Tang D, Tanida I, Tannous BA, Tavernarakis N, Taylor GS, Taylor GA, Taylor JP, Terada LS, Terman A, Tettamanti G, Thevissen K, Thompson CB, Thorburn A, Thumm M, Tian F, Tian Y, Tocchini-Valentini G, Tolkovsky AM, Tomino Y, Tönges L, Tooze SA, Tournier C, Tower J, Towns R, Trajkovic V, Travassos LH, Tsai TF, Tschan MP, Tsubata T, Tsung A, Turk B, Turner LS, Tyagi SC, Uchiyama Y, Ueno T, Umekawa M, Umemiya-Shirafuji R, Unni VK, Vaccaro MI, Valente EM, Van den Berghe G, van der Klei IJ, van Doorn W, van Dyk LF, van Egmond M, van Grunsven LA, Vandenabeele P, Vandenberghe WP, Vanhorebeek I, Vaquero EC, Velasco G, Vellai T, Vicencio JM, Vierstra RD, Vila M, Vindis C, Viola G, Viscomi MT, Voitsekhovskaja OV, von Haefen C, Votruba M, Wada K, Wade-Martins R, Walker CL, Walsh CM, Walter J, Wan XB, Wang A, Wang C, Wang D, Wang F, Wang F, Wang G, Wang H, Wang HG, Wang HD, Wang J, Wang K, Wang M, Wang RC, Wang X, Wang X, Wang YJ, Wang Y, Wang Z, Wang ZC, Wang Z, Wansink DG, Ward DM, Watada H, Waters SL, Webster P, Wei L, Weihl CC, Weiss WA, Welford SM, Wen LP, Whitehouse CA, Whitton JL, Whitworth AJ, Wileman T, Wiley JW, Wilkinson S, Willbold D, Williams RL, Williamson PR, Wouters BG, Wu C, Wu DC, Wu WK, Wyttenbach A, Xavier RJ, Xi Z, Xia P, Xiao G, Xie Z, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamamoto A, Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, Youle RJ, Younes A, Yu L, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zacarin E, Zacks D, Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ 3rd, Zeitlin SO, Zhang H, Zhang HL, Zhang J, Zhang JP, Zhang L, Zhang L, Zhang MY, Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, Zoladek T, Zong WX, Zorzano A, Zschocke J, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012; **8**: 445-544 [PMID: 22966490 DOI: 10.4161/auto.19496]

35 **Bjørkøy G**, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J Cell Biol* 2005; **171**: 603-614 [PMID: 16286508 DOI: 10.1083/jcb.200507002]

36 **Mizushima N**, Yoshimori T. How to interpret LC3 immunoblotting. *Autophagy* 2007; **3**: 542-545 [PMID: 17611390 DOI: 10.4161/auto.4600]

37 **Islam MA**, Sooro MA, Zhang P. Autophagic Regulation of p62 is Critical for Cancer Therapy. *Int J Mol Sci* 2018; **19** [PMID: 29738493 DOI: 10.3390/ijms19051405]

38 **Zhang NP**, Liu XJ, Xie L, Shen XZ, Wu J. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. *Lab Invest* 2019; **99**: 749-763 [PMID: 30700851 DOI: 10.1038/s41374-018-0177-6]

39 **Mizushima N**, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. *Annu Rev Cell Dev Biol* 2011; **27**: 107-132 [PMID: 21801009 DOI: 10.1146/annurev-cellbio-092910-154005]

40 **Komatsu M**, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, Hamazaki J, Nishito Y, Iemura S, Natsume T, Yanagawa T, Uwayama J, Warabi E, Yoshida H, Ishii T, Kobayashi A, Yamamoto M, Yue Z, Uchiyama Y, Kominami E, Tanaka K. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell* 2007; **131**: 1149-1163 [PMID: 18083104 DOI: 10.1016/j.cell.2007.10.035]

41 **Czaja MJ**, Ding WX, Donohue TM Jr, Friedman SL, Kim JS, Komatsu M, Lemasters JJ, Lemoine A, Lin JD, Ou JH, Perlmutter DH, Randall G, Ray RB, Tsung A, Yin XM. Functions of autophagy in normal and diseased liver. *Autophagy* 2013; **9**: 1131-1158 [PMID: 23774882 DOI: 10.4161/auto.25063]

42 **Yin XM**, Ding WX, Gao W. Autophagy in the liver. *Hepatology* 2008; **47**: 1773-1785 [PMID: 18393362 DOI: 10.1002/hep.22146]

43 **Galluzzi L**, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P, Colombo MI, Cuervo AM, Debnath J, Deretic V, Dikic I, Eskelinen EL, Fimia GM, Fulda S, Gewirtz DA, Green DR, Hansen M, Harper JW, Jäättelä M, Johansen T, Juhasz G, Kimmelman AC, Kraft C, Ktistakis NT, Kumar S, Levine B, Lopez-Otin C, Madeo F, Martens S, Martinez J, Melendez A, Mizushima N, Münz C, Murphy LO, Penninger JM, Piacentini M, Reggiori F, Rubinsztein DC, Ryan KM, Santambrogio L, Scorrano L, Simon AK, Simon HU, Simonsen A, Tavernarakis N, Tooze SA, Yoshimori T, Yuan J, Yue Z, Zhong Q, Kroemer G. Molecular definitions of autophagy and related processes. *EMBO J* 2017; **36**: 1811-1836 [PMID: 28596378 DOI: 10.15252/embj.201796697]

44 **Kim J**, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* 2011; **13**: 132-141 [PMID: 21258367 DOI: 10.1038/ncb2152]

45 **Egan DF**, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, Asara JM, Fitzpatrick J, Dillin A, Viollet B, Kundu M, Hansen M, Shaw RJ. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science* 2011; **331**: 456-461 [PMID: 21205641 DOI: 10.1126/science.1196371]

46 **Angarola B**, Ferguson SM. Coordination of Rheb lysosomal membrane interactions with mTORC1 activation. *F1000Res* 2020; **9** [PMID: 32518628 DOI: 10.12688/f1000research.22367.1]

47 **Raben N**, Puertollano R. TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress. *Annu Rev Cell Dev Biol* 2016; **32**: 255-278 [PMID: 27298091 DOI: 10.1146/annurev-cellbio-111315-125407]

48 **Settembre C**, Ballabio A. TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes. *Autophagy* 2011; **7**: 1379-1381 [PMID: 21785263 DOI: 10.4161/auto.7.11.17166]

49 **Settembre C**, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P, Sardiello M, Rubinsztein DC, Ballabio A. TFEB links autophagy to lysosomal biogenesis. *Science* 2011; **332**: 1429-1433 [PMID: 21617040 DOI: 10.1126/science.1204592]

50 **Settembre C**, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nat Rev Mol Cell Biol* 2013; **14**: 283-296 [PMID: 23609508 DOI: 10.1038/nrm3565]

51 **Martina JA**, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. *Autophagy* 2012; **8**: 903-914 [PMID: 22576015 DOI: 10.4161/auto.19653]

52 **Medina DL**, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, Montefusco S, Scotto-Rosato A, Prezioso C, Forrester A, Settembre C, Wang W, Gao Q, Xu H, Sandri M, Rizzuto R, De Matteis MA, Ballabio A. Lysosomal calcium signalling regulates autophagy through calcineurin and ​TFEB. *Nat Cell Biol* 2015; **17**: 288-299 [PMID: 25720963 DOI: 10.1038/ncb3114]

53 **Chao X**, Wang H, Jaeschke H, Ding WX. Role and mechanisms of autophagy in acetaminophen-induced liver injury. *Liver Int* 2018; **38**: 1363-1374 [PMID: 29682868 DOI: 10.1111/liv.13866]

54 **Santambrogio L**, Cuervo AM. Chasing the elusive mammalian microautophagy. *Autophagy* 2011; **7**: 652-654 [PMID: 21460618 DOI: 10.4161/auto.7.6.15287]

55 **Olsvik HL**, Svenning S, Abudu YP, Brech A, Stenmark H, Johansen T, Mejlvang J. Endosomal microautophagy is an integrated part of the autophagic response to amino acid starvation. *Autophagy* 2019; **15**: 182-183 [PMID: 30295124 DOI: 10.1080/15548627.2018.1532265]

56 **Ke PY**. Diverse Functions of Autophagy in Liver Physiology and Liver Diseases. *Int J Mol Sci* 2019; **20** [PMID: 30642133 DOI: 10.3390/ijms20020300]

57 **Oku M**, Sakai Y. Three Distinct Types of Microautophagy Based on Membrane Dynamics and Molecular Machineries. *Bioessays* 2018; **40**: e1800008 [PMID: 29708272 DOI: 10.1002/bies.201800008]

58 **Kaushik S**, Cuervo AM. The coming of age of chaperone-mediated autophagy. *Nat Rev Mol Cell Biol* 2018; **19**: 365-381 [PMID: 29626215 DOI: 10.1038/s41580-018-0001-6]

59 **Tekirdag K**, Cuervo AM. Chaperone-mediated autophagy and endosomal microautophagy: Joint by a chaperone. *J Biol Chem* 2018; **293**: 5414-5424 [PMID: 29247007 DOI: 10.1074/jbc.R117.818237]

60 **Park C**, Suh Y, Cuervo AM. Regulated degradation of Chk1 by chaperone-mediated autophagy in response to DNA damage. *Nat Commun* 2015; **6**: 6823 [PMID: 25880015 DOI: 10.1038/ncomms7823]

61 **Cuervo AM**, Knecht E, Terlecky SR, Dice JF. Activation of a selective pathway of lysosomal proteolysis in rat liver by prolonged starvation. *Am J Physiol* 1995; **269**: C1200-C1208 [PMID: 7491910 DOI: 10.1152/ajpcell.1995.269.5.C1200]

62 **Kiffin R**, Christian C, Knecht E, Cuervo AM. Activation of chaperone-mediated autophagy during oxidative stress. *Mol Biol Cell* 2004; **15**: 4829-4840 [PMID: 15331765 DOI: 10.1091/mbc.e04-06-0477]

63 **Dohi E**, Tanaka S, Seki T, Miyagi T, Hide I, Takahashi T, Matsumoto M, Sakai N. Hypoxic stress activates chaperone-mediated autophagy and modulates neuronal cell survival. *Neurochem Int* 2012; **60**: 431-442 [PMID: 22306777 DOI: 10.1016/j.neuint.2012.01.020]

64 **Finn PF**, Dice JF. Ketone bodies stimulate chaperone-mediated autophagy. *J Biol Chem* 2005; **280**: 25864-25870 [PMID: 15883160 DOI: 10.1074/jbc.M502456200]

65 **Ferreira JV**, Fôfo H, Bejarano E, Bento CF, Ramalho JS, Girão H, Pereira P. STUB1/CHIP is required for HIF1A degradation by chaperone-mediated autophagy. *Autophagy* 2013; **9**: 1349-1366 [PMID: 23880665 DOI: 10.4161/auto.25190]

66 **Singh R**, Cuervo AM. Autophagy in the cellular energetic balance. *Cell Metab* 2011; **13**: 495-504 [PMID: 21531332 DOI: 10.1016/j.cmet.2011.04.004]

67 **Farré JC**, Subramani S. Mechanistic insights into selective autophagy pathways: lessons from yeast. *Nat Rev Mol Cell Biol* 2016; **17**: 537-552 [PMID: 27381245 DOI: 10.1038/nrm.2016.74]

68 **Kraft C**, Deplazes A, Sohrmann M, Peter M. Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease. *Nat Cell Biol* 2008; **10**: 602-610 [PMID: 18391941 DOI: 10.1038/ncb1723]

69 **Dunn WA Jr**, Cregg JM, Kiel JA, van der Klei IJ, Oku M, Sakai Y, Sibirny AA, Stasyk OV, Veenhuis M. Pexophagy: the selective autophagy of peroxisomes. *Autophagy* 2005; **1**: 75-83 [PMID: 16874024 DOI: 10.4161/auto.1.2.1737]

70 **Mancias JD**, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. *Nature* 2014; **509**: 105-109 [PMID: 24695223 DOI: 10.1038/nature13148]

71 **Nakatogawa H**, Mochida K. Reticulophagy and nucleophagy: New findings and unsolved issues. *Autophagy* 2015; **11**: 2377-2378 [PMID: 26566146 DOI: 10.1080/15548627.2015.1106665]

72 **Singh R**, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. *Nature* 2009; **458**: 1131-1135 [PMID: 19339967 DOI: 10.1038/nature07976]

73 **Lee S**, Kim JS. Mitophagy: therapeutic potentials for liver disease and beyond. *Toxicol Res* 2014; **30**: 243-250 [PMID: 25584143 DOI: 10.5487/TR.2014.30.4.243]

74 **Khaminets A**, Heinrich T, Mari M, Grumati P, Huebner AK, Akutsu M, Liebmann L, Stolz A, Nietzsche S, Koch N, Mauthe M, Katona I, Qualmann B, Weis J, Reggiori F, Kurth I, Hübner CA, Dikic I. Regulation of endoplasmic reticulum turnover by selective autophagy. *Nature* 2015; **522**: 354-358 [PMID: 26040720 DOI: 10.1038/nature14498]

75 **Mochida K**, Oikawa Y, Kimura Y, Kirisako H, Hirano H, Ohsumi Y, Nakatogawa H. Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus. *Nature* 2015; **522**: 359-362 [PMID: 26040717 DOI: 10.1038/nature14506]

76 **Ellgaard L**, Sevier CS, Bulleid NJ. How Are Proteins Reduced in the Endoplasmic Reticulum? *Trends Biochem Sci* 2018; **43**: 32-43 [PMID: 29153511 DOI: 10.1016/j.tibs.2017.10.006]

77 **Grumati P**, Dikic I, Stolz A. ER-phagy at a glance. *J Cell Sci* 2018; **131** [PMID: 30177506 DOI: 10.1242/jcs.217364]

78 **Gatica D**, Lahiri V, Klionsky DJ. Cargo recognition and degradation by selective autophagy. *Nat Cell Biol* 2018; **20**: 233-242 [PMID: 29476151 DOI: 10.1038/s41556-018-0037-z]

79 **Smith MD**, Harley ME, Kemp AJ, Wills J, Lee M, Arends M, von Kriegsheim A, Behrends C, Wilkinson S. CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis. *Dev Cell* 2018; **44**: 217-232.e11 [PMID: 29290589 DOI: 10.1016/j.devcel.2017.11.024]

80 **Ding WX**, Manley S, Ni HM. The emerging role of autophagy in alcoholic liver disease. *Exp Biol Med (Maywood)* 2011; **236**: 546-556 [PMID: 21478210 DOI: 10.1258/ebm.2011.010360]

81 **Wang L**, Khambu B, Zhang H, Yin XM. Autophagy in alcoholic liver disease, self-eating triggered by drinking. *Clin Res Hepatol Gastroenterol* 2015; **39 Suppl 1**: S2-S6 [PMID: 26186877 DOI: 10.1016/j.clinre.2015.05.023]

82 **Zubiete-Franco I**, García-Rodríguez JL, Martínez-Uña M, Martínez-Lopez N, Woodhoo A, Juan VG, Beraza N, Lage-Medina S, Andrade F, Fernandez ML, Aldámiz-Echevarría L, Fernández-Ramos D, Falcon-Perez JM, Lopitz-Otsoa F, Fernandez-Tussy P, Barbier-Torres L, Luka Z, Wagner C, García-Monzón C, Lu SC, Aspichueta P, Mato JM, Martínez-Chantar ML, Varela-Rey M. Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis. *J Hepatol* 2016; **64**: 409-418 [PMID: 26394163 DOI: 10.1016/j.jhep.2015.08.037]

83 **Xiong J**, Wang K, He J, Zhang G, Zhang D, Chen F. TFE3 Alleviates Hepatic Steatosis through Autophagy-Induced Lipophagy and PGC1α-Mediated Fatty Acid β-Oxidation. *Int J Mol Sci* 2016; **17**: 387 [PMID: 26999124 DOI: 10.3390/ijms17030387]

84 **Chen K**, Yuan R, Zhang Y, Geng S, Li L. Tollip Deficiency Alters Atherosclerosis and Steatosis by Disrupting Lipophagy. *J Am Heart Assoc* 2017; **6** [PMID: 28396568 DOI: 10.1161/JAHA.116.004078]

85 **Hung TM**, Yuan RH, Huang WP, Chen YH, Lin YC, Lin CW, Lai HS, Lee PH. Increased Autophagy Markers Are Associated with Ductular Reaction during the Development of Cirrhosis. *Am J Pathol* 2015; **185**: 2454-2467 [PMID: 26158232 DOI: 10.1016/j.ajpath.2015.05.010]

86 **Tian Y**, Kuo CF, Sir D, Wang L, Govindarajan S, Petrovic LM, Ou JH. Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis. *Cell Death Differ* 2015; **22**: 1025-1034 [PMID: 25526090 DOI: 10.1038/cdd.2014.201]

87 **Zhang Z**, Zhao S, Yao Z, Wang L, Shao J, Chen A, Zhang F, Zheng S. Autophagy regulates turnover of lipid droplets *via* ROS-dependent Rab25 activation in hepatic stellate cell. *Redox Biol* 2017; **11**: 322-334 [PMID: 28038427 DOI: 10.1016/j.redox.2016.12.021]

88 **Martinez-Lopez N**, Singh R. Autophagy and Lipid Droplets in the Liver. *Annu Rev Nutr* 2015; **35**: 215-237 [PMID: 26076903 DOI: 10.1146/annurev-nutr-071813-105336]

89 **Schulze RJ**, Sathyanarayan A, Mashek DG. Breaking fat: The regulation and mechanisms of lipophagy. *Biochim Biophys Acta Mol Cell Biol Lipids* 2017; **1862**: 1178-1187 [PMID: 28642194 DOI: 10.1016/j.bbalip.2017.06.008]

90 **Zhang Z**, Yao Z, Chen Y, Qian L, Jiang S, Zhou J, Shao J, Chen A, Zhang F, Zheng S. Lipophagy and liver disease: New perspectives to better understanding and therapy. *Biomed Pharmacother* 2018; **97**: 339-348 [PMID: 29091883 DOI: 10.1016/j.biopha.2017.07.168]

91 **Kounakis K**, Chaniotakis M, Markaki M, Tavernarakis N. Emerging Roles of Lipophagy in Health and Disease. *Front Cell Dev Biol* 2019; **7**: 185 [PMID: 31552248 DOI: 10.3389/fcell.2019.00185]

92 **Ding WX**, Ni HM, Li M, Liao Y, Chen X, Stolz DB, Dorn GW 2nd, Yin XM. Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. *J Biol Chem* 2010; **285**: 27879-27890 [PMID: 20573959 DOI: 10.1074/jbc.M110.119537]

93 **Ding WX**, Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. *Biol Chem* 2012; **393**: 547-564 [PMID: 22944659 DOI: 10.1515/hsz-2012-0119]

94 **Menzies RA**, Gold PH. The turnover of mitochondria in a variety of tissues of young adult and aged rats. *J Biol Chem* 1971; **246**: 2425-2429 [PMID: 5553400]

95 **Pfeifer U**. Inhibition by insulin of the formation of autophagic vacuoles in rat liver. A morphometric approach to the kinetics of intracellular degradation by autophagy. *J Cell Biol* 1978; **78**: 152-167 [PMID: 670291 DOI: 10.1083/jcb.78.1.152]

96 **Lemasters JJ**. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. *Rejuvenation Res* 2005; **8**: 3-5 [PMID: 15798367 DOI: 10.1089/rej.2005.8.3]

97 **Kim I**, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. *Arch Biochem Biophys* 2007; **462**: 245-253 [PMID: 17475204 DOI: 10.1016/j.abb.2007.03.034]

98 **Mizushima N**, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. *Nature* 2008; **451**: 1069-1075 [PMID: 18305538 DOI: 10.1038/nature06639]

99 **Youle RJ**, Narendra DP. Mechanisms of mitophagy. *Nat Rev Mol Cell Biol* 2011; **12**: 9-14 [PMID: 21179058 DOI: 10.1038/nrm3028]

100 **Zhao L**, Li H, Wang Y, Zheng A, Cao L, Liu J. Autophagy Deficiency Leads to Impaired Antioxidant Defense *via* p62-FOXO1/3 Axis. *Oxid Med Cell Longev* 2019; **2019**: 2526314 [PMID: 31949875 DOI: 10.1155/2019/2526314]

101 **Lemasters JJ**. Variants of mitochondrial autophagy: Types 1 and 2 mitophagy and micromitophagy (Type 3). *Redox Biol* 2014; **2**: 749-754 [PMID: 25009776 DOI: 10.1016/j.redox.2014.06.004]

102 **Flores-Toro JA**, Go KL, Leeuwenburgh C, Kim JS. Autophagy in the liver: cell's cannibalism and beyond. *Arch Pharm Res* 2016; **39**: 1050-1061 [PMID: 27515049 DOI: 10.1007/s12272-016-0807-8]

103 **Ke PY**. Mitophagy in the Pathogenesis of Liver Diseases. *Cells* 2020; **9** [PMID: 32235615 DOI: 10.3390/cells9040831]

104 **Panzitt K**, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. *Gastroenterology* 2007; **132**: 330-342 [PMID: 17241883 DOI: 10.1053/j.gastro.2006.08.026]

105 **Chen CL**, Tseng YW, Wu JC, Chen GY, Lin KC, Hwang SM, Hu YC. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation. *Biomaterials* 2015; **44**: 71-81 [PMID: 25617127 DOI: 10.1016/j.biomaterials.2014.12.023]

106 **Liu Z**, Wei X, Zhang A, Li C, Bai J, Dong J. Long non-coding RNA HNF1A-AS1 functioned as an oncogene and autophagy promoter in hepatocellular carcinoma through sponging hsa-miR-30b-5p. *Biochem Biophys Res Commun* 2016; **473**: 1268-1275 [PMID: 27084450 DOI: 10.1016/j.bbrc.2016.04.054]

107 **Yang L**, Zhang X, Li H, Liu J. The long noncoding RNA HOTAIR activates autophagy by upregulating ATG3 and ATG7 in hepatocellular carcinoma. *Mol Biosyst* 2016; **12**: 2605-2612 [PMID: 27301338 DOI: 10.1039/c6mb00114a]

108 **Xiong H**, Ni Z, He J, Jiang S, Li X, He J, Gong W, Zheng L, Chen S, Li B, Zhang N, Lyu X, Huang G, Chen B, Zhang Y, He F. LncRNA HULC triggers autophagy *via* stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. *Oncogene* 2017; **36**: 3528-3540 [PMID: 28166203 DOI: 10.1038/onc.2016.521]

109 **Islam Khan MZ**, Tam SY, Law HKW. Autophagy-Modulating Long Non-coding RNAs (LncRNAs) and Their Molecular Events in Cancer. *Front Genet* 2018; **9**: 750 [PMID: 30693021 DOI: 10.3389/fgene.2018.00750]

110 **Horos R**, Büscher M, Kleinendorst R, Alleaume AM, Tarafder AK, Schwarzl T, Dziuba D, Tischer C, Zielonka EM, Adak A, Castello A, Huber W, Sachse C, Hentze MW. The Small Non-coding Vault RNA1-1 Acts as a Riboregulator of Autophagy. *Cell* 2019; **176**: 1054-1067.e12 [PMID: 30773316 DOI: 10.1016/j.cell.2019.01.030]

111 **Zhao Y**, Wang Z, Zhang W, Zhang L. MicroRNAs play an essential role in autophagy regulation in various disease phenotypes. *Biofactors* 2019; **45**: 844-856 [PMID: 31418958 DOI: 10.1002/biof.1555]

112 **Khambu B**, Huda N, Chen X, Antoine DJ, Li Y, Dai G, Köhler UA, Zong WX, Waguri S, Werner S, Oury TD, Dong Z, Yin XM. HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers. *J Clin Invest* 2018; **128**: 2419-2435 [PMID: 29558368 DOI: 10.1172/JCI91814]

113 **Lee YA**, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin XM, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, Friedman SL. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. *Nat Commun* 2018; **9**: 4962 [PMID: 30470740 DOI: 10.1038/s41467-018-07338-z]

114 **Lee JM**, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA, Moore DD. Nutrient-sensing nuclear receptors coordinate autophagy. *Nature* 2014; **516**: 112-115 [PMID: 25383539 DOI: 10.1038/nature13961]

115 **Seok S**, Fu T, Choi SE, Li Y, Zhu R, Kumar S, Sun X, Yoon G, Kang Y, Zhong W, Ma J, Kemper B, Kemper JK. Transcriptional regulation of autophagy by an FXR-CREB axis. *Nature* 2014; **516**: 108-111 [PMID: 25383523 DOI: 10.1038/nature13949]

116 **Kim H**, Williams D, Qiu Y, Song Z, Yang Z, Kimler V, Goldberg A, Zhang R, Yang Z, Chen X, Wang L, Fang D, Lin JD, Zhang K. Regulation of hepatic autophagy by stress-sensing transcription factor CREBH. *FASEB J* 2019; **33**: 7896-7914 [PMID: 30912978 DOI: 10.1096/fj.201802528R]

117 **Xu J**, Camfield R, Gorski SM. The interplay between exosomes and autophagy - partners in crime. *J Cell Sci* 2018; **131** [PMID: 30076239 DOI: 10.1242/jcs.215210]

118 **Zheng J**, Tan J, Miao YY, Zhang Q. Extracellular vesicles degradation pathway based autophagy lysosome pathway. *Am J Transl Res* 2019; **11**: 1170-1183 [PMID: 30972154]

119 **Yu L**, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, Mi N, Zhao Y, Liu Z, Wan F, Hailey DW, Oorschot V, Klumperman J, Baehrecke EH, Lenardo MJ. Termination of autophagy and reformation of lysosomes regulated by mTOR. *Nature* 2010; **465**: 942-946 [PMID: 20526321 DOI: 10.1038/nature09076]

120 **Chen Y**, Yu L. Recent progress in autophagic lysosome reformation. *Traffic* 2017; **18**: 358-361 [PMID: 28371052 DOI: 10.1111/tra.12484]

121 **Chen Y**, Yu L. Development of Research into Autophagic Lysosome Reformation. *Mol Cells* 2018; **41**: 45-49 [PMID: 29370688 DOI: 10.14348/molcells.2018.2265]

122 **Buratta S**, Tancini B, Sagini K, Delo F, Chiaradia E, Urbanelli L, Emiliani C. Lysosomal Exocytosis, Exosome Release and Secretory Autophagy: The Autophagic- and Endo-Lysosomal Systems Go Extracellular. *Int J Mol Sci* 2020; **21** [PMID: 32276321 DOI: 10.3390/ijms21072576]

123 **Galluzzi L**, Green DR. Autophagy-Independent Functions of the Autophagy Machinery. *Cell* 2019; **177**: 1682-1699 [PMID: 31199916 DOI: 10.1016/j.cell.2019.05.026]

124 **Virgin HW**, Levine B. Autophagy genes in immunity. *Nat Immunol* 2009; **10**: 461-470 [PMID: 19381141 DOI: 10.1038/ni.1726]

125 **Saitoh T**, Akira S. Regulation of innate immune responses by autophagy-related proteins. *J Cell Biol* 2010; **189**: 925-935 [PMID: 20548099 DOI: 10.1083/jcb.201002021]

126 **Levine B**, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature* 2011; **469**: 323-335 [PMID: 21248839 DOI: 10.1038/nature09782]

127 **Mihalache CC**, Simon HU. Autophagy regulation in macrophages and neutrophils. *Exp Cell Res* 2012; **318**: 1187-1192 [PMID: 22245582 DOI: 10.1016/j.yexcr.2011.12.021]

128 **Shi CS**, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, Sher A, Kehrl JH. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. *Nat Immunol* 2012; **13**: 255-263 [PMID: 22286270 DOI: 10.1038/ni.2215]

129 **Puleston DJ**, Simon AK. Autophagy in the immune system. *Immunology* 2014; **141**: 1-8 [PMID: 23991647 DOI: 10.1111/imm.12165]

130 **Chen P**, Cescon M, Bonaldo P. Autophagy-mediated regulation of macrophages and its applications for cancer. *Autophagy* 2014; **10**: 192-200 [PMID: 24300480 DOI: 10.4161/auto.26927]

131 **Liu K**, Zhao E, Ilyas G, Lalazar G, Lin Y, Haseeb M, Tanaka KE, Czaja MJ. Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. *Autophagy* 2015; **11**: 271-284 [PMID: 25650776 DOI: 10.1080/15548627.2015.1009787]

132 **Codogno P**, Mehrpour M, Proikas-Cezanne T. Canonical and non-canonical autophagy: variations on a common theme of self-eating? *Nat Rev Mol Cell Biol* 2011; **13**: 7-12 [PMID: 22166994 DOI: 10.1038/nrm3249]

133 **Heckmann BL**, Boada-Romero E, Cunha LD, Magne J, Green DR. LC3-Associated Phagocytosis and Inflammation. *J Mol Biol* 2017; **429**: 3561-3576 [PMID: 28847720 DOI: 10.1016/j.jmb.2017.08.012]

134 **Martinez J**. LAP it up, fuzz ball: a short history of LC3-associated phagocytosis. *Curr Opin Immunol* 2018; **55**: 54-61 [PMID: 30286399 DOI: 10.1016/j.coi.2018.09.011]

135 **Münz C**. Non-canonical Functions of Macroautophagy Proteins During Endocytosis by Myeloid Antigen Presenting Cells. *Front Immunol* 2018; **9**: 2765 [PMID: 30542350 DOI: 10.3389/fimmu.2018.02765]

136 **Schneider JL**, Cuervo AM. Liver autophagy: much more than just taking out the trash. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 187-200 [PMID: 24192609 DOI: 10.1038/nrgastro.2013.211]

137 **Cuervo AM**, Macian F. Autophagy and the immune function in aging. *Curr Opin Immunol* 2014; **29**: 97-104 [PMID: 24929664 DOI: 10.1016/j.coi.2014.05.006]

138 **Gutierrez MG**, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. *Cell* 2004; **119**: 753-766 [PMID: 15607973 DOI: 10.1016/j.cell.2004.11.038]

139 **Czaja MJ**. Function of Autophagy in Nonalcoholic Fatty Liver Disease. *Dig Dis Sci* 2016; **61**: 1304-1313 [PMID: 26725058 DOI: 10.1007/s10620-015-4025-x]

140 **Wei J**, Long L, Yang K, Guy C, Shrestha S, Chen Z, Wu C, Vogel P, Neale G, Green DR, Chi H. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. *Nat Immunol* 2016; **17**: 277-285 [PMID: 26808230 DOI: 10.1038/ni.3365]

141 **Peral de Castro C**, Jones SA, Ní Cheallaigh C, Hearnden CA, Williams L, Winter J, Lavelle EC, Mills KH, Harris J. Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. *J Immunol* 2012; **189**: 4144-4153 [PMID: 22972933 DOI: 10.4049/jimmunol.1201946]

142 **Kroemer G**, Mariño G, Levine B. Autophagy and the integrated stress response. *Mol Cell* 2010; **40**: 280-293 [PMID: 20965422 DOI: 10.1016/j.molcel.2010.09.023]

143 **Amelio I**, Melino G, Knight RA. Cell death pathology: cross-talk with autophagy and its clinical implications. *Biochem Biophys Res Commun* 2011; **414**: 277-281 [PMID: 21963447 DOI: 10.1016/j.bbrc.2011.09.080]

144 **Yonekawa T**, Thorburn A. Autophagy and cell death. *Essays Biochem* 2013; **55**: 105-117 [PMID: 24070475 DOI: 10.1042/bse0550105]

145 **Boya P**, González-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D, Souquere S, Yoshimori T, Pierron G, Codogno P, Kroemer G. Inhibition of macroautophagy triggers apoptosis. *Mol Cell Biol* 2005; **25**: 1025-1040 [PMID: 15657430 DOI: 10.1128/MCB.25.3.1025-1040.2005]

146 **Maiuri MC**, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. *Nat Rev Mol Cell Biol* 2007; **8**: 741-752 [PMID: 17717517 DOI: 10.1038/nrm2239]

147 **Eisenberg-Lerner A**, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. *Cell Death Differ* 2009; **16**: 966-975 [PMID: 19325568 DOI: 10.1038/cdd.2009.33]

148 **Nikoletopoulou V**, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. *Biochim Biophys Acta* 2013; **1833**: 3448-3459 [PMID: 23770045 DOI: 10.1016/j.bbamcr.2013.06.001]

149 **Wang K**. Autophagy and apoptosis in liver injury. *Cell Cycle* 2015; **14**: 1631-1642 [PMID: 25927598 DOI: 10.1080/15384101.2015.1038685]

150 **Baehrecke EH**. Autophagy: dual roles in life and death? *Nat Rev Mol Cell Biol* 2005; **6**: 505-510 [PMID: 15928714 DOI: 10.1038/nrm1666]

151 **Levine B**, Yuan J. Autophagy in cell death: an innocent convict? *J Clin Invest* 2005; **115**: 2679-2688 [PMID: 16200202 DOI: 10.1172/JCI26390]

152 **Mariño G**, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. *Nat Rev Mol Cell Biol* 2014; **15**: 81-94 [PMID: 24401948 DOI: 10.1038/nrm3735]

153 **Ni HM**, Bockus A, Boggess N, Jaeschke H, Ding WX. Activation of autophagy protects against acetaminophen-induced hepatotoxicity. *Hepatology* 2012; **55**: 222-232 [PMID: 21932416 DOI: 10.1002/hep.24690]

154 **Lockshin RA**, Zakeri Z. Cell death in health and disease. *J Cell Mol Med* 2007; **11**: 1214-1224 [PMID: 18031301 DOI: 10.1111/j.1582-4934.2007.00150.x]

155 **Strozyk E**, Kulms D. The role of AKT/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. *Int J Mol Sci* 2013; **14**: 15260-15285 [PMID: 23887651 DOI: 10.3390/ijms140815260]

156 **Liang Q**, Xiao Y, Liu K, Zhong C, Zeng M, Xiao F. Cr(VI)-Induced Autophagy Protects L-02 Hepatocytes from Apoptosis Through the ROS-AKT-mTOR Pathway. *Cell Physiol Biochem* 2018; **51**: 1863-1878 [PMID: 30504711 DOI: 10.1159/000495713]

157 **Zhou B**, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. *Semin Cancer Biol* 2020; **66**: 89-100 [PMID: 30880243 DOI: 10.1016/j.semcancer.2019.03.002]

158 **Liu J**, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D. Autophagy-Dependent Ferroptosis: Machinery and Regulation. *Cell Chem Biol* 2020; **27**: 420-435 [PMID: 32160513 DOI: 10.1016/j.chembiol.2020.02.005]

159 **Gao M**, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. *Cell Res* 2016; **26**: 1021-1032 [PMID: 27514700 DOI: 10.1038/cr.2016.95]

160 **Hou W**, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, Kang R, Tang D. Autophagy promotes ferroptosis by degradation of ferritin. *Autophagy* 2016; **12**: 1425-1428 [PMID: 27245739 DOI: 10.1080/15548627.2016.1187366]

161 **Kang R**, Tang D. Autophagy and Ferroptosis - What's the Connection? *Curr Pathobiol Rep* 2017; **5**: 153-159 [PMID: 29038744 DOI: 10.1007/s40139-017-0139-5]

162 **Bai Y**, Meng L, Han L, Jia Y, Zhao Y, Gao H, Kang R, Wang X, Tang D, Dai E. Lipid storage and lipophagy regulates ferroptosis. *Biochem Biophys Res Commun* 2019; **508**: 997-1003 [PMID: 30545638 DOI: 10.1016/j.bbrc.2018.12.039]

163 **Guo H**, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. *Nat Med* 2015; **21**: 677-687 [PMID: 26121197 DOI: 10.1038/nm.3893]

164 **Broz P**, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. *Nat Rev Immunol* 2016; **16**: 407-420 [PMID: 27291964 DOI: 10.1038/nri.2016.58]

165 **Shibutani ST**, Saitoh T, Nowag H, Münz C, Yoshimori T. Autophagy and autophagy-related proteins in the immune system. *Nat Immunol* 2015; **16**: 1014-1024 [PMID: 26382870 DOI: 10.1038/ni.3273]

166 **de Lavera I**, Pavon AD, Paz MV, Oropesa-Avila M, de la Mata M, Alcocer-Gomez E, Garrido-Maraver J, Cotan D, Alvarez-Cordoba M, Sanchez-Alcazar JA. The Connections Among Autophagy, Inflammasome and Mitochondria. *Curr Drug Targets* 2017; **18**: 1030-1038 [PMID: 27231105 DOI: 10.2174/1389450117666160527143143]

167 **Sanjuan MA**, Dillon CP, Tait SW, Moshiach S, Dorsey F, Connell S, Komatsu M, Tanaka K, Cleveland JL, Withoff S, Green DR. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. *Nature* 2007; **450**: 1253-1257 [PMID: 18097414 DOI: 10.1038/nature06421]

168 **Yordy B**, Iwasaki A. Autophagy in the control and pathogenesis of viral infection. *Curr Opin Virol* 2011; **1**: 196-203 [PMID: 21927636 DOI: 10.1016/j.coviro.2011.05.016]

169 **Oh JE**, Lee HK. Autophagy as an innate immune modulator. *Immune Netw* 2013; **13**: 1-9 [PMID: 23559894 DOI: 10.4110/in.2013.13.1.1]

170 **Schroder K**, Tschopp J. The inflammasomes. *Cell* 2010; **140**: 821-832 [PMID: 20303873 DOI: 10.1016/j.cell.2010.01.040]

171 **Wang Z**, Zhang S, Xiao Y, Zhang W, Wu S, Qin T, Yue Y, Qian W, Li L. NLRP3 Inflammasome and Inflammatory Diseases. *Oxid Med Cell Longev* 2020; **2020**: 4063562 [PMID: 32148650 DOI: 10.1155/2020/4063562]

172 **Thorburn A**. Autophagy and its effects: making sense of double-edged swords. *PLoS Biol* 2014; **12**: e1001967 [PMID: 25313680 DOI: 10.1371/journal.pbio.1001967]

173 **White E**. Deconvoluting the context-dependent role for autophagy in cancer. *Nat Rev Cancer* 2012; **12**: 401-410 [PMID: 22534666 DOI: 10.1038/nrc3262]

174 **Amaravadi R**, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. *Genes Dev* 2016; **30**: 1913-1930 [PMID: 27664235 DOI: 10.1101/gad.287524.116]

175 **Deretic V**, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. *Nat Rev Immunol* 2013; **13**: 722-737 [PMID: 24064518 DOI: 10.1038/nri3532]

176 **Codogno P**, Meijer AJ. Autophagy in the liver. *J Hepatol* 2013; **59**: 389-391 [PMID: 23669287 DOI: 10.1016/j.jhep.2013.02.031]

177 **Gual P**, Gilgenkrantz H, Lotersztajn S. Autophagy in chronic liver diseases: the two faces of Janus. *Am J Physiol Cell Physiol* 2017; **312**: C263-C273 [PMID: 27903585 DOI: 10.1152/ajpcell.00295.2016]

178 **Ueno T**, Komatsu M. Autophagy in the liver: functions in health and disease. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 170-184 [PMID: 28053338 DOI: 10.1038/nrgastro.2016.185]

179 **Weiskirchen R**, Tacke F. Relevance of Autophagy in Parenchymal and Non-Parenchymal Liver Cells for Health and Disease. *Cells* 2019; **8** [PMID: 30609663 DOI: 10.3390/cells8010016]

180 **Allaire M**, Rautou PE, Codogno P, Lotersztajn S. Autophagy in liver diseases: Time for translation? *J Hepatol* 2019; **70**: 985-998 [PMID: 30711404 DOI: 10.1016/j.jhep.2019.01.026]

181 **Yan S**, Huda N, Khambu B, Yin XM. Relevance of autophagy to fatty liver diseases and potential therapeutic applications. *Amino Acids* 2017; **49**: 1965-1979 [PMID: 28478585 DOI: 10.1007/s00726-017-2429-y]

182 **Khambu B**, Yan S, Huda N, Liu G, Yin XM. Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease. *Liver Res* 2018; **2**: 112-119 [PMID: 31123622 DOI: 10.1016/j.livres.2018.09.004]

183 **Khambu B**, Yan S, Huda N, Liu G, Yin XM. Homeostatic Role of Autophagy in Hepatocytes. *Semin Liver Dis* 2018; **38**: 308-319 [PMID: 30357768 DOI: 10.1055/s-0038-1669939]

184 **Hazari Y**, Bravo-San Pedro JM, Hetz C, Galluzzi L, Kroemer G. Autophagy in hepatic adaptation to stress. *J Hepatol* 2020; **72**: 183-196 [PMID: 31849347 DOI: 10.1016/j.jhep.2019.08.026]

185 **Deretic V**, Levine B. Autophagy balances inflammation in innate immunity. *Autophagy* 2018; **14**: 243-251 [PMID: 29165043 DOI: 10.1080/15548627.2017.1402992]

186 **Eslam M**, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020; **158**: 1999-2014.e1 [PMID: 32044314 DOI: 10.1053/j.gastro.2019.11.312]

187 **Eslam M**, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; **73**: 202-209 [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039]

188 **Marra F**, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. *J Hepatol* 2018; **68**: 280-295 [PMID: 29154964 DOI: 10.1016/j.jhep.2017.11.014]

189 **Friedman SL**, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med* 2018; **24**: 908-922 [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9]

190 **Hammoutene A**, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. *J Hepatol* 2019; **70**: 1278-1291 [PMID: 30797053 DOI: 10.1016/j.jhep.2019.02.012]

191 **Cingolani F**, Czaja MJ. Regulation and Functions of Autophagic Lipolysis. *Trends Endocrinol Metab* 2016; **27**: 696-705 [PMID: 27365163 DOI: 10.1016/j.tem.2016.06.003]

192 **Zechner R**, Kienesberger PC, Haemmerle G, Zimmermann R, Lass A. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. *J Lipid Res* 2009; **50**: 3-21 [PMID: 18952573 DOI: 10.1194/jlr.R800031-JLR200]

193 **Lee IH**, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. *Proc Natl Acad Sci U S A* 2008; **105**: 3374-3379 [PMID: 18296641 DOI: 10.1073/pnas.0712145105]

194 **Tomaipitinca L**, Mandatori S, Mancinelli R, Giulitti F, Petrungaro S, Moresi V, Facchiano A, Ziparo E, Gaudio E, Giampietri C. The Role of Autophagy in Liver Epithelial Cells and Its Impact on Systemic Homeostasis. *Nutrients* 2019; **11** [PMID: 30979078 DOI: 10.3390/nu11040827]

195 **Kurahashi T**, Hamashima S, Shirato T, Lee J, Homma T, Kang ES, Fujii J. An SOD1 deficiency enhances lipid droplet accumulation in the fasted mouse liver by aborting lipophagy. *Biochem Biophys Res Commun* 2015; **467**: 866-871 [PMID: 26474701 DOI: 10.1016/j.bbrc.2015.10.052]

196 **Rodriguez-Navarro JA**, Kaushik S, Koga H, Dall'Armi C, Shui G, Wenk MR, Di Paolo G, Cuervo AM. Inhibitory effect of dietary lipids on chaperone-mediated autophagy. *Proc Natl Acad Sci U S A* 2012; **109**: E705-E714 [PMID: 22331875 DOI: 10.1073/pnas.1113036109]

197 **Liu HY**, Han J, Cao SY, Hong T, Zhuo D, Shi J, Liu Z, Cao W. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. *J Biol Chem* 2009; **284**: 31484-31492 [PMID: 19758991 DOI: 10.1074/jbc.M109.033936]

198 **Koga H**, Kaushik S, Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion. *FASEB J* 2010; **24**: 3052-3065 [PMID: 20375270 DOI: 10.1096/fj.09-144519]

199 **Liu K**, Lou J, Wen T, Yin J, Xu B, Ding W, Wang A, Liu D, Zhang C, Chen D, Li N. Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX. *Liver Int* 2013; **33**: 1566-1574 [PMID: 23875779 DOI: 10.1111/Liv.12238]

200 **Kovsan J**, Blüher M, Tarnovscki T, Klöting N, Kirshtein B, Madar L, Shai I, Golan R, Harman-Boehm I, Schön MR, Greenberg AS, Elazar Z, Bashan N, Rudich A. Altered autophagy in human adipose tissues in obesity. *J Clin Endocrinol Metab* 2011; **96**: E268-E277 [PMID: 21047928 DOI: 10.1210/jc.2010-1681]

201 **Yang L**, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. *Cell Metab* 2010; **11**: 467-478 [PMID: 20519119 DOI: 10.1016/j.cmet.2010.04.005]

202 **Nuñez CE**, Rodrigues VS, Gomes FS, Moura RF, Victorio SC, Bombassaro B, Chaim EA, Pareja JC, Geloneze B, Velloso LA, Araujo EP. Defective regulation of adipose tissue autophagy in obesity. *Int J Obes (Lond)* 2013; **37**: 1473-1480 [PMID: 23478428 DOI: 10.1038/ijo.2013.27]

203 **Liu Y**, Palanivel R, Rai E, Park M, Gabor TV, Scheid MP, Xu A, Sweeney G. Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin sensitivity during high-fat diet feeding in mice. *Diabetes* 2015; **64**: 36-48 [PMID: 25071026 DOI: 10.2337/db14-0267]

204 **Lavallard VJ**, Meijer AJ, Codogno P, Gual P. Autophagy, signaling and obesity. *Pharmacol Res* 2012; **66**: 513-525 [PMID: 22982482 DOI: 10.1016/j.phrs.2012.09.003]

205 **Gual P**, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. *Biochimie* 2005; **87**: 99-109 [PMID: 15733744 DOI: 10.1016/j.biochi.2004.10.019]

206 **Tremblay F**, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, Nowotny P, Waldhäusl W, Marette A, Roden M. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. *Diabetes* 2005; **54**: 2674-2684 [PMID: 16123357 DOI: 10.2337/diabetes.54.9.2674]

207 **Hotamisligil GS**. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell* 2010; **140**: 900-917 [PMID: 20303879 DOI: 10.1016/j.cell.2010.02.034]

208 **Codogno P**, Meijer AJ. Autophagy: a potential link between obesity and insulin resistance. *Cell Metab* 2010; **11**: 449-451 [PMID: 20519116 DOI: 10.1016/j.cmet.2010.05.006]

209 **Inami Y**, Yamashina S, Izumi K, Ueno T, Tanida I, Ikejima K, Watanabe S. Hepatic steatosis inhibits autophagic proteolysis *via* impairment of autophagosomal acidification and cathepsin expression. *Biochem Biophys Res Commun* 2011; **412**: 618-625 [PMID: 21856284 DOI: 10.1016/j.bbrc.2011.08.012]

210 **Fukuo Y**, Yamashina S, Sonoue H, Arakawa A, Nakadera E, Aoyama T, Uchiyama A, Kon K, Ikejima K, Watanabe S. Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease. *Hepatol Res* 2014; **44**: 1026-1036 [PMID: 24299564 DOI: 10.1111/hepr.12282]

211 **Wang X**, Zhang X, Chu ESH, Chen X, Kang W, Wu F, To KF, Wong VWS, Chan HLY, Chan MTV, Sung JJY, Wu WKK, Yu J. Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. *FASEB J* 2018; **32**: 37-51 [PMID: 28842428 DOI: 10.1096/fj.201601393R]

212 **Mizunoe Y**, Sudo Y, Okita N, Hiraoka H, Mikami K, Narahara T, Negishi A, Yoshida M, Higashibata R, Watanabe S, Kaneko H, Natori D, Furuichi T, Yasukawa H, Kobayashi M, Higami Y. Involvement of lysosomal dysfunction in autophagosome accumulation and early pathologies in adipose tissue of obese mice. *Autophagy* 2017; **13**: 642-653 [PMID: 28121218 DOI: 10.1080/15548627.2016.1274850]

213 **Ju L**, Han J, Zhang X, Deng Y, Yan H, Wang C, Li X, Chen S, Alimujiang M, Li X, Fang Q, Yang Y, Jia W. Obesity-associated inflammation triggers an autophagy-lysosomal response in adipocytes and causes degradation of perilipin 1. *Cell Death Dis* 2019; **10**: 121 [PMID: 30741926 DOI: 10.1038/s41419-019-1393-8]

214 **Mizunoe Y**, Kobayashi M, Tagawa R, Nakagawa Y, Shimano H, Higami Y. Association between Lysosomal Dysfunction and Obesity-Related Pathology: A Key Knowledge to Prevent Metabolic Syndrome. *Int J Mol Sci* 2019; **20**: 3688 [PMID: 31357643DOI: 10.3390/ijms20153688]

215 **Qian Q**, Zhang Z, Li M, Savage K, Cheng D, Rauckhorst AJ, Ankrum JA, Taylor EB, Ding WX, Xiao Y, Cao HJ, Yang L. Hepatic Lysosomal iNOS Activity Impairs Autophagy in Obesity. *Cell Mol Gastroenterol Hepatol* 2019; **8**: 95-110 [PMID: 30926581 DOI: 10.1016/j.jcmgh.2019.03.005]

216 **Wu H**, Wang Y, Li W, Chen H, Du L, Liu D, Wang X, Xu T, Liu L, Chen Q. Deficiency of mitophagy receptor FUNDC1 impairs mitochondrial quality and aggravates dietary-induced obesity and metabolic syndrome. *Autophagy* 2019; **15**: 1882-1898 [PMID: 30898010 DOI: 10.1080/15548627.2019.1596482]

217 **Su Z**, Nie Y, Huang X, Zhu Y, Feng B, Tang L, Zheng G. Mitophagy in Hepatic Insulin Resistance: Therapeutic Potential and Concerns. *Front Pharmacol* 2019; **10**: 1193 [PMID: 31649547 DOI: 10.3389/fphar.2019.01193]

218 **Kim KH**, Jeong YT, Oh H, Kim SH, Cho JM, Kim YN, Kim SS, Kim DH, Hur KY, Kim HK, Ko T, Han J, Kim HL, Kim J, Back SH, Komatsu M, Chen H, Chan DC, Konishi M, Itoh N, Choi CS, Lee MS. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. *Nat Med* 2013; **19**: 83-92 [PMID: 23202295 DOI: 10.1038/nm.3014]

219 **Zhu S**, Wu Y, Ye X, Ma L, Qi J, Yu D, Wei Y, Lin G, Ren G, Li D. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. *Mol Cell Biochem* 2016; **420**: 107-119 [PMID: 27435856 DOI: 10.1007/s11010-016-2774-2]

220 **Shen J**, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. *J Hepatol* 2012; **56**: 1363-1370 [PMID: 22314419 DOI: 10.1016/j.jhep.2011.12.025]

221 **Adams AC**, Halstead CA, Hansen BC, Irizarry AR, Martin JA, Myers SR, Reynolds VL, Smith HW, Wroblewski VJ, Kharitonenkov A. LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. *PLoS One* 2013; **8**: e65763 [PMID: 23823755 DOI: 10.1371/journal.pone.0065763]

222 **Kharitonenkov A**, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, Li S, Koester A, Ford AM, Coskun T, Dunbar JD, Cheng CC, Frye CC, Bumol TF, Moller DE. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. *PLoS One* 2013; **8**: e58575 [PMID: 23536797 DOI: 10.1371/journal.pone.0058575]

223 **Gaich G**, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. *Cell Metab* 2013; **18**: 333-340 [PMID: 24011069 DOI: 10.1016/j.cmet.2013.08.005]

224 **Romero M**, Zorzano A. Role of autophagy in the regulation of adipose tissue biology. *Cell Cycle* 2019; **18**: 1435-1445 [PMID: 31135269 DOI: 10.1080/15384101.2019.1624110]

225 **Wang L**, Liu X, Nie J, Zhang J, Kimball SR, Zhang H, Zhang WJ, Jefferson LS, Cheng Z, Ji Q, Shi Y. ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis. *Hepatology* 2015; **61**: 486-496 [PMID: 25203315 DOI: 10.1002/hep.27420]

226 **Sinha RA**, Yen PM. Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD. *Cell Biosci* 2016; **6**: 46 [PMID: 27437098 DOI: 10.1186/s13578-016-0113-7]

227 **Chi HC**, Tsai CY, Tsai MM, Yeh CT, Lin KH. Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. *J Biomed Sci* 2019; **26**: 24 [PMID: 30849993 DOI: 10.1186/s12929-019-0517-x]

228 **Pang L**, Liu K, Liu D, Lv F, Zang Y, Xie F, Yin J, Shi Y, Wang Y, Chen D. Differential effects of reticulophagy and mitophagy on nonalcoholic fatty liver disease. *Cell Death Dis* 2018; **9**: 90 [PMID: 29367738 DOI: 10.1038/s41419-017-0136-y]

229 **Yamada T**, Murata D, Adachi Y, Itoh K, Kameoka S, Igarashi A, Kato T, Araki Y, Huganir RL, Dawson TM, Yanagawa T, Okamoto K, Iijima M, Sesaki H. Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease. *Cell Metab* 2018; **28**: 588-604.e5 [PMID: 30017357 DOI: 10.1016/j.cmet.2018.06.014]

230 **Lee K**, Haddad A, Osme A, Kim C, Borzou A, Ilchenko S, Allende D, Dasarathy S, McCullough A, Sadygov RG, Kasumov T. Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits. *Mol Cell Proteomics* 2018; **17**: 2371-2386 [PMID: 30171159 DOI: 10.1074/mcp.RA118.000961]

231 **Shao N**, Yu XY, Ma XF, Lin WJ, Hao M, Kuang HY. Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway. *Gastroenterol Res Pract* 2018; **2018**: 1864307 [PMID: 29849583 DOI: 10.1155/2018/1864307]

232 **Li R**, Xin T, Li D, Wang C, Zhu H, Zhou H. Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy. *Redox Biol* 2018; **18**: 229-243 [PMID: 30056271 DOI: 10.1016/j.redox.2018.07.011]

233 **Yu X**, Hao M, Liu Y, Ma X, Lin W, Xu Q, Zhou H, Shao N, Kuang H. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation *via* mitophagy. *Eur J Pharmacol* 2019; **864**: 172715 [PMID: 31593687 DOI: 10.1016/j.ejphar.2019.172715]

234 **Zhou T**, Chang L, Luo Y, Zhou Y, Zhang J. Mst1 inhibition attenuates non-alcoholic fatty liver disease *via* reversing Parkin-related mitophagy. *Redox Biol* 2019; **21**: 101120 [PMID: 30708325 DOI: 10.1016/j.redox.2019.101120]

235 **Niso-Santano M**, Malik SA, Pietrocola F, Bravo-San Pedro JM, Mariño G, Cianfanelli V, Ben-Younès A, Troncoso R, Markaki M, Sica V, Izzo V, Chaba K, Bauvy C, Dupont N, Kepp O, Rockenfeller P, Wolinski H, Madeo F, Lavandero S, Codogno P, Harper F, Pierron G, Tavernarakis N, Cecconi F, Maiuri MC, Galluzzi L, Kroemer G. Unsaturated fatty acids induce non-canonical autophagy. *EMBO J* 2015; **34**: 1025-1041 [PMID: 25586377 DOI: 10.15252/embj.201489363]

236 **Singh R**, Xiang Y, Wang Y, Baikati K, Cuervo AM, Luu YK, Tang Y, Pessin JE, Schwartz GJ, Czaja MJ. Autophagy regulates adipose mass and differentiation in mice. *J Clin Invest* 2009; **119**: 3329-3339 [PMID: 19855132 DOI: 10.1172/JCI39228]

237 **Mei S**, Ni HM, Manley S, Bockus A, Kassel KM, Luyendyk JP, Copple BL, Ding WX. Differential roles of unsaturated and saturated fatty acids on autophagy and apoptosis in hepatocytes. *J Pharmacol Exp Ther* 2011; **339**: 487-498 [PMID: 21856859 DOI: 10.1124/jpet.111.184341]

238 **Deng X**, Pan X, Cheng C, Liu B, Zhang H, Zhang Y, Xu K. Regulation of SREBP-2 intracellular trafficking improves impaired autophagic flux and alleviates endoplasmic reticulum stress in NAFLD. *Biochim Biophys Acta Mol Cell Biol Lipids* 2017; **1862**: 337-350 [PMID: 28011404 DOI: 10.1016/j.bbalip.2016.12.007]

239 **Maus M**, Cuk M, Patel B, Lian J, Ouimet M, Kaufmann U, Yang J, Horvath R, Hornig-Do HT, Chrzanowska-Lightowlers ZM, Moore KJ, Cuervo AM, Feske S. Store-Operated Ca2+ Entry Controls Induction of Lipolysis and the Transcriptional Reprogramming to Lipid Metabolism. *Cell Metab* 2017; **25**: 698-712 [PMID: 28132808 DOI: 10.1016/j.cmet.2016.12.021]

240 **Li S**, Dou X, Ning H, Song Q, Wei W, Zhang X, Shen C, Li J, Sun C, Song Z. Sirtuin 3 acts as a negative regulator of autophagy dictating hepatocyte susceptibility to lipotoxicity. *Hepatology* 2017; **66**: 936-952 [PMID: 28437863 DOI: 10.1002/hep.29229]

241 **Sinha RA**, Farah BL, Singh BK, Siddique MM, Li Y, Wu Y, Ilkayeva OR, Gooding J, Ching J, Zhou J, Martinez L, Xie S, Bay BH, Summers SA, Newgard CB, Yen PM. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. *Hepatology* 2014; **59**: 1366-1380 [PMID: 23929677 DOI: 10.1002/hep.26667]

242 **Ding WX**. Drinking coffee burns hepatic fat by inducing lipophagy coupled with mitochondrial β-oxidation. *Hepatology* 2014; **59**: 1235-1238 [PMID: 24114874 DOI: 10.1002/hep.26736]

243 **Molloy JW**, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. *Hepatology* 2012; **55**: 429-436 [PMID: 21987293 DOI: 10.1002/hep.24731]

244 **Anty R**, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S, Gire C, Amzolini A, Ben-Amor I, Saint-Paul MC, Mariné-Barjoan E, Pariente A, Gugenheim J, Gual P, Tran A. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. *J Hepatol* 2012; **57**: 1090-1096 [PMID: 22820478 DOI: 10.1016/j.jhep.2012.07.014]

245 **Chen R**, Wang Q, Song S, Liu F, He B, Gao X. Protective role of autophagy in methionine-choline deficient diet-induced advanced nonalcoholic steatohepatitis in mice. *Eur J Pharmacol* 2016; **770**: 126-133 [PMID: 26593434 DOI: 10.1016/j.ejphar.2015.11.012]

246 **Ji G**, Wang Y, Deng Y, Li X, Jiang Z. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. *Lipids Health Dis* 2015; **14**: 134 [PMID: 26498332 DOI: 10.1186/s12944-015-0139-6]

247 **Ding S**, Jiang J, Zhang G, Bu Y, Zhang G, Zhao X. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. *PLoS One* 2017; **12**: e0183541 [PMID: 28817690 DOI: 10.1371/journal.pone.0183541]

248 **Xiao L**, Liang S, Ge L, Qiu S, Wan H, Wu S, Fei J, Peng S, Zeng X. Si-Wei-Qing-Gan-Tang Improves Non-Alcoholic Steatohepatitis by Modulating the Nuclear Factor-κB Signal Pathway and Autophagy in Methionine and Choline Deficient Diet-Fed Rats. *Front Pharmacol* 2020; **11**: 530 [PMID: 32425782 DOI: 10.3389/fphar.2020.00530]

249 **Wang X**, Zhang ZF, Zheng GH, Wang AM, Sun CH, Qin SP, Zhuang J, Lu J, Ma DF, Zheng YL. The Inhibitory Effects of Purple Sweet Potato Color on Hepatic Inflammation Is Associated with Restoration of NAD⁺ Levels and Attenuation of NLRP3 Inflammasome Activation in High-Fat-Diet-Treated Mice. *Molecules* 2017; **22** [PMID: 28786950 DOI: 10.3390/molecules22081315]

250 **Kim HM**, Kim Y, Lee ES, Huh JH, Chung CH. Caffeic acid ameliorates hepatic steatosis and reduces ER stress in high fat diet-induced obese mice by regulating autophagy. *Nutrition* 2018; **55-56**: 63-70 [PMID: 29960159 DOI: 10.1016/j.nut.2018.03.010]

251 **Elmansi AM**, El-Karef AA, Shishtawy MMEl, Eissa LA. Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways. *Ann Hepatol* 2017; **16**: 607-618 [PMID: 28611265 DOI: 10.5604/01.3001.0010.0307]

252 **Liu C**, Liu L, Zhu HD, Sheng JQ, Wu XL, He XX, Tian DA, Liao JZ, Li PY. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. *Sci Rep* 2018; **8**: 4108 [PMID: 29515134 DOI: 10.1038/s41598-018-22339-0]

253 **Alexaki A**, Gupta SD, Majumder S, Kono M, Tuymetova G, Harmon JM, Dunn TM, Proia RL. Autophagy regulates sphingolipid levels in the liver. *J Lipid Res* 2014; **55**: 2521-2531 [PMID: 25332431 DOI: 10.1194/jlr.M051862]

254 **Menikdiwela KR**, Ramalingam L, Rasha F, Wang S, Dufour JM, Kalupahana NS, Sunahara KKS, Martins JO, Moustaid-Moussa N. Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system. *Cell Death Dis* 2020; **11**: 87 [PMID: 32015340 DOI: 10.1038/s41419-020-2275-9]

255 **Tanaka S**, Hikita H, Tatsumi T, Sakamori R, Nozaki Y, Sakane S, Shiode Y, Nakabori T, Saito Y, Hiramatsu N, Tabata K, Kawabata T, Hamasaki M, Eguchi H, Nagano H, Yoshimori T, Takehara T. Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. *Hepatology* 2016; **64**: 1994-2014 [PMID: 27637015 DOI: 10.1002/hep.28820]

256 **Yan H**, Gao Y, Zhang Y. Inhibition of JNK suppresses autophagy and attenuates insulin resistance in a rat model of nonalcoholic fatty liver disease. *Mol Med Rep* 2017; **15**: 180-186 [PMID: 27909723 DOI: 10.3892/mmr.2016.5966]

257 **Lavallard VJ**, Gual P. Autophagy and non-alcoholic fatty liver disease. *Biomed Res Int* 2014; **2014**: 120179 [PMID: 25295245 DOI: 10.1155/2014/120179]

258 **Mao Y**, Yu F, Wang J, Guo C, Fan X. Autophagy: a new target for nonalcoholic fatty liver disease therapy. *Hepat Med* 2016; **8**: 27-37 [PMID: 27099536 DOI: 10.2147/HMER.S98120]

259 **Schneider JL**, Suh Y, Cuervo AM. Deficient chaperone-mediated autophagy in liver leads to metabolic dysregulation. *Cell Metab* 2014; **20**: 417-432 [PMID: 25043815 DOI: 10.1016/j.cmet.2014.06.009]

260 **Kaushik S**, Cuervo AM. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. *Nat Cell Biol* 2015; **17**: 759-770 [PMID: 25961502 DOI: 10.1038/ncb3166]

261 **Schneider JL**, Villarroya J, Diaz-Carretero A, Patel B, Urbanska AM, Thi MM, Villarroya F, Santambrogio L, Cuervo AM. Loss of hepatic chaperone-mediated autophagy accelerates proteostasis failure in aging. *Aging Cell* 2015; **14**: 249-264 [PMID: 25620427 DOI: 10.1111/acel.12310]

262 **Brunt EM**, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999; **94**: 2467-2474 [PMID: 10484010 DOI: 10.1111/j.1572-0241.1999.01377.x]

263 **Kleiner DE**, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]

264 **Bedossa P**, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. *Hepatology* 2012; **56**: 1751-1759 [PMID: 22707395 DOI: 10.1002/hep.25889]

265 **Harada M**, Hanada S, Toivola DM, Ghori N, Omary MB. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. *Hepatology* 2008; **47**: 2026-2035 [PMID: 18454506 DOI: 10.1002/hep.22294]

266 **González-Rodríguez A**, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillón J, Lo Iacono O, Corazzari M, Fimia GM, Piacentini M, Muntané J, Boscá L, García-Monzón C, Martín-Sanz P, Valverde ÁM. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. *Cell Death Dis* 2014; **5**: e1179 [PMID: 24743734 DOI: 10.1038/cddis.2014.162]

267 **Li P**, He K, Li J, Liu Z, Gong J. The role of Kupffer cells in hepatic diseases. *Mol Immunol* 2017; **85**: 222-229 [PMID: 28314211 DOI: 10.1016/j.molimm.2017.02.018]

268 **Tacke F**. Targeting hepatic macrophages to treat liver diseases. *J Hepatol* 2017; **66**: 1300-1312 [PMID: 28267621 DOI: 10.1016/j.jhep.2017.02.026]

269 **Thomas H**. NAFLD: A critical role for the NLRP3 inflammasome in NASH. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 197 [PMID: 28223701 DOI: 10.1038/nrgastro.2017.21]

270 **Feldstein AE**, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression *via* a lysosomal pathway. *Hepatology* 2004; **40**: 185-194 [PMID: 15239102 DOI: 10.1002/hep.20283]

271 **Tang Y**, Cao G, Min X, Wang T, Sun S, Du X, Zhang W. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation. *J Physiol Biochem* 2018; **74**: 503-510 [PMID: 30019185 DOI: 10.1007/s13105-018-0644-y]

272 **Xu X**, Grijalva A, Skowronski A, van Eijk M, Serlie MJ, Ferrante AW Jr. Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. *Cell Metab* 2013; **18**: 816-830 [PMID: 24315368 DOI: 10.1016/j.cmet.2013.11.001]

273 **Grijalva A**, Xu X, Ferrante AW Jr. Autophagy Is Dispensable for Macrophage-Mediated Lipid Homeostasis in Adipose Tissue. *Diabetes* 2016; **65**: 967-980 [PMID: 26868294 DOI: 10.2337/db15-1219]

274 **Bieghs V**, Hendrikx T, van Gorp PJ, Verheyen F, Guichot YD, Walenbergh SM, Jeurissen ML, Gijbels M, Rensen SS, Bast A, Plat J, Kalhan SC, Koek GH, Leitersdorf E, Hofker MH, Lütjohann D, Shiri-Sverdlov R. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. *Gastroenterology* 2013; **144**: 167-178.e1 [PMID: 23041327 DOI: 10.1053/j.gastro.2012.09.062]

275 **Houben T**, Oligschlaeger Y, Hendrikx T, Bitorina AV, Walenbergh SMA, van Gorp PJ, Gijbels MJJ, Friedrichs S, Plat J, Schaap FG, Lütjohann D, Hofker MH, Shiri-Sverdlov R. Cathepsin D regulates lipid metabolism in murine steatohepatitis. *Sci Rep* 2017; **7**: 3494 [PMID: 28615690 DOI: 10.1038/s41598-017-03796-5]

276 **Ford ES**, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; **287**: 356-359 [PMID: 11790215 DOI: 10.1001/jama.287.3.356]

277 **Noureddin M**, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. *Hepatology* 2013; **58**: 1644-1654 [PMID: 23686698 DOI: 10.1002/hep.26465]

278 **Li Z**, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. *Hepatology* 2008; **47**: 1495-1503 [PMID: 18220271 DOI: 10.1002/hep.22183]

279 **Sunny NE**, Bril F, Cusi K. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. *Trends Endocrinol Metab* 2017; **28**: 250-260 [PMID: 27986466 DOI: 10.1016/j.tem.2016.11.006]

280 **Simões ICM**, Fontes A, Pinton P, Zischka H, Wieckowski MR. Mitochondria in non-alcoholic fatty liver disease. *Int J Biochem Cell Biol* 2018; **95**: 93-99 [PMID: 29288054 DOI: 10.1016/j.biocel.2017.12.019]

281 **Hammoutene A**, Lasselin J, Vion A, Colnot N, Paradis V, Lotersztajn S, Boulanger C, Rautou P. Defective autophagy in liver sinusoidal endothelial cells promotes non alcoholic steatohepatitis and fibrosis development. *J Hepatol* 2018; **68**: S29 [DOI: 10.1016/S0168-8278(18)30276-9]

282 **Hammoutene A**, Biquard L, Lasselin J, Kheloufi M, Tanguy M, Vion AC, Mérian J, Colnot N, Loyer X, Tedgui A, Codogno P, Lotersztajn S, Paradis V, Boulanger CM, Rautou PE. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. *J Hepatol* 2020; **72**: 528-538 [PMID: 31726115 DOI: 10.1016/j.jhep.2019.10.028]

283 **Scita G**, Di Fiore PP. The endocytic matrix. *Nature* 2010; **463**: 464-473 [PMID: 20110990 DOI: 10.1038/nature08910]

284 **Zhao GN**, Zhang P, Gong J, Zhang XJ, Wang PX, Yin M, Jiang Z, Shen LJ, Ji YX, Tong J, Wang Y, Wei QF, Wang Y, Zhu XY, Zhang X, Fang J, Xie Q, She ZG, Wang Z, Huang Z, Li H. Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4. *Nat Med* 2017; **23**: 742-752 [PMID: 28481357 DOI: 10.1038/nm.4334]

285 **Zhang X**, Wu WK, Xu W, Man K, Wang X, Han J, Leung WY, Wu R, Liu K, Yu J. C-X-C Motif Chemokine 10 Impairs Autophagy and Autolysosome Formation in Non-alcoholic Steatohepatitis. *Theranostics* 2017; **7**: 2822-2836 [PMID: 28824718 DOI: 10.7150/thno.19068]

286 **Zakhari S**. Overview: how is alcohol metabolized by the body? *Alcohol Res Health* 2006; **29**: 245-254 [PMID: 17718403]

287 **Dey A**, Cederbaum AI. Alcohol and oxidative liver injury. *Hepatology* 2006; **43**: S63-S74 [PMID: 16447273 DOI: 10.1002/hep.20957]

288 **Ding WX**, Li M, Chen X, Ni HM, Lin CW, Gao W, Lu B, Stolz DB, Clemens DL, Yin XM. Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. *Gastroenterology* 2010; **139**: 1740-1752 [PMID: 20659474 DOI: 10.1053/j.gastro.2010.07.041]

289 **Kong X**, Yang Y, Ren L, Shao T, Li F, Zhao C, Liu L, Zhang H, McClain CJ, Feng W. Activation of autophagy attenuates EtOH-LPS-induced hepatic steatosis and injury through MD2 associated TLR4 signaling. *Sci Rep* 2017; **7**: 9292 [PMID: 28839246 DOI: 10.1038/s41598-017-09045-z]

290 **Thomes PG**, Ehlers RA, Trambly CS, Clemens DL, Fox HS, Tuma DJ, Donohue TM. Multilevel regulation of autophagosome content by ethanol oxidation in HepG2 cells. *Autophagy* 2013; **9**: 63-73 [PMID: 23090141 DOI: 10.4161/auto.22490]

291 **Wu D**, Wang X, Zhou R, Yang L, Cederbaum AI. Alcohol steatosis and cytotoxicity: the role of cytochrome P4502E1 and autophagy. *Free Radic Biol Med* 2012; **53**: 1346-1357 [PMID: 22819980 DOI: 10.1016/j.freeradbiomed.2012.07.005]

292 **Sid B**, Verrax J, Calderon PB. Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. *Biochem Pharmacol* 2013; **86**: 200-209 [PMID: 23688501 DOI: 10.1016/j.bcp.2013.05.007]

293 **Ding WX**, Li M, Yin XM. Selective taste of ethanol-induced autophagy for mitochondria and lipid droplets. *Autophagy* 2011; **7**: 248-249 [PMID: 21150309 DOI: 10.4161/auto.7.2.14347]

294 **Scherz-Shouval R**, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *EMBO J* 2007; **26**: 1749-1760 [PMID: 17347651 DOI: 10.1038/sj.emboj.7601623]

295 **Thomes PG**, Trambly CS, Thiele GM, Duryee MJ, Fox HS, Haorah J, Donohue TM Jr. Proteasome activity and autophagosome content in liver are reciprocally regulated by ethanol treatment. *Biochem Biophys Res Commun* 2012; **417**: 262-267 [PMID: 22142844 DOI: 10.1016/j.bbrc.2011.11.097]

296 **Yeon JE**, Califano S, Xu J, Wands JR, De La Monte SM. Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. *Hepatology* 2003; **38**: 703-714 [PMID: 12939597 DOI: 10.1053/jhep.2003.50368]

297 **Shulga N**, Hoek JB, Pastorino JG. Elevated PTEN levels account for the increased sensitivity of ethanol-exposed cells to tumor necrosis factor-induced cytotoxicity. *J Biol Chem* 2005; **280**: 9416-9424 [PMID: 15623531 DOI: 10.1074/jbc.M409505200]

298 **Liuzzi JP**, Yoo C. Role of zinc in the regulation of autophagy during ethanol exposure in human hepatoma cells. *Biol Trace Elem Res* 2013; **156**: 350-356 [PMID: 24061963 DOI: 10.1007/s12011-013-9816-3]

299 **Wu D**, Wang X, Zhou R, Cederbaum A. CYP2E1 enhances ethanol-induced lipid accumulation but impairs autophagy in HepG2 E47 cells. *Biochem Biophys Res Commun* 2010; **402**: 116-122 [PMID: 20932821 DOI: 10.1016/j.bbrc.2010.09.127]

300 **Guo R**, Xu X, Babcock SA, Zhang Y, Ren J. Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy. *J Hepatol* 2015; **62**: 647-656 [PMID: 25457208 DOI: 10.1016/j.jhep.2014.10.009]

301 **Denaës T**, Lodder J, Chobert MN, Ruiz I, Pawlotsky JM, Lotersztajn S, Teixeira-Clerc F. The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway. *Sci Rep* 2016; **6**: 28806 [PMID: 27346657 DOI: 10.1038/srep28806]

302 **Thomes PG**, Trambly CS, Fox HS, Tuma DJ, Donohue TM Jr. Acute and Chronic Ethanol Administration Differentially Modulate Hepatic Autophagy and Transcription Factor EB. *Alcohol Clin Exp Res* 2015; **39**: 2354-2363 [PMID: 26556759 DOI: 10.1111/acer.12904]

303 **Ni HM**, Du K, You M, Ding WX. Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity. *Am J Pathol* 2013; **183**: 1815-1825 [PMID: 24095927 DOI: 10.1016/j.ajpath.2013.08.011]

304 **Huang H**, Tindall DJ. Dynamic FoxO transcription factors. *J Cell Sci* 2007; **120**: 2479-2487 [PMID: 17646672 DOI: 10.1242/jcs.001222]

305 **Eid N**, Ito Y, Maemura K, Otsuki Y. Elevated autophagic sequestration of mitochondria and lipid droplets in steatotic hepatocytes of chronic ethanol-treated rats: an immunohistochemical and electron microscopic study. *J Mol Histol* 2013; **44**: 311-326 [PMID: 23371376 DOI: 10.1007/s10735-013-9483-x]

306 **Lin CW**, Zhang H, Li M, Xiong X, Chen X, Chen X, Dong XC, Yin XM. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. *J Hepatol* 2013; **58**: 993-999 [PMID: 23339953 DOI: 10.1016/j.jhep.2013.01.011]

307 **Kharbanda KK**, McVicker DL, Zetterman RK, Donohue TM Jr. Ethanol consumption reduces the proteolytic capacity and protease activities of hepatic lysosomes. *Biochim Biophys Acta* 1995; **1245**: 421-429 [PMID: 8541322 DOI: 10.1016/0304-4165(95)00121-2]

308 **Chao X**, Wang S, Zhao K, Li Y, Williams JA, Li T, Chavan H, Krishnamurthy P, He XC, Li L, Ballabio A, Ni HM, Ding WX. Impaired TFEB-Mediated Lysosome Biogenesis and Autophagy Promote Chronic Ethanol-Induced Liver Injury and Steatosis in Mice. *Gastroenterology* 2018; **155**: 865-879.e12 [PMID: 29782848 DOI: 10.1053/j.gastro.2018.05.027]

309 **Rautou PE**, Mansouri A, Lebrec D, Durand F, Valla D, Moreau R. Autophagy in liver diseases. *J Hepatol* 2010; **53**: 1123-1134 [PMID: 20810185 DOI: 10.1016/j.jhep.2010.07.006]

310 **You M**, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. *Gastroenterology* 2004; **127**: 1798-1808 [PMID: 15578517 DOI: 10.1053/j.gastro.2004.09.049]

311 **Komatsu M**, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol* 2010; **12**: 213-223 [PMID: 20173742 DOI: 10.1038/ncb2021]

312 **Lu Y**, Cederbaum AI. Autophagy Protects against CYP2E1/Chronic Ethanol-Induced Hepatotoxicity. *Biomolecules* 2015; **5**: 2659-2674 [PMID: 26501338 DOI: 10.3390/biom5042659]

313 **Liu L**, Xie P, Li W, Wu Y, An W. Augmenter of Liver Regeneration Protects against Ethanol-Induced Acute Liver Injury by Promoting Autophagy. *Am J Pathol* 2019; **189**: 552-567 [PMID: 30553838 DOI: 10.1016/j.ajpath.2018.11.006]

314 **Yan S**, Zhou J, Chen X, Dong Z, Yin XM. Diverse Consequences in Liver Injury in Mice with Different Autophagy Functional Status Treated with Alcohol. *Am J Pathol* 2019; **189**: 1744-1762 [PMID: 31199920 DOI: 10.1016/j.ajpath.2019.05.011]

315 **Williams JA**, Ding WX. A Mechanistic Review of Mitophagy and Its Role in Protection against Alcoholic Liver Disease. *Biomolecules* 2015; **5**: 2619-2642 [PMID: 26501336 DOI: 10.3390/biom5042619]

316 **Eid N**, Ito Y, Otsuki Y. Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases. *Front Pharmacol* 2016; **7**: 100 [PMID: 27199746 DOI: 10.3389/fphar.2016.00100]

317 **Xiong X**, Tao R, DePinho RA, Dong XC. The autophagy-related gene 14 (Atg14) is regulated by forkhead box O transcription factors and circadian rhythms and plays a critical role in hepatic autophagy and lipid metabolism. *J Biol Chem* 2012; **287**: 39107-39114 [PMID: 22992773 DOI: 10.1074/jbc.M112.412569]

318 **Harada M**. Autophagy is involved in the elimination of intracellular inclusions, Mallory-Denk bodies, in hepatocytes. *Med Mol Morphol* 2010; **43**: 13-18 [PMID: 20340001 DOI: 10.1007/s00795-009-0476-5]

319 **Strnad P**, Zatloukal K, Stumptner C, Kulaksiz H, Denk H. Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. *Biochim Biophys Acta* 2008; **1782**: 764-774 [PMID: 18805482 DOI: 10.1016/j.bbadis.2008.08.008]

320 **Schulze RJ**, Rasineni K, Weller SG, Schott MB, Schroeder B, Casey CA, McNiven MA. Ethanol exposure inhibits hepatocyte lipophagy by inactivating the small guanosine triphosphatase Rab7. *Hepatol Commun* 2017; **1**: 140-152 [PMID: 29404450 DOI: 10.1002/hep4.1021]

321 **Rasineni K**, Donohue TM Jr, Thomes PG, Yang L, Tuma DJ, McNiven MA, Casey CA. Ethanol-induced steatosis involves impairment of lipophagy, associated with reduced Dynamin2 activity. *Hepatol Commun* 2017; **1**: 501-512 [PMID: 29152606 DOI: 10.1002/hep4.1063]

322 **Eid N**, Ito Y, Horibe A, Otsuki Y. Ethanol-induced mitophagy in liver is associated with activation of the PINK1-Parkin pathway triggered by oxidative DNA damage. *Histol Histopathol* 2016; **31**: 1143-1159 [PMID: 26935412 DOI: 10.14670/HH-11-747]

323 **Eid N**, Ito Y, Horibe A, Otsuki Y, Kondo Y. Ethanol-Induced Mitochondrial Damage in Sertoli Cells is Associated with Parkin Overexpression and Activation of Mitophagy. *Cells* 2019; **8** [PMID: 30934625 DOI: 10.3390/cells8030283]

324 **Williams JA**, Ni HM, Ding Y, Ding WX. Parkin regulates mitophagy and mitochondrial function to protect against alcohol-induced liver injury and steatosis in mice. *Am J Physiol Gastrointest Liver Physiol* 2015; **309**: G324-G340 [PMID: 26159696 DOI: 10.1152/ajpgi.00108.2015]

325 **Eid N**, Ito Y, Otsuki Y. Mitophagy in steatotic hepatocytes of ethanol-treated wild-type and Parkin knockout mice. *Am J Physiol Gastrointest Liver Physiol* 2015; **309**: G513-G514 [PMID: 26374875 DOI: 10.1152/ajpgi.00254.2015]

326 **Yu X**, Xu Y, Zhang S, Sun J, Liu P, Xiao L, Tang Y, Liu L, Yao P. Quercetin Attenuates Chronic Ethanol-Induced Hepatic Mitochondrial Damage through Enhanced Mitophagy. *Nutrients* 2016; **8** [PMID: 26742072 DOI: 10.3390/nu8010027]

327 **Zhou H**, Wang S, Hu S, Chen Y, Ren J. ER-Mitochondria Microdomains in Cardiac Ischemia-Reperfusion Injury: A Fresh Perspective. *Front Physiol* 2018; **9**: 755 [PMID: 29962971 DOI: 10.3389/fphys.2018.00755]

328 **Zhou H**, Zhu P, Wang J, Toan S, Ren J. DNA-PKcs promotes alcohol-related liver disease by activating Drp1-related mitochondrial fission and repressing FUNDC1-required mitophagy. *Signal Transduct Target Ther* 2019; **4**: 56 [PMID: 31839999 DOI: 10.1038/s41392-019-0094-1]

329 **Ilyas G**, Cingolani F, Zhao E, Tanaka K, Czaja MJ. Decreased Macrophage Autophagy Promotes Liver Injury and Inflammation from Alcohol. *Alcohol Clin Exp Res* 2019; **43**: 1403-1413 [PMID: 30964198 DOI: 10.1111/acer.14041]

330 **Liang S**, Zhong Z, Kim SY, Uchiyama R, Roh YS, Matsushita H, Gottlieb RA, Seki E. Murine macrophage autophagy protects against alcohol-induced liver injury by degrading interferon regulatory factor 1 (IRF1) and removing damaged mitochondria. *J Biol Chem* 2019; **294**: 12359-12369 [PMID: 31235522 DOI: 10.1074/jbc.RA119.007409]

331 **Xie ZY**, Xiao ZH, Wang FF. Inhibition of autophagy reverses alcohol-induced hepatic stellate cells activation through activation of Nrf2-Keap1-ARE signaling pathway. *Biochimie* 2018; **147**: 55-62 [PMID: 29305174 DOI: 10.1016/j.biochi.2017.12.013]

332 **Szabo G**, Kamath PS, Shah VH, Thursz M, Mathurin P; EASL-AASLD Joint Meeting. Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. *Hepatology* 2019; **69**: 2271-2283 [PMID: 30645002 DOI: 10.1002/hep.30369]

333 **You Y**, Li WZ, Zhang S, Hu B, Li YX, Li HD, Tang HH, Li QW, Guan YY, Liu LX, Bao WL, Shen X. SNX10 mediates alcohol-induced liver injury and steatosis by regulating the activation of chaperone-mediated autophagy. *J Hepatol* 2018; **69**: 129-141 [PMID: 29452206 DOI: 10.1016/j.jhep.2018.01.038]

334 **Cai Y**, Jogasuria A, Yin H, Xu MJ, Hu X, Wang J, Kim C, Wu J, Lee K, Gao B, You M. The Detrimental Role Played by Lipocalin-2 in Alcoholic Fatty Liver in Mice. *Am J Pathol* 2016; **186**: 2417-2428 [PMID: 27427417 DOI: 10.1016/j.ajpath.2016.05.006]

335 **Han W**, Fu X, Xie J, Meng Z, Gu Y, Wang X, Li L, Pan H, Huang W. MiR-26a enhances autophagy to protect against ethanol-induced acute liver injury. *J Mol Med (Berl)* 2015; **93**: 1045-1055 [PMID: 25877859 DOI: 10.1007/s00109-015-1282-2]

336 **Babuta M**, Furi I, Bala S, Bukong TN, Lowe P, Catalano D, Calenda C, Kodys K, Szabo G. Dysregulated Autophagy and Lysosome Function Are Linked to Exosome Production by Micro-RNA 155 in Alcoholic Liver Disease. *Hepatology* 2019; **70**: 2123-2141 [PMID: 31090940 DOI: 10.1002/hep.30766]

337 **Thomes PG**, Rasineni K, Yang L, Donohue TM Jr, Kubik JL, McNiven MA, Casey CA. Ethanol withdrawal mitigates fatty liver by normalizing lipid catabolism. *Am J Physiol Gastrointest Liver Physiol* 2019; **316**: G509-G518 [PMID: 30714813 DOI: 10.1152/ajpgi.00376.2018]

338 **Kirchgesner T**, Danse E. Drink responsibly! Rapid regression of fatty liver disease on enhanced CT after alcohol withdrawal. *JBR-BTR* 2014; **97**: 44 [PMID: 24765774 DOI: 10.5334/jbr-btr.13]

339 **Thiele M**, Rausch V, Fluhr G, Kjærgaard M, Piecha F, Mueller J, Straub BK, Lupșor-Platon M, De-Ledinghen V, Seitz HK, Detlefsen S, Madsen B, Krag A, Mueller S. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification. *J Hepatol* 2018; **68**: 1025-1032 [PMID: 29343427 DOI: 10.1016/j.jhep.2017.12.029]

340 **Yan S**, Khambu B, Hong H, Liu G, Huda N, Yin XM. Autophagy, Metabolism, and Alcohol-Related Liver Disease: Novel Modulators and Functions. *Int J Mol Sci* 2019; **20** [PMID: 31614437 DOI: 10.3390/ijms20205029]

341 **Yang L**, Yang C, Thomes PG, Kharbanda KK, Casey CA, McNiven MA, Donohue TM Jr. Lipophagy and Alcohol-Induced Fatty Liver. *Front Pharmacol* 2019; **10**: 495 [PMID: 31143122 DOI: 10.3389/fphar.2019.00495]

342 **Chao X**, Ding WX. Role and mechanisms of autophagy in alcohol-induced liver injury. *Adv Pharmacol* 2019; **85**: 109-131 [PMID: 31307584 DOI: 10.1016/bs.apha.2019.01.008]

343 **Tang L**, Yang F, Fang Z, Hu C. Resveratrol Ameliorates Alcoholic Fatty Liver by Inducing Autophagy. *Am J Chin Med* 2016; **44**: 1207-1220 [PMID: 27627919 DOI: 10.1142/S0192415X16500671]

344 **Atef MM**, Hafez YM, Alshenawy HA, Emam MN. Ameliorative effects of autophagy inducer, simvastatin on alcohol-induced liver disease in a rat model. *J Cell Biochem* 2018 [PMID: 30417426 DOI: 10.1002/jcb.28042]

345 **Guo X**, Cui R, Zhao J, Mo R, Peng L, Yan M. Corosolic acid protects hepatocytes against ethanol-induced damage by modulating mitogen-activated protein kinases and activating autophagy. *Eur J Pharmacol* 2016; **791**: 578-588 [PMID: 27663281 DOI: 10.1016/j.ejphar.2016.09.031]

346 **Li Y**, Chen M, Wang J, Guo X, Xiao L, Liu P, Liu L, Tang Y, Yao P. Quercetin ameliorates autophagy in alcohol liver disease associated with lysosome through mTOR-TFEB pathway. *J Funct Foods* 2019; **52**: 177-185 [DOI: 10.1016/j.jff.2018.10.033]

347 **Shi X**, Sun R, Zhao Y, Fu R, Wang R, Zhao H, Wang Z, Tang F, Zhang N, Tian X, Yao J. Promotion of autophagosome–lysosome fusion *via* salvianolic acid A-mediated SIRT1 upregulation ameliorates alcoholic liver disease. *RSC Adv* 2018; **8**: 20411-20422 [DOI: 10.1039/C8RA00798E]

348 **Lemasters JJ**, Zhong Z. Mitophagy in hepatocytes: Types, initiators and role in adaptive ethanol metabolism☆. *Liver Res* 2018; **2**: 125-132 [PMID: 31157120 DOI: 10.1016/j.livres.2018.09.005]

349 **Mao Y**, Da L, Tang H, Yang J, Lei Y, Tiollais P, Li T, Zhao M. Hepatitis B virus X protein reduces starvation-induced cell death through activation of autophagy and inhibition of mitochondrial apoptotic pathway. *Biochem Biophys Res Commun* 2011; **415**: 68-74 [PMID: 22020078 DOI: 10.1016/j.bbrc.2011.10.013]

350 **Liu B**, Fang M, Hu Y, Huang B, Li N, Chang C, Huang R, Xu X, Yang Z, Chen Z, Liu W. Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation. *Autophagy* 2014; **10**: 416-430 [PMID: 24401568 DOI: 10.4161/auto.27286]

351 **Cho HK**, Cheong KJ, Kim HY, Cheong J. Endoplasmic reticulum stress induced by hepatitis B virus X protein enhances cyclo-oxygenase 2 expression *via* activating transcription factor 4. *Biochem J* 2011; **435**: 431-439 [PMID: 21244365 DOI: 10.1042/BJ20102071]

352 **Li B**, Gao B, Ye L, Han X, Wang W, Kong L, Fang X, Zeng Y, Zheng H, Li S, Wu Z, Ye L. Hepatitis B virus X protein (HBx) activates ATF6 and IRE1-XBP1 pathways of unfolded protein response. *Virus Res* 2007; **124**: 44-49 [PMID: 17092596 DOI: 10.1016/j.virusres.2006.09.011]

353 **Xu Z**, Jensen G, Yen TS. Activation of hepatitis B virus S promoter by the viral large surface protein *via* induction of stress in the endoplasmic reticulum. *J Virol* 1997; **71**: 7387-7392 [PMID: 9311817 DOI: 10.1128/JVI.71.10.7387-7392.1997]

354 **Hsieh YH**, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. *Carcinogenesis* 2004; **25**: 2023-2032 [PMID: 15180947 DOI: 10.1093/carcin/bgh207]

355 **Na B**, Huang Z, Wang Q, Qi Z, Tian Y, Lu CC, Yu J, Hanes MA, Kakar S, Huang EJ, Ou JH, Liu L, Yen TS. Transgenic expression of entire hepatitis B virus in mice induces hepatocarcinogenesis independent of chronic liver injury. *PLoS One* 2011; **6**: e26240 [PMID: 22022578 DOI: 10.1371/journal.pone.0026240]

356 **Li J**, Liu Y, Wang Z, Liu K, Wang Y, Liu J, Ding H, Yuan Z. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. *J Virol* 2011; **85**: 6319-6333 [PMID: 21507968 DOI: 10.1128/JVI.02627-10]

357 **Tang H**, Da L, Mao Y, Li Y, Li D, Xu Z, Li F, Wang Y, Tiollais P, Li T, Zhao M. Hepatitis B virus X protein sensitizes cells to starvation-induced autophagy *via* up-regulation of beclin 1 expression. *Hepatology* 2009; **49**: 60-71 [PMID: 19065679 DOI: 10.1002/hep.22581]

358 **Zhong L**, Shu W, Dai W, Gao B, Xiong S. Reactive Oxygen Species-Mediated c-Jun NH2-Terminal Kinase Activation Contributes to Hepatitis B Virus X Protein-Induced Autophagy *via* Regulation of the Beclin-1/Bcl-2 Interaction. *J Virol* 2017; **91** [PMID: 28515304 DOI: 10.1128/JVI.00001-17]

359 **Fu S**, Wang J, Hu X, Zhou RR, Fu Y, Tang D, Kang R, Huang Y, Sun L, Li N, Fan XG. Crosstalk between hepatitis B virus X and high-mobility group box 1 facilitates autophagy in hepatocytes. *Mol Oncol* 2018; **12**: 322-338 [PMID: 29316268 DOI: 10.1002/1878-0261.12165]

360 **Cheng LS**, Li J, Liu Y, Wang FP, Wang SQ, She WM, Wu SD, Qi XL, Zhou YP, Jiang W. HMGB1-induced autophagy: a new pathway to maintain Treg function during chronic hepatitis B virus infection. *Clin Sci (Lond)* 2017; **131**: 381-394 [PMID: 28082516 DOI: 10.1042/CS20160704]

361 **Kim SJ**, Khan M, Quan J, Till A, Subramani S, Siddiqui A. Hepatitis B virus disrupts mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis. *PLoS Pathog* 2013; **9**: e1003722 [PMID: 24339771 DOI: 10.1371/journal.ppat.1003722]

362 **Huang XY**, Li D, Chen ZX, Huang YH, Gao WY, Zheng BY, Wang XZ. Hepatitis B Virus X protein elevates Parkin-mediated mitophagy through Lon Peptidase in starvation. *Exp Cell Res* 2018; **368**: 75-83 [PMID: 29689279 DOI: 10.1016/j.yexcr.2018.04.016]

363 **Wang J**, Shi Y, Yang H. [Infection with hepatitis B virus enhances basal autophagy]. *Wei Sheng Wu Xue Bao* 2010; **50**: 1651-1656 [PMID: 21365919]

364 **Lin CL**, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. *J Biomed Sci* 2008; **15**: 137-145 [PMID: 18058038 DOI: 10.1007/s11373-007-9225-8]

365 **Xie M**, Yang Z, Liu Y, Zheng M. The role of HBV-induced autophagy in HBV replication and HBV related-HCC. *Life Sci* 2018; **205**: 107-112 [PMID: 29709654 DOI: 10.1016/j.lfs.2018.04.051]

366 **Choi Y**, Bowman JW, Jung JU. Autophagy during viral infection - a double-edged sword. *Nat Rev Microbiol* 2018; **16**: 341-354 [PMID: 29556036 DOI: 10.1038/s41579-018-0003-6]

367 **Sir D**, Ou JH. Autophagy in viral replication and pathogenesis. *Mol Cells* 2010; **29**: 1-7 [PMID: 20077024 DOI: 10.1007/s10059-010-0014-2]

368 **Sir D**, Ann DK, Ou JH. Autophagy by hepatitis B virus and for hepatitis B virus. *Autophagy* 2010; **6**: 548-549 [PMID: 20305390 DOI: 10.4161/auto.6.4.11669]

369 **Sir D**, Tian Y, Chen WL, Ann DK, Yen TS, Ou JH. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. *Proc Natl Acad Sci U S A* 2010; **107**: 4383-4388 [PMID: 20142477 DOI: 10.1073/pnas.0911373107]

370 **Tian Y**, Sir D, Kuo CF, Ann DK, Ou JH. Autophagy required for hepatitis B virus replication in transgenic mice. *J Virol* 2011; **85**: 13453-13456 [PMID: 21957292 DOI: 10.1128/JVI.06064-11]

371 **Lan SH**, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. *Hepatology* 2014; **59**: 505-517 [PMID: 23913306 DOI: 10.1002/hep.26659]

372 **Luo MX**, Wong SH, Chan MT, Yu L, Yu SS, Wu F, Xiao Z, Wang X, Zhang L, Cheng AS, Ng SS, Chan FK, Cho CH, Yu J, Sung JJ, Wu WK. Autophagy Mediates HBx-Induced Nuclear Factor-κB Activation and Release of IL-6, IL-8, and CXCL2 in Hepatocytes. *J Cell Physiol* 2015; **230**: 2382-2389 [PMID: 25708728 DOI: 10.1002/jcp.24967]

373 **Hu S**, Liu X, Gao Y, Zhou R, Wei M, Dong J, Yan H, Zhao Y. Hepatitis B Virus Inhibits Neutrophil Extracellular Trap Release by Modulating Reactive Oxygen Species Production and Autophagy. *J Immunol* 2019; **202**: 805-815 [PMID: 30567731 DOI: 10.4049/jimmunol.1800871]

374 **Lin Y**, Wu C, Wang X, Liu S, Kemper T, Li F, Squire A, Zhu Y, Zhang J, Chen X, Lu M. Synaptosomal-associated protein 29 is required for the autophagic degradation of hepatitis B virus. *FASEB J* 2019; **33**: 6023-6034 [PMID: 30742775 DOI: 10.1096/fj.201801995RR]

375 **Lin Y**, Wu C, Wang X, Liu S, Zhao K, Kemper T, Yu H, Li M, Zhang J, Chen M, Zhu Y, Chen X, Lu M. Glucosamine promotes hepatitis B virus replication through its dual effects in suppressing autophagic degradation and inhibiting MTORC1 signaling. *Autophagy* 2020; **16**: 548-561 [PMID: 31204557 DOI: 10.1080/15548627.2019.1632104]

376 **Gracia-Sancho J**, Guixé-Muntet S, Hide D, Bosch J. Modulation of autophagy for the treatment of liver diseases. *Expert Opin Investig Drugs* 2014; **23**: 965-977 [PMID: 24749698 DOI: 10.1517/13543784.2014.912274]

377 **Döring T**, Zeyen L, Bartusch C, Prange R. Hepatitis B Virus Subverts the Autophagy Elongation Complex Atg5-12/16L1 and Does Not Require Atg8/LC3 Lipidation for Viral Maturation. *J Virol* 2018; **92** [PMID: 29367244 DOI: 10.1128/JVI.01513-17]

378 **Shin GC**, Kang HS, Lee AR, Kim KH. Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. *Autophagy* 2016; **12**: 2451-2466 [PMID: 27740879 DOI: 10.1080/15548627.2016.1239002]

379 **Khabir M**, Aliche AZ, Sureau C, Blanchet M, Labonté P. Hepatitis Delta Virus Alters the Autophagy Process To Promote Its Genome Replication. *J Virol* 2020; **94** [PMID: 31748400 DOI: 10.1128/jvi.01936-19]

380 **Khan M**, Imam H, Siddiqui A. Subversion of cellular autophagy during virus infection: Insights from hepatitis B and hepatitis C viruses. *Liver Res* 2018; **2**: 146-156 [PMID: 31803515 DOI: 10.1016/j.livres.2018.09.002]

381 **Wang L**, Ou JH. Hepatitis C virus and autophagy. *Biol Chem* 2015; **396**: 1215-1222 [PMID: 26024249 DOI: 10.1515/hsz-2015-0172]

382 **Chan ST**, Ou JJ. Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response. *Viruses* 2017; **9** [PMID: 28805674 DOI: 10.3390/v9080224]

383 **Wang J**, Kang R, Huang H, Xi X, Wang B, Wang J, Zhao Z. Hepatitis C virus core protein activates autophagy through EIF2AK3 and ATF6 UPR pathway-mediated MAP1LC3B and ATG12 expression. *Autophagy* 2014; **10**: 766-784 [PMID: 24589849 DOI: 10.4161/auto.27954]

384 **Huang H**, Kang R, Wang J, Luo G, Yang W, Zhao Z. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy. *Autophagy* 2013; **9**: 175-195 [PMID: 23169238 DOI: 10.4161/auto.22791]

385 **Kim JY**, Wang L, Lee J, Ou JJ. Hepatitis C Virus Induces the Localization of Lipid Rafts to Autophagosomes for Its RNA Replication. *J Virol* 2017; **91** [PMID: 28747506 DOI: 10.1128/JVI.00541-17]

386 **Sir D**, Kuo CF, Tian Y, Liu HM, Huang EJ, Jung JU, Machida K, Ou JH. Replication of hepatitis C virus RNA on autophagosomal membranes. *J Biol Chem* 2012; **287**: 18036-18043 [PMID: 22496373 DOI: 10.1074/jbc.M111.320085]

387 **Ferraris P**, Blanchard E, Roingeard P. Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes. *J Gen Virol* 2010; **91**: 2230-2237 [PMID: 20484561 DOI: 10.1099/vir.0.022186-0]

388 **Wang L**, Ou JJ. Regulation of Autophagy by Hepatitis C Virus for Its Replication. *DNA Cell Biol* 2018; **37**: 287-290 [PMID: 29350547 DOI: 10.1089/dna.2017.4115]

389 **Wang L**, Kim JY, Liu HM, Lai MMC, Ou JJ. HCV-induced autophagosomes are generated *via* homotypic fusion of phagophores that mediate HCV RNA replication. *PLoS Pathog* 2017; **13**: e1006609 [PMID: 28931085 DOI: 10.1371/journal.ppat.1006609]

390 **Shrivastava S**, Devhare P, Sujijantarat N, Steele R, Kwon YC, Ray R, Ray RB. Knockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway. *J Virol* 2016; **90**: 1387-1396 [PMID: 26581990 DOI: 10.1128/JVI.02383-15]

391 **Mori H**, Fukuhara T, Ono C, Tamura T, Sato A, Fauzyah Y, Wada M, Okamoto T, Noda T, Yoshimori T, Matsuura Y. Induction of selective autophagy in cells replicating hepatitis C virus genome. *J Gen Virol* 2018; **99**: 1643-1657 [PMID: 30311874 DOI: 10.1099/jgv.0.001161]

392 **Mohl BP**, Tedbury PR, Griffin S, Harris M. Hepatitis C virus-induced autophagy is independent of the unfolded protein response. *J Virol* 2012; **86**: 10724-10732 [PMID: 22837205 DOI: 10.1128/JVI.01667-12]

393 **Dreux M**, Gastaminza P, Wieland SF, Chisari FV. The autophagy machinery is required to initiate hepatitis C virus replication. *Proc Natl Acad Sci U S A* 2009; **106**: 14046-14051 [PMID: 19666601 DOI: 10.1073/pnas.0907344106]

394 **Romero-Brey I**, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, Santarella-Mellwig R, Habermann A, Hoppe S, Kallis S, Walther P, Antony C, Krijnse-Locker J, Bartenschlager R. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. *PLoS Pathog* 2012; **8**: e1003056 [PMID: 23236278 DOI: 10.1371/journal.ppat.1003056]

395 **Paul D**, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. *J Virol* 2013; **87**: 10612-10627 [PMID: 23885072 DOI: 10.1128/JVI.01370-13]

396 **Ke PY**, Chen SS. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. *J Clin Invest* 2011; **121**: 37-56 [PMID: 21135505 DOI: 10.1172/JCI41474]

397 **Chan ST**, Lee J, Narula M, Ou JJ. Suppression of Host Innate Immune Response by Hepatitis C Virus *via* Induction of Autophagic Degradation of TRAF6. *J Virol* 2016; **90**: 10928-10935 [PMID: 27681126 DOI: 10.1128/JVI.01365-16]

398 **Sir D**, Chen WL, Choi J, Wakita T, Yen TS, Ou JH. Induction of incomplete autophagic response by hepatitis C virus *via* the unfolded protein response. *Hepatology* 2008; **48**: 1054-1061 [PMID: 18688877 DOI: 10.1002/hep.22464]

399 **Dash S**, Chava S, Aydin Y, Chandra PK, Ferraris P, Chen W, Balart LA, Wu T, Garry RF. Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. *Viruses* 2016; **8** [PMID: 27223299 DOI: 10.3390/v8050150]

400 **Taguwa S**, Kambara H, Fujita N, Noda T, Yoshimori T, Koike K, Moriishi K, Matsuura Y. Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus. *J Virol* 2011; **85**: 13185-13194 [PMID: 21994453 DOI: 10.1128/JVI.06099-11]

401 **Vescovo T**, Romagnoli A, Perdomo AB, Corazzari M, Ciccosanti F, Alonzi T, Nardacci R, Ippolito G, Tripodi M, Garcia-Monzon C, Lo Iacono O, Piacentini M, Fimia GM. Autophagy protects cells from HCV-induced defects in lipid metabolism. *Gastroenterology* 2012; **142**: 644-653.e3 [PMID: 22155365 DOI: 10.1053/j.gastro.2011.11.033]

402 **Chu VC**, Bhattacharya S, Nomoto A, Lin J, Zaidi SK, Oberley TD, Weinman SA, Azhar S, Huang TT. Persistent expression of hepatitis C virus non-structural proteins leads to increased autophagy and mitochondrial injury in human hepatoma cells. *PLoS One* 2011; **6**: e28551 [PMID: 22164304 DOI: 10.1371/journal.pone.0028551]

403 **Kim SJ**, Syed GH, Khan M, Chiu WW, Sohail MA, Gish RG, Siddiqui A. Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. *Proc Natl Acad Sci U S A* 2014; **111**: 6413-6418 [PMID: 24733894 DOI: 10.1073/pnas.1321114111]

404 **Jassey A**, Liu CH, Changou CA, Richardson CD, Hsu HY, Lin LT. Hepatitis C Virus Non-Structural Protein 5A (NS5A) Disrupts Mitochondrial Dynamics and Induces Mitophagy. *Cells* 2019; **8** [PMID: 30934919 DOI: 10.3390/cells8040290]

405 **Hara Y**, Yanatori I, Ikeda M, Kiyokage E, Nishina S, Tomiyama Y, Toida K, Kishi F, Kato N, Imamura M, Chayama K, Hino K. Hepatitis C virus core protein suppresses mitophagy by interacting with parkin in the context of mitochondrial depolarization. *Am J Pathol* 2014; **184**: 3026-3039 [PMID: 25244949 DOI: 10.1016/j.ajpath.2014.07.024]

406 **Ren H**, Elgner F, Jiang B, Himmelsbach K, Medvedev R, Ploen D, Hildt E. The Autophagosomal SNARE Protein Syntaxin 17 Is an Essential Factor for the Hepatitis C Virus Life Cycle. *J Virol* 2016; **90**: 5989-6000 [PMID: 27099307 DOI: 10.1128/JVI.00551-16]

407 **Kurt R**, Chandra PK, Aboulnasr F, Panigrahi R, Ferraris P, Aydin Y, Reiss K, Wu T, Balart LA, Dash S. Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture. *PLoS One* 2015; **10**: e0125962 [PMID: 25961570 DOI: 10.1371/journal.pone.0125962]

408 **Matsui C**, Deng L, Minami N, Abe T, Koike K, Shoji I. Hepatitis C Virus NS5A Protein Promotes the Lysosomal Degradation of Hepatocyte Nuclear Factor 1α *via* Chaperone-Mediated Autophagy. *J Virol* 2018; **92** [PMID: 29695419 DOI: 10.1128/JVI.00639-18]

409 **Zhang MQ**, Li JR, Peng ZG, Zhang JP. Differential Effects of Autophagy-Related 10 Protein on HCV Replication and Autophagy Flux Are Mediated by Its Cysteine44 and Cysteine135. *Front Immunol* 2018; **9**: 2176 [PMID: 30319633 DOI: 10.3389/fimmu.2018.02176]

410 **Zhao Q**, Hu ZY, Zhang JP, Jiang JD, Ma YY, Li JR, Peng ZG, Chen JH. Dual Roles of Two Isoforms of Autophagy-related Gene ATG10 in HCV-Subgenomic replicon Mediated Autophagy Flux and Innate Immunity. *Sci Rep* 2017; **7**: 11250 [PMID: 28900156 DOI: 10.1038/s41598-017-11105-3]

411 **Mizui T**, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N, Ikejima K, Kitamura T, Enomoto N, Sakai T, Kominami E, Watanabe S. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. *J Gastroenterol* 2010; **45**: 195-203 [PMID: 19760134 DOI: 10.1007/s00535-009-0132-9]

412 **Kim JY**, Ou JJ. Regulation of Apolipoprotein E Trafficking by Hepatitis C Virus-Induced Autophagy. *J Virol* 2018; **92** [PMID: 29695434 DOI: 10.1128/JVI.00211-18]

413 **Zhang L**. Autophagy in hepatitis B or C virus infection: An incubator and a potential therapeutic target. *Life Sci* 2020; **242**: 117206 [PMID: 31866520 DOI: 10.1016/j.lfs.2019.117206]

414 **Lazar C**, Uta M, Branza-Nichita N. Modulation of the unfolded protein response by the human hepatitis B virus. *Front Microbiol* 2014; **5**: 433 [PMID: 25191311 DOI: 10.3389/fmicb.2014.00433]

415 **Ait-Goughoulte M**, Kanda T, Meyer K, Ryerse JS, Ray RB, Ray R. Hepatitis C virus genotype 1a growth and induction of autophagy. *J Virol* 2008; **82**: 2241-2249 [PMID: 18077704 DOI: 10.1128/JVI.02093-07]

416 **Rautou PE**, Cazals-Hatem D, Feldmann G, Mansouri A, Grodet A, Barge S, Martinot-Peignoux M, Duces A, Bièche I, Lebrec D, Bedossa P, Paradis V, Marcellin P, Valla D, Asselah T, Moreau R. Changes in autophagic response in patients with chronic hepatitis C virus infection. *Am J Pathol* 2011; **178**: 2708-2715 [PMID: 21641393 DOI: 10.1016/j.ajpath.2011.02.021]

417 **Aweya JJ**, Mak TM, Lim SG, Tan YJ. The p7 protein of the hepatitis C virus induces cell death differently from the influenza A virus viroporin M2. *Virus Res* 2013; **172**: 24-34 [PMID: 23246447 DOI: 10.1016/j.virusres.2012.12.005]

418 **Ríos-Ocampo WA**, Daemen T, Buist-Homan M, Faber KN, Navas MC, Moshage H. Hepatitis C virus core or NS3/4A protein expression preconditions hepatocytes against oxidative stress and endoplasmic reticulum stress. *Redox Rep* 2019; **24**: 17-26 [PMID: 30909829 DOI: 10.1080/13510002.2019.1596431]

419 **Su WC**, Chao TC, Huang YL, Weng SC, Jeng KS, Lai MM. Rab5 and class III phosphoinositide 3-kinase Vps34 are involved in hepatitis C virus NS4B-induced autophagy. *J Virol* 2011; **85**: 10561-10571 [PMID: 21835792 DOI: 10.1128/JVI.00173-11]

420 **Tanida I**, Fukasawa M, Ueno T, Kominami E, Wakita T, Hanada K. Knockdown of autophagy-related gene decreases the production of infectious hepatitis C virus particles. *Autophagy* 2009; **5**: 937-945 [PMID: 19625776 DOI: 10.4161/auto.5.7.9243]

421 **Tsuchida T**, Friedman SL. Mechanisms of hepatic stellate cell activation. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 397-411 [PMID: 28487545 DOI: 10.1038/nrgastro.2017.38]

422 **Williams MJ**, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. *Gastroenterology* 2014; **146**: 349-356 [PMID: 24315991 DOI: 10.1053/j.gastro.2013.11.034]

423 **Sato K**, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances. *Hepatology* 2019; **69**: 420-430 [PMID: 30070383 DOI: 10.1002/hep.30150]

424 **Gouw AS**, Clouston AD, Theise ND. Ductular reactions in human liver: diversity at the interface. *Hepatology* 2011; **54**: 1853-1863 [PMID: 21983984 DOI: 10.1002/hep.24613]

425 **Clouston AD**, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. *Hepatology* 2005; **41**: 809-818 [PMID: 15793848 DOI: 10.1002/hep.20650]

426 **Richardson MM**, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. *Gastroenterology* 2007; **133**: 80-90 [PMID: 17631134 DOI: 10.1053/j.gastro.2007.05.012]

427 **Wood MJ**, Gadd VL, Powell LW, Ramm GA, Clouston AD. Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. *Hepatology* 2014; **59**: 848-857 [PMID: 24037895 DOI: 10.1002/hep.26706]

428 **Ni HM**, Bockus A, Wozniak AL, Jones K, Weinman S, Yin XM, Ding WX. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. *Autophagy* 2011; **7**: 188-204 [PMID: 21107021 DOI: 10.4161/auto.7.2.14181]

429 **Song Y**, Zhao Y, Wang F, Tao L, Xiao J, Yang C. Autophagy in hepatic fibrosis. *Biomed Res Int* 2014; **2014**: 436242 [PMID: 24779010 DOI: 10.1155/2014/436242]

430 **Kwanten WJ**, Martinet W, Michielsen PP, Francque SM. Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue. *World J Gastroenterol* 2014; **20**: 7325-7338 [PMID: 24966603 DOI: 10.3748/wjg.v20.i23.7325]

431 **Li J**, Chen K, Li S, Feng J, Liu T, Wang F, Zhang R, Xu S, Zhou Y, Zhou S, Xia Y, Lu J, Zhou Y, Guo C. Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis *via* the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy. *Drug Des Devel Ther* 2016; **10**: 619-630 [PMID: 26929597 DOI: 10.2147/DDDT.S98740]

432 **Gordy C**, He YW. The crosstalk between autophagy and apoptosis: where does this lead? *Protein Cell* 2012; **3**: 17-27 [PMID: 22314807 DOI: 10.1007/s13238-011-1127-x]

433 **Mao YQ**, Fan XM. Autophagy: A new therapeutic target for liver fibrosis. *World J Hepatol* 2015; **7**: 1982-1986 [PMID: 26261688 DOI: 10.4254/wjh.v7.i16.1982]

434 **Miyamae Y**, Nishito Y, Nakai N, Nagumo Y, Usui T, Masuda S, Kambe T, Nagao M. Tetrandrine induces lipid accumulation through blockade of autophagy in a hepatic stellate cell line. *Biochem Biophys Res Commun* 2016; **477**: 40-46 [PMID: 27270032 DOI: 10.1016/j.bbrc.2016.06.018]

435 **He W**, Wang B, Yang J, Zhuang Y, Wang L, Huang X, Chen J. Chloroquine improved carbon tetrachloride-induced liver fibrosis through its inhibition of the activation of hepatic stellate cells: role of autophagy. *Biol Pharm Bull* 2014; **37**: 1505-1509 [PMID: 25177034 DOI: 10.1248/bpb.b14-00297]

436 **Lee AY**, Lee JW, Kim JE, Mock HJ, Park S, Kim S, Hong SH, Kim JY, Park EJ, Kang KS, Kim KP, Cho MH. Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model. *Biochem Biophys Res Commun* 2017; **494**: 460-469 [PMID: 29066349 DOI: 10.1016/j.bbrc.2017.10.110]

437 **Zhang XW**, Mi S, Li Z, Zhou JC, Xie J, Hua F, Li K, Cui B, Lv XX, Yu JJ, Hu ZW. Antagonism of Interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10/STAT3-suppressed autophagy in hepatocytes. *Oncotarget* 2017; **8**: 9922-9934 [PMID: 28039485 DOI: 10.18632/oncotarget.14266]

438 **Singh R**, Cuervo AM. Lipophagy: connecting autophagy and lipid metabolism. *Int J Cell Biol* 2012; **2012**: 282041 [PMID: 22536247 DOI: 10.1155/2012/282041]

439 **Hernández-Gea V**, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Czaja MJ, Friedman SL. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology* 2012; **142**: 938-946 [PMID: 22240484 DOI: 10.1053/j.gastro.2011.12.044]

440 **Thoen LF**, Guimarães EL, Dollé L, Mannaerts I, Najimi M, Sokal E, van Grunsven LA. A role for autophagy during hepatic stellate cell activation. *J Hepatol* 2011; **55**: 1353-1360 [PMID: 21803012 DOI: 10.1016/j.jhep.2011.07.010]

441 **Thoen LF**, Guimarães EL, Grunsven LA. Autophagy: a new player in hepatic stellate cell activation. *Autophagy* 2012; **8**: 126-128 [PMID: 22082960 DOI: 10.4161/auto.8.1.18105]

442 **Hernández-Gea V**, Hilscher M, Rozenfeld R, Lim MP, Nieto N, Werner S, Devi LA, Friedman SL. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. *J Hepatol* 2013; **59**: 98-104 [PMID: 23485523 DOI: 10.1016/j.jhep.2013.02.016]

443 **Vere CC**, Streba CT, Streba L, Rogoveanu I. Lipid serum profile in patients with viral liver cirrhosis. *Med Princ Pract* 2012; **21**: 566-568 [PMID: 22722340 DOI: 10.1159/000339206]

444 **Kim KM**, Han CY, Kim JY, Cho SS, Kim YS, Koo JH, Lee JM, Lim SC, Kang KW, Kim JS, Hwang SJ, Ki SH, Kim SG. Gα12 overexpression induced by miR-16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells. *J Hepatol* 2018; **68**: 493-504 [PMID: 29080810 DOI: 10.1016/j.jhep.2017.10.011]

445 **Qu Y**, Zhang Q, Cai X, Li F, Ma Z, Xu M, Lu L. Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis *via* autophagy activation. *J Cell Mol Med* 2017; **21**: 2491-2502 [PMID: 28382720 DOI: 10.1111/jcmm.13170]

446 **Deng J**, Huang Q, Wang Y, Shen P, Guan F, Li J, Huang H, Shi C. Hypoxia-inducible factor-1alpha regulates autophagy to activate hepatic stellate cells. *Biochem Biophys Res Commun* 2014; **454**: 328-334 [PMID: 25450397 DOI: 10.1016/j.bbrc.2014.10.076]

447 **Fu MY**, He YJ, Lv X, Liu ZH, Shen Y, Ye GR, Deng YM, Shu JC. Transforming growth factor‑β1 reduces apoptosis *via* autophagy activation in hepatic stellate cells. *Mol Med Rep* 2014; **10**: 1282-1288 [PMID: 25059289 DOI: 10.3892/mmr.2014.2383]

448 **Li J**, Zeng C, Zheng B, Liu C, Tang M, Jiang Y, Chang Y, Song W, Wang Y, Yang C. HMGB1-induced autophagy facilitates hepatic stellate cells activation: a new pathway in liver fibrosis. *Clin Sci (Lond)* 2018; **132**: 1645-1667 [PMID: 29907694 DOI: 10.1042/CS20180177]

449 **Zhang Z**, Guo M, Zhao S, Shao J, Zheng S. ROS-JNK1/2-dependent activation of autophagy is required for the induction of anti-inflammatory effect of dihydroartemisinin in liver fibrosis. *Free Radic Biol Med* 2016; **101**: 272-283 [PMID: 27989749 DOI: 10.1016/j.freeradbiomed.2016.10.498]

450 **Kim RS**, Hasegawa D, Goossens N, Tsuchida T, Athwal V, Sun X, Robinson CL, Bhattacharya D, Chou HI, Zhang DY, Fuchs BC, Lee Y, Hoshida Y, Friedman SL. The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. *Sci Rep* 2016; **6**: 39342 [PMID: 27996033 DOI: 10.1038/srep39342]

451 **Hong Y**, Li S, Wang J, Li Y. In vitro inhibition of hepatic stellate cell activation by the autophagy-related lipid droplet protein ATG2A. *Sci Rep* 2018; **8**: 9232 [PMID: 29915313 DOI: 10.1038/s41598-018-27686-6]

452 **Wu L**, Zhang Q, Mo W, Feng J, Li S, Li J, Liu T, Xu S, Wang W, Lu X, Yu Q, Chen K, Xia Y, Lu J, Xu L, Zhou Y, Fan X, Guo C. Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy *via* the TGF-β1/Smads and PI3K/Akt pathways. *Sci Rep* 2017; **7**: 9289 [PMID: 28839277 DOI: 10.1038/s41598-017-09673-5]

453 **Qiu YN**, Wang GH, Zhou F, Hao JJ, Tian L, Guan LF, Geng XK, Ding YC, Wu HW, Zhang KZ. PM2.5 induces liver fibrosis *via* triggering ROS-mediated mitophagy. *Ecotoxicol Environ Saf* 2019; **167**: 178-187 [PMID: 30336408 DOI: 10.1016/j.ecoenv.2018.08.050]

454 **Tian Z**, Chen Y, Yao N, Hu C, Wu Y, Guo D, Liu J, Yang Y, Chen T, Zhao Y, He Y. Role of mitophagy regulation by ROS in hepatic stellate cells during acute liver failure. *Am J Physiol Gastrointest Liver Physiol* 2018; **315**: G374-G384 [PMID: 29648877 DOI: 10.1152/ajpgi.00032.2018]

455 **Li J**, Zhao YR, Tian Z. Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis. *World J Hepatol* 2019; **11**: 412-420 [PMID: 31183002 DOI: 10.4254/wjh.v11.i5.412]

456 **Wu H**, Chen G, Wang J, Deng M, Yuan F, Gong J. TIM-4 interference in Kupffer cells against CCL4-induced liver fibrosis by mediating Akt1/Mitophagy signalling pathway. *Cell Prolif* 2020; **53**: e12731 [PMID: 31755616 DOI: 10.1111/cpr.12731]

457 **Ding N**, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. *Cell* 2013; **153**: 601-613 [PMID: 23622244 DOI: 10.1016/j.cell.2013.03.028]

458 **Duran A**, Hernandez ED, Reina-Campos M, Castilla EA, Subramaniam S, Raghunandan S, Roberts LR, Kisseleva T, Karin M, Diaz-Meco MT, Moscat J. p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer. *Cancer Cell* 2016; **30**: 595-609 [PMID: 27728806 DOI: 10.1016/j.ccell.2016.09.004]

459 **Zhang Z**, Yao Z, Wang L, Ding H, Shao J, Chen A, Zhang F, Zheng S. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. *Autophagy* 2018; **14**: 2083-2103 [PMID: 30081711 DOI: 10.1080/15548627.2018.1503146]

460 **Krenkel O**, Tacke F. Liver macrophages in tissue homeostasis and disease. *Nat Rev Immunol* 2017; **17**: 306-321 [PMID: 28317925 DOI: 10.1038/nri.2017.11]

461 **Lodder J**, Denaës T, Chobert MN, Wan J, El-Benna J, Pawlotsky JM, Lotersztajn S, Teixeira-Clerc F. Macrophage autophagy protects against liver fibrosis in mice. *Autophagy* 2015; **11**: 1280-1292 [PMID: 26061908 DOI: 10.1080/15548627.2015.1058473]

462 **Ilyas G**, Zhao E, Liu K, Lin Y, Tesfa L, Tanaka KE, Czaja MJ. Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1β. *J Hepatol* 2016; **64**: 118-127 [PMID: 26325539 DOI: 10.1016/j.jhep.2015.08.019]

463 **Sun K**, Xu L, Jing Y, Han Z, Chen X, Cai C, Zhao P, Zhao X, Yang L, Wei L. Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-κB-IL1α/β-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis. *Cancer Lett* 2017; **388**: 198-207 [PMID: 28011320 DOI: 10.1016/j.canlet.2016.12.004]

464 **Habib A**, Chokr D, Wan J, Hegde P, Mabire M, Siebert M, Ribeiro-Parenti L, Le Gall M, Lettéron P, Pilard N, Mansouri A, Brouillet A, Tardelli M, Weiss E, Le Faouder P, Guillou H, Cravatt BF, Moreau R, Trauner M, Lotersztajn S. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. *Gut* 2019; **68**: 522-532 [PMID: 30301768 DOI: 10.1136/gutjnl-2018-316137]

465 **Ruart M**, Chavarria L, Campreciós G, Suárez-Herrera N, Montironi C, Guixé-Muntet S, Bosch J, Friedman SL, Garcia-Pagán JC, Hernández-Gea V. Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. *J Hepatol* 2019; **70**: 458-469 [PMID: 30367898 DOI: 10.1016/j.jhep.2018.10.015]

466 **Luo X**, Wang D, Zhu X, Wang G, You Y, Ning Z, Li Y, Jin S, Huang Y, Hu Y, Chen T, Meng Y, Li X. Autophagic degradation of caveolin-1 promotes liver sinusoidal endothelial cells defenestration. *Cell Death Dis* 2018; **9**: 576 [PMID: 29760379 DOI: 10.1038/s41419-018-0567-0]

467 **Boteon YL**, Laing R, Mergental H, Reynolds GM, Mirza DF, Afford SC, Bhogal RH. Mechanisms of autophagy activation in endothelial cell and their targeting during normothermic machine liver perfusion. *World J Gastroenterol* 2017; **23**: 8443-8451 [PMID: 29358854 DOI: 10.3748/wjg.v23.i48.8443]

468 **Pozniak KN**, Pearen MA, Pereira TN, Kramer CSM, Kalita-De Croft P, Nawaratna SK, Fernandez-Rojo MA, Gobert GN, Tirnitz-Parker JEE, Olynyk JK, Shepherd RW, Lewindon PJ, Ramm GA. Taurocholate Induces Biliary Differentiation of Liver Progenitor Cells Causing Hepatic Stellate Cell Chemotaxis in the Ductular Reaction: Role in Pediatric Cystic Fibrosis Liver Disease. *Am J Pathol* 2017; **187**: 2744-2757 [PMID: 28935574 DOI: 10.1016/j.ajpath.2017.08.024]

469 **Hung TM**, Huang YJ, Lin YC, Chen YH, Wu YM, Lee PH. A critical role of autophagy in regulating the mesenchymal transition of ductular cells in liver cirrhosis. *Sci Rep* 2019; **9**: 10673 [PMID: 31337842 DOI: 10.1038/s41598-019-46764-x]

470 **Hung TM**, Hsiao CC, Lin CW, Lee PH. Complex Cell Type-Specific Roles of Autophagy in Liver Fibrosis and Cirrhosis. *Pathogens* 2020; **9** [PMID: 32197543 DOI: 10.3390/pathogens9030225]

471 **Degenhardt K**, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* 2006; **10**: 51-64 [PMID: 16843265 DOI: 10.1016/j.ccr.2006.06.001]

472 **Yazdani HO**, Huang H, Tsung A. Autophagy: Dual Response in the Development of Hepatocellular Carcinoma. *Cells* 2019; **8** [PMID: 30695997 DOI: 10.3390/cells8020091]

473 **Guo JY**, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V, Coller HA, Dipaola RS, Gelinas C, Rabinowitz JD, White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. *Genes Dev* 2011; **25**: 460-470 [PMID: 21317241 DOI: 10.1101/gad.2016311]

474 **Elgendy M**, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. *Mol Cell* 2011; **42**: 23-35 [PMID: 21353614 DOI: 10.1016/j.molcel.2011.02.009]

475 **Lim SC**, Han SI. Ursodeoxycholic acid effectively kills drug-resistant gastric cancer cells through induction of autophagic death. *Oncol Rep* 2015; **34**: 1261-1268 [PMID: 26133914 DOI: 10.3892/or.2015.4076]

476 **White DL**, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. *Gastroenterology* 2017; **152**: 812-820.e5 [PMID: 27889576 DOI: 10.1053/j.gastro.2016.11.020]

477 **West J**, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. *Aliment Pharmacol Ther* 2017; **45**: 983-990 [PMID: 28144999 DOI: 10.1111/apt.13961]

478 **Chang Y**, Yan W, He X, Zhang L, Li C, Huang H, Nace G, Geller DA, Lin J, Tsung A. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. *Gastroenterology* 2012; **143**: 177-87.e8 [PMID: 22504094 DOI: 10.1053/j.gastro.2012.04.009]

479 **Ni HM**, Chao X, Yang H, Deng F, Wang S, Bai Q, Qian H, Cui Y, Cui W, Shi Y, Zong WX, Wang Z, Yang L, Ding WX. Dual Roles of Mammalian Target of Rapamycin in Regulating Liver Injury and Tumorigenesis in Autophagy-Defective Mouse Liver. *Hepatology* 2019; **70**: 2142-2155 [PMID: 31095752 DOI: 10.1002/hep.30770]

480 **Cui J**, Gong Z, Shen HM. The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets. *Biochim Biophys Acta* 2013; **1836**: 15-26 [PMID: 23428608 DOI: 10.1016/j.bbcan.2013.02.003]

481 **Sun K**, Guo XL, Zhao QD, Jing YY, Kou XR, Xie XQ, Zhou Y, Cai N, Gao L, Zhao X, Zhang SS, Song JR, Li D, Deng WJ, Li R, Wu MC, Wei LX. Paradoxical role of autophagy in the dysplastic and tumor-forming stages of hepatocarcinoma development in rats. *Cell Death Dis* 2013; **4**: e501 [PMID: 23429287 DOI: 10.1038/cddis.2013.35]

482 **Taniguchi K**, Yamachika S, He F, Karin M. p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer. *FEBS Lett* 2016; **590**: 2375-2397 [PMID: 27404485 DOI: 10.1002/1873-3468.12301]

483 **Lazova R**, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. *Clin Cancer Res* 2012; **18**: 370-379 [PMID: 22080440 DOI: 10.1158/1078-0432.CCR-11-1282]

484 **Wu DH**, Jia CC, Chen J, Lin ZX, Ruan DY, Li X, Lin Q, Min-Dong, Ma XK, Wan XB, Cheng N, Chen ZH, Xing YF, Wu XY, Wen JY. Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. *Tumour Biol* 2014; **35**: 12225-12233 [PMID: 25256671 DOI: 10.1007/s13277-014-2531-7]

485 **Takamura A**, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N. Autophagy-deficient mice develop multiple liver tumors. *Genes Dev* 2011; **25**: 795-800 [PMID: 21498569 DOI: 10.1101/gad.2016211]

486 **Bao L**, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T, Dash S. Impaired autophagy response in human hepatocellular carcinoma. *Exp Mol Pathol* 2014; **96**: 149-154 [PMID: 24369267 DOI: 10.1016/j.yexmp.2013.12.002]

487 **Shi YH**, Ding ZB, Zhou J, Qiu SJ, Fan J. Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. *Autophagy* 2009; **5**: 380-382 [PMID: 19145109 DOI: 10.4161/auto.5.3.7658]

488 **Ding ZB**, Shi YH, Zhou J, Qiu SJ, Xu Y, Dai Z, Shi GM, Wang XY, Ke AW, Wu B, Fan J. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. *Cancer Res* 2008; **68**: 9167-9175 [PMID: 19010888 DOI: 10.1158/0008-5472.CAN-08-1573]

489 **DeNicola GM**, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature* 2011; **475**: 106-109 [PMID: 21734707 DOI: 10.1038/nature10189]

490 **Jain A**, Lamark T, Sjøttem E, Larsen KB, Awuh JA, Øvervatn A, McMahon M, Hayes JD, Johansen T. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. *J Biol Chem* 2010; **285**: 22576-22591 [PMID: 20452972 DOI: 10.1074/jbc.M110.118976]

491 **Lau A**, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E, Zhang DD. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. *Mol Cell Biol* 2010; **30**: 3275-3285 [PMID: 20421418 DOI: 10.1128/MCB.00248-10]

492 **Inami Y**, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M, Lee MS, Tanaka K, Komatsu M. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. *J Cell Biol* 2011; **193**: 275-284 [PMID: 21482715 DOI: 10.1083/jcb.201102031]

493 **Ni HM**, Woolbright BL, Williams J, Copple B, Cui W, Luyendyk JP, Jaeschke H, Ding WX. Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. *J Hepatol* 2014; **61**: 617-625 [PMID: 24815875 DOI: 10.1016/j.jhep.2014.04.043]

494 **Saito T**, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K, Hirose Y, Nagahashi M, Iso T, Fukutomi T, Ohishi M, Endo K, Uemura T, Nishito Y, Okuda S, Obata M, Kouno T, Imamura R, Tada Y, Obata R, Yasuda D, Takahashi K, Fujimura T, Pi J, Lee MS, Ueno T, Ohe T, Mashino T, Wakai T, Kojima H, Okabe T, Nagano T, Motohashi H, Waguri S, Soga T, Yamamoto M, Tanaka K, Komatsu M. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. *Nat Commun* 2016; **7**: 12030 [PMID: 27345495 DOI: 10.1038/ncomms12030]

495 **Mitsuishi Y**, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. *Cancer Cell* 2012; **22**: 66-79 [PMID: 22789539 DOI: 10.1016/j.ccr.2012.05.016]

496 **Perra A**, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. *J Hepatol* 2014; **61**: 1088-1096 [PMID: 25010260 DOI: 10.1016/j.jhep.2014.06.033]

497 **Turcios L**, Chacon E, Garcia C, Eman P, Cornea V, Jiang J, Spear B, Liu C, Watt DS, Marti F, Gedaly R. Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma. *PLoS One* 2019; **14**: e0212538 [PMID: 30794613 DOI: 10.1371/journal.pone.0212538]

498 **Wang W**, Xu L, Liu P, Jairam K, Yin Y, Chen K, Sprengers D, Peppelenbosch MP, Pan Q, Smits R. Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. *Neoplasia* 2016; **18**: 711-723 [PMID: 27851986 DOI: 10.1016/j.neo.2016.10.004]

499 **Kiyono K**, Suzuki HI, Matsuyama H, Morishita Y, Komuro A, Kano MR, Sugimoto K, Miyazono K. Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. *Cancer Res* 2009; **69**: 8844-8852 [PMID: 19903843 DOI: 10.1158/0008-5472.CAN-08-4401]

500 **Xie R**, Wang F, McKeehan WL, Liu L. Autophagy enhanced by microtubule- and mitochondrion-associated MAP1S suppresses genome instability and hepatocarcinogenesis. *Cancer Res* 2011; **71**: 7537-7546 [PMID: 22037873 DOI: 10.1158/0008-5472.CAN-11-2170]

501 **Jung KH**, Noh JH, Kim JK, Eun JW, Bae HJ, Chang YG, Kim MG, Park WS, Lee JY, Lee SY, Chu IS, Nam SW. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer. *Hepatology* 2012; **56**: 644-657 [PMID: 22392728 DOI: 10.1002/hep.25699]

502 **Xie HJ**, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H, Nam SW. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. *PLoS One* 2012; **7**: e34265 [PMID: 22496786 DOI: 10.1371/journal.pone.0034265]

503 **Zou M**, Lu N, Hu C, Liu W, Sun Y, Wang X, You Q, Gu C, Xi T, Guo Q. Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A *via* inhibition of mTOR signaling. *Cell Signal* 2012; **24**: 1722-1732 [PMID: 22560876 DOI: 10.1016/j.cellsig.2012.04.009]

504 **Luo Z**, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, Chu Y, Yi J, Wang X, Sun Y, Jeong LS, Liu J, Jia L. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. *Cancer Res* 2012; **72**: 3360-3371 [PMID: 22562464 DOI: 10.1158/0008-5472.CAN-12-0388]

505 **Yang D**, Li L, Liu H, Wu L, Luo Z, Li H, Zheng S, Gao H, Chu Y, Sun Y, Liu J, Jia L. Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. *Cell Death Differ* 2013; **20**: 235-247 [PMID: 22935614 DOI: 10.1038/cdd.2012.113]

506 **Wang Y**, Han C, Lu L, Magliato S, Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. *Hepatology* 2013; **58**: 995-1010 [PMID: 23504944 DOI: 10.1002/hep.26394]

507 **Chang CP**, Yang MC, Liu HS, Lin YS, Lei HY. Concanavalin A induces autophagy in hepatoma cells and has a therapeutic effect in a murine in situ hepatoma model. *Hepatology* 2007; **45**: 286-296 [PMID: 17256764 DOI: 10.1002/hep.21509]

508 **Lei HY**, Chang CP. Induction of autophagy by concanavalin A and its application in anti-tumor therapy. *Autophagy* 2007; **3**: 402-404 [PMID: 17471013 DOI: 10.4161/auto.4280]

509 **Chang CP**, Yang MC, Lei HY. Concanavalin A/IFN-gamma triggers autophagy-related necrotic hepatocyte death through IRGM1-mediated lysosomal membrane disruption. *PLoS One* 2011; **6**: e28323 [PMID: 22163006 DOI: 10.1371/journal.pone.0028323]

510 **Qian H**, Yang Y. Alterations of cellular organelles in human liver-derived hepatoma G2 cells induced by adriamycin. *Anticancer Drugs* 2009; **20**: 779-786 [PMID: 19617817 DOI: 10.1097/CAD.0b013e32832f4e6f]

511 **Yang F**, Gao YH, Wu KW, Deng R, Li DD, Wei ZX, Jiang S, Wu XQ, Feng GK, Li HJ, Zhu XF. A novel sesquiterpene Hirsutanol A induces autophagical cell death in human hepatocellular carcinoma cells by increasing reactive oxygen species. *Chin J Cancer* 2010; **29**: 655-660 [PMID: 20591217 DOI: 10.5732/cjc.009.10702]

512 **Xie SQ**, Li Q, Zhang YH, Wang JH, Mei ZH, Zhao J, Wang CJ. NPC-16, a novel naphthalimide-polyamine conjugate, induced apoptosis and autophagy in human hepatoma HepG2 cells and Bel-7402 cells. *Apoptosis* 2011; **16**: 27-34 [PMID: 20809291 DOI: 10.1007/s10495-010-0537-1]

513 **Zhang JQ**, Li YM, Liu T, He WT, Chen YT, Chen XH, Li X, Zhou WC, Yi JF, Ren ZJ. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. *World J Gastroenterol* 2010; **16**: 4281-4290 [PMID: 20818811 DOI: 10.3748/wjg.v16.i34.4281]

514 **Wang N**, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. *J Cell Biochem* 2010; **111**: 1426-1436 [PMID: 20830746 DOI: 10.1002/jcb.22869]

515 **Wang N**, Pan W, Zhu M, Zhang M, Hao X, Liang G, Feng Y. Fangchinoline induces autophagic cell death *via* p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. *Br J Pharmacol* 2011; **164**: 731-742 [PMID: 21418191 DOI: 10.1111/j.1476-5381.2011.01349.x]

516 **Hou Q**, Tang X, Liu H, Tang J, Yang Y, Jing X, Xiao Q, Wang W, Gou X, Wang Z. Berberine induces cell death in human hepatoma cells *in vitro* by downregulating CD147. *Cancer Sci* 2011; **102**: 1287-1292 [PMID: 21443647 DOI: 10.1111/j.1349-7006.2011.01933.x]

517 **Qian H**, Yang Y, Wang X. Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. *Eur J Pharm Sci* 2011; **43**: 125-131 [PMID: 21514382 DOI: 10.1016/j.ejps.2011.04.002]

518 **Andrzejak M**, Price M, Kessel DH. Apoptotic and autophagic responses to photodynamic therapy in 1c1c7 murine hepatoma cells. *Autophagy* 2011; **7**: 979-984 [PMID: 21555918 DOI: 10.4161/auto.7.9.15865]

519 **Hu M**, Huang H, Zhao R, Li P, Li M, Miao H, Chen N, Chen M. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma. *Oncol Rep* 2014; **31**: 649-656 [PMID: 24297300 DOI: 10.3892/or.2013.2890]

520 **Song J**, Qu Z, Guo X, Zhao Q, Zhao X, Gao L, Sun K, Shen F, Wu M, Wei L. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. *Autophagy* 2009; **5**: 1131-1144 [PMID: 19786832 DOI: 10.4161/auto.5.8.9996]

521 **Chen LH**, Loong CC, Su TL, Lee YJ, Chu PM, Tsai ML, Tsai PH, Tu PH, Chi CW, Lee HC, Chiou SH. Autophagy inhibition enhances apoptosis triggered by BO-1051, an N-mustard derivative, and involves the ATM signaling pathway. *Biochem Pharmacol* 2011; **81**: 594-605 [PMID: 21184746 DOI: 10.1016/j.bcp.2010.12.011]

522 **Ding ZB**, Hui B, Shi YH, Zhou J, Peng YF, Gu CY, Yang H, Shi GM, Ke AW, Wang XY, Song K, Dai Z, Shen YH, Fan J. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin *via* reactive oxygen species modulation. *Clin Cancer Res* 2011; **17**: 6229-6238 [PMID: 21825039 DOI: 10.1158/1078-0432.CCR-11-0816]

523 **Shimizu S**, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. *Int J Cancer* 2012; **131**: 548-557 [PMID: 21858812 DOI: 10.1002/ijc.26374]

524 **Du H**, Yang W, Chen L, Shi M, Seewoo V, Wang J, Lin A, Liu Z, Qiu W. Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells. *Oncol Rep* 2012; **27**: 143-150 [PMID: 21935576 DOI: 10.3892/or.2011.1464]

525 **Xu N**, Zhang J, Shen C, Luo Y, Xia L, Xue F, Xia Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. *Biochem Biophys Res Commun* 2012; **423**: 826-831 [PMID: 22713463 DOI: 10.1016/j.bbrc.2012.06.048]

526 **Yu HC**, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. *J Biol Chem* 2013; **288**: 18249-18259 [PMID: 23677989 DOI: 10.1074/jbc.M112.446385]

527 **Wu B**, Cui J, Yang XM, Liu ZY, Song F, Li L, Jiang JL, Chen ZN. Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. *Cell Death Dis* 2017; **8**: e2925 [PMID: 28703811 DOI: 10.1038/cddis.2017.251]

528 **Shi YH**, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, Wang XY, Dai Z, Peng YF, Gu CY, Qiu SJ, Fan J. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma *via* ER stress-related apoptosis. *Autophagy* 2011; **7**: 1159-1172 [PMID: 21691147 DOI: 10.4161/auto.7.10.16818]

529 **Bareford MD**, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. *Cancer Res* 2011; **71**: 4955-4967 [PMID: 21622715 DOI: 10.1158/0008-5472.CAN-11-0898]

530 **Li X**, Zhou Y, Yang L, Ma Y, Peng X, Yang S, Li H, Liu J. LncRNA NEAT1 promotes autophagy *via* regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma. *J Cell Physiol* 2020; **235**: 3402-3413 [PMID: 31549407 DOI: 10.1002/jcp.29230]

531 **Jin F**, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang CY, Zen K, Li L. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. *Cell Death Dis* 2017; **8**: e2540 [PMID: 28079894 DOI: 10.1038/cddis.2016.461]

532 **Prieto-Domínguez N**, Ordóñez R, Fernández A, Méndez-Blanco C, Baulies A, Garcia-Ruiz C, Fernández-Checa JC, Mauriz JL, González-Gallego J. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. *J Pineal Res* 2016; **61**: 396-407 [PMID: 27484637 DOI: 10.1111/jpi.12358]

533 **Li W**, Li Y, Siraj S, Jin H, Fan Y, Yang X, Huang X, Wang X, Wang J, Liu L, Du L, Chen Q. FUN14 Domain-Containing 1-Mediated Mitophagy Suppresses Hepatocarcinogenesis by Inhibition of Inflammasome Activation in Mice. *Hepatology* 2019; **69**: 604-621 [PMID: 30053328 DOI: 10.1002/hep.30191]

534 **Huang Q**, Zhan L, Cao H, Li J, Lyu Y, Guo X, Zhang J, Ji L, Ren T, An J, Liu B, Nie Y, Xing J. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. *Autophagy* 2016; **12**: 999-1014 [PMID: 27124102 DOI: 10.1080/15548627.2016.1166318]

535 **Liu K**, Lee J, Kim JY, Wang L, Tian Y, Chan ST, Cho C, Machida K, Chen D, Ou JJ. Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells. *Mol Cell* 2017; **68**: 281-292.e5 [PMID: 29033320 DOI: 10.1016/j.molcel.2017.09.022]

536 **Gómez de Cedrón M**, Ramírez de Molina A. Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism. *J Lipid Res* 2016; **57**: 193-206 [PMID: 26630911 DOI: 10.1194/jlr.R061812]

537 **Zhao T**, Du H, Ding X, Walls K, Yan C. Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-/-) mice. *Oncogene* 2015; **34**: 1938-1948 [PMID: 24882582 DOI: 10.1038/onc.2014.143]

538 **Mukhopadhyay S**, Schlaepfer IR, Bergman BC, Panda PK, Praharaj PP, Naik PP, Agarwal R, Bhutia SK. ATG14 facilitated lipophagy in cancer cells induce ER stress mediated mitoptosis through a ROS dependent pathway. *Free Radic Biol Med* 2017; **104**: 199-213 [PMID: 28069524 DOI: 10.1016/j.freeradbiomed.2017.01.007]

539 **Lu GD**, Ang YH, Zhou J, Tamilarasi J, Yan B, Lim YC, Srivastava S, Salto-Tellez M, Hui KM, Shen HM, Nguyen LN, Tan BC, Silver DL, Hooi SC. CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma. *Hepatology* 2015; **61**: 965-978 [PMID: 25363290 DOI: 10.1002/hep.27593]

540 **Kon M**, Kiffin R, Koga H, Chapochnick J, Macian F, Varticovski L, Cuervo AM. Chaperone-mediated autophagy is required for tumor growth. *Sci Transl Med* 2011; **3**: 109ra117 [PMID: 22089453 DOI: 10.1126/scitranslmed.3003182]

541 **Chava S**, Lee C, Aydin Y, Chandra PK, Dash A, Chedid M, Thung SN, Moroz K, Wu T, Nayak NC, Dash S. Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma. *Oncotarget* 2017; **8**: 40019-40036 [PMID: 28402954 DOI: 10.18632/oncotarget.16685]

542 **Dash S**, Aydin Y, Moroz K. Chaperone-Mediated Autophagy in the Liver: Good or Bad? *Cells* 2019; **8** [PMID: 31652893 DOI: 10.3390/cells8111308]

543 **Wu WKK**, Zhang L, Chan MTV. Autophagy, NAFLD and NAFLD-Related HCC. *Adv Exp Med Biol* 2018; **1061**: 127-138 [PMID: 29956211 DOI: 10.1007/978-981-10-8684-7\_10]

544 **Niture S**, Gyamfi MA, Lin M, Chimeh U, Dong X, Zheng W, Moore J, Kumar D. TNFAIP8 regulates autophagy, cell steatosis, and promotes hepatocellular carcinoma cell proliferation. *Cell Death Dis* 2020; **11**: 178 [PMID: 32152268 DOI: 10.1038/s41419-020-2369-4]

545 **Liu L**, Liao JZ, He XX, Li PY. The role of autophagy in hepatocellular carcinoma: friend or foe. *Oncotarget* 2017; **8**: 57707-57722 [PMID: 28915706 DOI: 10.18632/oncotarget.17202]

546 **Huang F**, Wang BR, Wang YG. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. *World J Gastroenterol* 2018; **24**: 4643-4651 [PMID: 30416312 DOI: 10.3748/wjg.v24.i41.4643]

547 **Yang S**, Yang L, Li X, Li B, Li Y, Zhang X, Ma Y, Peng X, Jin H, Li H. New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies. *Am J Cancer Res* 2019; **9**: 1329-1353 [PMID: 31392073]

548 **Chen P**, Bonaldo P. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. *Int Rev Cell Mol Biol* 2013; **301**: 1-35 [PMID: 23317816 DOI: 10.1016/B978-0-12-407704-1.00001-4]

549 **Lin H**, Yan J, Wang Z, Hua F, Yu J, Sun W, Li K, Liu H, Yang H, Lv Q, Xue J, Hu ZW. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. *Hepatology* 2013; **57**: 171-182 [PMID: 22859216 DOI: 10.1002/hep.25991]

550 **Chen W**, Ma T, Shen XN, Xia XF, Xu GD, Bai XL, Liang TB. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. *Cancer Res* 2012; **72**: 1363-1372 [PMID: 22287548 DOI: 10.1158/0008-5472.CAN-11-2684]

551 **Chen KD**, Lin CC, Tsai MC, Huang KT, Chiu KW. Tumor microenvironment mediated by suppression of autophagic flux drives liver malignancy. *Biomed J* 2018; **41**: 163-168 [PMID: 30080656 DOI: 10.1016/j.bj.2018.03.002]

552 **Hu T**, Li P, Luo Z, Chen X, Zhang J, Wang C, Chen P, Dong Z. Chloroquine inhibits hepatocellular carcinoma cell growth *in vitro* and in vivo. *Oncol Rep* 2016; **35**: 43-49 [PMID: 26530158 DOI: 10.3892/or.2015.4380]

553 **Wang Y**, Zhao H, Wang D, Hao M, Kong C, Zhao X, Gao Y, Li J, Liu B, Yang B, Zhang H, Jiang J. Inhibition of Autophagy Promoted Apoptosis and Suppressed Growth of Hepatocellular Carcinoma Upon Photothermal Exposure. *J Biomed Nanotechnol* 2019; **15**: 813-821 [PMID: 30841973 DOI: 10.1166/jbn.2019.2714]

554 **Amaravadi RK**, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. *Clin Cancer Res* 2011; **17**: 654-666 [PMID: 21325294 DOI: 10.1158/1078-0432.CCR-10-2634]

555 **Di Fazio P**, Matrood S. Targeting autophagy in liver cancer. *Transl Gastroenterol Hepatol* 2018; **3**: 39 [PMID: 30148224 DOI: 10.21037/tgh.2018.06.09]

556 **Peng YF**, Shi YH, Ding ZB, Ke AW, Gu CY, Hui B, Zhou J, Qiu SJ, Dai Z, Fan J. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice *via* impairing anoikis resistance and colonization of HCC cells. *Autophagy* 2013; **9**: 2056-2068 [PMID: 24157892 DOI: 10.4161/auto.26398]

557 **Gao L**, Song JR, Zhang JW, Zhao X, Zhao QD, Sun K, Deng WJ, Li R, Lv G, Cheng HY, Wei LX. Chloroquine promotes the anticancer effect of TACE in a rabbit VX2 Liver tumor model. *Int J Biol Sci* 2013; **9**: 322-330 [PMID: 23569437 DOI: 10.7150/ijbs.5925]

558 **Wang X**, Deng Q, Feng K, Chen S, Jiang J, Xia F, Ma K, Bie P. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression *via* autophagy and the CD133 feedback loop. *Oncol Rep* 2018; **40**: 241-251 [PMID: 29749472 DOI: 10.3892/or.2018.6403]

559 **Zhao Z**, Wu J, Liu X, Liang M, Zhou X, Ouyang S, Yao J, Wang J, Luo B. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma *via* autophagy. *Cancer Lett* 2018; **421**: 73-81 [PMID: 29458142 DOI: 10.1016/j.canlet.2018.02.024]

560 **Prieto-Domínguez N**, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J, Mauriz JL. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. *Front Pharmacol* 2016; **7**: 151 [PMID: 27375485 DOI: 10.3389/fphar.2016.00151]

561 **Zhao P**, Li M, Wang Y, Chen Y, He C, Zhang X, Yang T, Lu Y, You J, Lee RJ, Xiang G. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles. *Acta Biomater* 2018; **72**: 248-255 [PMID: 29555460 DOI: 10.1016/j.actbio.2018.03.022]

562 **Hou YJ**, Dong LW, Tan YX, Yang GZ, Pan YF, Li Z, Tang L, Wang M, Wang Q, Wang HY. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma. *Lab Invest* 2011; **91**: 1146-1157 [PMID: 21647092 DOI: 10.1038/labinvest.2011.97]

563 **Sasaki M**, Nitta T, Sato Y, Nakanuma Y. Autophagy may occur at an early stage of cholangiocarcinogenesis *via* biliary intraepithelial neoplasia. *Hum Pathol* 2015; **46**: 202-209 [PMID: 25466963 DOI: 10.1016/j.humpath.2014.09.016]

564 **Dong LW**, Hou YJ, Tan YX, Tang L, Pan YF, Wang M, Wang HY. Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. *Autophagy* 2011; **7**: 1222-1229 [PMID: 21654208 DOI: 10.4161/auto.7.10.16610]

565 **Wang TT**, Cao QH, Chen MY, Xia Q, Fan XJ, Ma XK, Lin Q, Jia CC, Dong M, Ruan DY, Lin ZX, Wen JY, Wei L, Li X, Chen ZH, Wang L, Wu XY, Wan XB. Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma. *PLoS One* 2013; **8**: e80317 [PMID: 24303007 DOI: 10.1371/journal.pone.0080317]

566 **Qu X**, Sheng J, Shen L, Su J, Xu Y, Xie Q, Wu Y, Zhang X, Sun L. Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS. *PLoS One* 2017; **12**: e0173712 [PMID: 28301876 DOI: 10.1371/journal.pone.0173712]

567 **Jia B**, Xue Y, Yan X, Li J, Wu Y, Guo R, Zhang J, Zhang L, Li Y, Liu Y, Sun L. Autophagy inhibitor chloroquine induces apoptosis of cholangiocarcinoma cells *via* endoplasmic reticulum stress. *Oncol Lett* 2018; **16**: 3509-3516 [PMID: 30127955 DOI: 10.3892/ol.2018.9131]

568 **O'Dell MR**, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N, Hezel AF. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. *Cancer Res* 2012; **72**: 1557-1567 [PMID: 22266220 DOI: 10.1158/0008-5472.CAN-11-3596]

569 **Huang JL**, Hezel AF. Autophagy in intra-hepatic cholangiocarcinoma. *Autophagy* 2012; **8**: 1148-1149 [PMID: 22751196 DOI: 10.4161/auto.20647]

570 **Hong ZF**, Zhao WX, Yin ZY, Xie CR, Xu YP, Chi XQ, Zhang S, Wang XM. Capsaicin Enhances the Drug Sensitivity of Cholangiocarcinoma through the Inhibition of Chemotherapeutic-Induced Autophagy. *PLoS One* 2015; **10**: e0121538 [PMID: 25933112 DOI: 10.1371/journal.pone.0121538]

571 **Ding X**, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, Ndzengue A, Li Y, Zhou Y, Huang S, Sinicrope FA, Zou X, Thomas MB, Smith CD, Roberts LR. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. *Oncotarget* 2016; **7**: 20080-20092 [PMID: 26956050 DOI: 10.18632/oncotarget.7914]

572 **Lomas DA**, Mahadeva R. Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. *J Clin Invest* 2002; **110**: 1585-1590 [PMID: 12464660 DOI: 10.1172/JCI16782]

573 **Huber R**, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. *Biochemistry* 1989; **28**: 8951-8966 [PMID: 2690952 DOI: 10.1021/bi00449a001]

574 **Greene CM**, Marciniak SJ, Teckman J, Ferrarotti I, Brantly ML, Lomas DA, Stoller JK, McElvaney NG. α1-Antitrypsin deficiency. *Nat Rev Dis Primers* 2016; **2**: 16051 [PMID: 27465791 DOI: 10.1038/nrdp.2016.51]

575 **Lomas DA**, Hurst JR, Gooptu B. Update on alpha-1 antitrypsin deficiency: New therapies. *J Hepatol* 2016; **65**: 413-424 [PMID: 27034252 DOI: 10.1016/j.jhep.2016.03.010]

576 **Rudnick DA**, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. *Hepatology* 2005; **42**: 514-521 [PMID: 16044402 DOI: 10.1002/hep.20815]

577 **Hazari YM**, Bashir A, Habib M, Bashir S, Habib H, Qasim MA, Shah NN, Haq E, Teckman J, Fazili KM. Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions. *Mutat Res* 2017; **773**: 14-25 [PMID: 28927525 DOI: 10.1016/j.mrrev.2017.03.001]

578 **Teckman JH**, Perlmutter DH. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. *Am J Physiol Gastrointest Liver Physiol* 2000; **279**: G961-G974 [PMID: 11052993 DOI: 10.1152/ajpgi.2000.279.5.G961]

579 **Teckman JH**, An JK, Loethen S, Perlmutter DH. Fasting in alpha1-antitrypsin deficient liver: constitutive [correction of consultative] activation of autophagy. *Am J Physiol Gastrointest Liver Physiol* 2002; **283**: G1156-G1165 [PMID: 12381530 DOI: 10.1152/ajpgi.00041.2002]

580 **Marciniak SJ**, Lomas DA. Alpha1-antitrypsin deficiency and autophagy. *N Engl J Med* 2010; **363**: 1863-1864 [PMID: 21047232 DOI: 10.1056/NEJMcibr1008007]

581 **Teckman JH**, Mangalat N. Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions. *Expert Rev Gastroenterol Hepatol* 2015; **9**: 261-268 [PMID: 25066184 DOI: 10.1586/17474124.2014.943187]

582 **Perlmutter DH**. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. *J Clin Invest* 2002; **110**: 1579-1583 [PMID: 12464659 DOI: 10.1172/JCI16787]

583 **Teckman JH**, An JK, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. *Am J Physiol Gastrointest Liver Physiol* 2004; **286**: G851-G862 [PMID: 14684378 DOI: 10.1152/ajpgi.00175.2003]

584 **Kamimoto T**, Shoji S, Hidvegi T, Mizushima N, Umebayashi K, Perlmutter DH, Yoshimori T. Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. *J Biol Chem* 2006; **281**: 4467-4476 [PMID: 16365039 DOI: 10.1074/jbc.M509409200]

585 **Kruse KB**, Brodsky JL, McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. *Mol Biol Cell* 2006; **17**: 203-212 [PMID: 16267277 DOI: 10.1091/mbc.e04-09-0779]

586 **Kaushal S**, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt EM, Teckman JH. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. *Exp Biol Med (Maywood)* 2010; **235**: 700-709 [PMID: 20511674 DOI: 10.1258/ebm.2010.009297]

587 **Perlmutter DH**. The role of autophagy in alpha-1-antitrypsin deficiency: a specific cellular response in genetic diseases associated with aggregation-prone proteins. *Autophagy* 2006; **2**: 258-263 [PMID: 16874089 DOI: 10.4161/auto.2882]

588 **Perlmutter DH**. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in alpha-1-antitrypsin deficiency. *Cell Death Differ* 2009; **16**: 39-45 [PMID: 18617899 DOI: 10.1038/cdd.2008.103]

589 **Lindblad D**, Blomenkamp K, Teckman J. Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. *Hepatology* 2007; **46**: 1228-1235 [PMID: 17886264 DOI: 10.1002/hep.21822]

590 **Yamamura T**, Ohsaki Y, Suzuki M, Shinohara Y, Tatematsu T, Cheng J, Okada M, Ohmiya N, Hirooka Y, Goto H, Fujimoto T. Inhibition of Niemann-Pick-type C1-like1 by ezetimibe activates autophagy in human hepatocytes and reduces mutant α1-antitrypsin Z deposition. *Hepatology* 2014; **59**: 1591-1599 [PMID: 24214142 DOI: 10.1002/hep.26930]

591 **Hidvegi T**, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, Maurice N, Mukherjee A, Goldbach C, Watkins S, Michalopoulos G, Perlmutter DH. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. *Science* 2010; **329**: 229-232 [PMID: 20522742 DOI: 10.1126/science.1190354]

592 **Pastore N**, Blomenkamp K, Annunziata F, Piccolo P, Mithbaokar P, Maria Sepe R, Vetrini F, Palmer D, Ng P, Polishchuk E, Iacobacci S, Polishchuk R, Teckman J, Ballabio A, Brunetti-Pierri N. Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency. *EMBO Mol Med* 2013; **5**: 397-412 [PMID: 23381957 DOI: 10.1002/emmm.201202046]

593 **Wang Y**, Cobanoglu MC, Li J, Hidvegi T, Hale P, Ewing M, Chu AS, Gong Z, Muzumdar R, Pak SC, Silverman GA, Bahar I, Perlmutter DH. An analog of glibenclamide selectively enhances autophagic degradation of misfolded α1-antitrypsin Z. *PLoS One* 2019; **14**: e0209748 [PMID: 30673724 DOI: 10.1371/journal.pone.0209748]

594 **Tang Y**, Fickert P, Trauner M, Marcus N, Blomenkamp K, Teckman J. Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease. *Am J Physiol Gastrointest Liver Physiol* 2016; **311**: G156-G165 [PMID: 27102560 DOI: 10.1152/ajpgi.00143.2015]

595 **Tang Y**, Blomenkamp KS, Fickert P, Trauner M, Teckman JH. NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. *PLoS One* 2018; **13**: e0200897 [PMID: 30067827 DOI: 10.1371/journal.pone.0200897]

596 **Puls F**, Goldschmidt I, Bantel H, Agne C, Bröcker V, Dämmrich M, Lehmann U, Berrang J, Pfister ED, Kreipe HH, Baumann U. Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease. *J Hepatol* 2013; **59**: 626-630 [PMID: 23707368 DOI: 10.1016/j.jhep.2013.05.018]

597 **Członkowska A**, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, Rybakowski JK, Weiss KH, Schilsky ML. Wilson disease. *Nat Rev Dis Primers* 2018; **4**: 21 [PMID: 30190489 DOI: 10.1038/s41572-018-0018-3]

598 **Polishchuk EV**, Merolla A, Lichtmannegger J, Romano A, Indrieri A, Ilyechova EY, Concilli M, De Cegli R, Crispino R, Mariniello M, Petruzzelli R, Ranucci G, Iorio R, Pietrocola F, Einer C, Borchard S, Zibert A, Schmidt HH, Di Schiavi E, Puchkova LV, Franco B, Kroemer G, Zischka H, Polishchuk RS. Activation of Autophagy, Observed in Liver Tissues From Patients With Wilson Disease and From ATP7B-Deficient Animals, Protects Hepatocytes From Copper-Induced Apoptosis. *Gastroenterology* 2019; **156**: 1173-1189.e5 [PMID: 30452922 DOI: 10.1053/j.gastro.2018.11.032]

599 **Farah BL**, Sinha RA, Wu Y, Singh BK, Lim A, Hirayama M, Landau DJ, Bay BH, Koeberl DD, Yen PM. Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa). *Sci Rep* 2017; **7**: 44408 [PMID: 28317891 DOI: 10.1038/srep44408]

600 **Farah BL**, Landau DJ, Sinha RA, Brooks ED, Wu Y, Fung SYS, Tanaka T, Hirayama M, Bay BH, Koeberl DD, Yen PM. Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. *J Hepatol* 2016; **64**: 370-379 [PMID: 26462884 DOI: 10.1016/j.jhep.2015.10.008]

601 **Cho JH**, Kim GY, Pan CJ, Anduaga J, Choi EJ, Mansfield BC, Chou JY. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia. *PLoS Genet* 2017; **13**: e1006819 [PMID: 28558013 DOI: 10.1371/journal.pgen.1006819]

602 **Aki T**, Unuma K, Uemura K. Emerging roles of mitochondria and autophagy in liver injury during sepsis. *Cell Stress* 2017; **1**: 79-89 [PMID: 31225438 DOI: 10.15698/cst2017.11.110]

603 **Qiu P**, Liu Y, Zhang J. Review: the Role and Mechanisms of Macrophage Autophagy in Sepsis. *Inflammation* 2019; **42**: 6-19 [PMID: 30194660 DOI: 10.1007/s10753-018-0890-8]

604 **Chang FY**, Chen HC, Chen PJ, Ho MS, Hsieh SL, Lin JC, Liu FT, Sytwu HK. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). *J Biomed Sci* 2020; **27**: 72 [PMID: 32498686 DOI: 10.1186/s12929-020-00663-w]

605 **Lee JP**, Foote A, Fan H, Peral de Castro C, Lang T, Jones SA, Gavrilescu N, Mills KH, Leech M, Morand EF, Harris J. Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophages. *Autophagy* 2016; **12**: 907-916 [PMID: 27163877 DOI: 10.1080/15548627.2016.1164358]

606 **Thiessen SE**, Derese I, Derde S, Dufour T, Pauwels L, Bekhuis Y, Pintelon I, Martinet W, Van den Berghe G, Vanhorebeek I. The Role of Autophagy in Critical Illness-induced Liver Damage. *Sci Rep* 2017; **7**: 14150 [PMID: 29074879 DOI: 10.1038/s41598-017-14405-w]

607 **Kemp MG**. Crosstalk Between Apoptosis and Autophagy: Environmental Genotoxins, Infection, and Innate Immunity. *J Cell Death* 2017; **9**: 1179670716685085 [PMID: 28469477 DOI: 10.1177/1179670716685085]

608 **Prabakaran T**, Bodda C, Krapp C, Zhang BC, Christensen MH, Sun C, Reinert L, Cai Y, Jensen SB, Skouboe MK, Nyengaard JR, Thompson CB, Lebbink RJ, Sen GC, van Loo G, Nielsen R, Komatsu M, Nejsum LN, Jakobsen MR, Gyrd-Hansen M, Paludan SR. Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1. *EMBO J* 2018; **37** [PMID: 29496741 DOI: 10.15252/embj.201797858]

609 **Hu Q**, Knight PH, Ren Y, Ren H, Zheng J, Wu X, Ren J, Sawyer RG. The emerging role of stimulator of interferons genes signaling in sepsis: Inflammation, autophagy, and cell death. *Acta Physiol (Oxf)* 2019; **225**: e13194 [PMID: 30269441 DOI: 10.1111/apha.13194]

610 **Lalazar G**, Ilyas G, Malik SA, Liu K, Zhao E, Amir M, Lin Y, Tanaka KE, Czaja MJ. Autophagy confers resistance to lipopolysaccharide-induced mouse hepatocyte injury. *Am J Physiol Gastrointest Liver Physiol* 2016; **311**: G377-G386 [PMID: 27469366 DOI: 10.1152/ajpgi.00124.2016]

611 **Oami T**, Watanabe E, Hatano M, Teratake Y, Fujimura L, Sakamoto A, Ito C, Toshimori K, Swanson PE, Oda S. Blocking Liver Autophagy Accelerates Apoptosis and Mitochondrial Injury in Hepatocytes and Reduces Time to Mortality in a Murine Sepsis Model. *Shock* 2018; **50**: 427-434 [PMID: 29076973 DOI: 10.1097/SHK.0000000000001040]

612 **Xiong X**, Ren Y, Cui Y, Li R, Wang C, Zhang Y. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation. *Biomed Pharmacother* 2017; **96**: 1292-1298 [PMID: 29174575 DOI: 10.1016/j.biopha.2017.11.083]

613 **Xing W**, Yang L, Peng Y, Wang Q, Gao M, Yang M, Xiao X. Ginsenoside Rg3 attenuates sepsis-induced injury and mitochondrial dysfunction in liver *via* AMPK-mediated autophagy flux. *Biosci Rep* 2017; **37** [PMID: 28779013 DOI: 10.1042/BSR20170934]

614 **Inata Y**, Kikuchi S, Samraj RS, Hake PW, O'Connor M, Ledford JR, O'Connor J, Lahni P, Wolfe V, Piraino G, Zingarelli B. Autophagy and mitochondrial biogenesis impairment contribute to age-dependent liver injury in experimental sepsis: dysregulation of AMP-activated protein kinase pathway. *FASEB J* 2018; **32**: 728-741 [PMID: 28974562 DOI: 10.1096/fj.201700576R]

615 **Ying L**, Zhao GJ, Wu Y, Ke HL, Hong GL, Zhang H, Dong N, Wu Y, Yao YM, Lu ZQ. Mitofusin 2 Promotes Apoptosis of CD4+ T Cells by Inhibiting Autophagy in Sepsis. *Mediators Inflamm* 2017; **2017**: 4926205 [PMID: 29358849 DOI: 10.1155/2017/4926205]

616 **Neumann Y**, Bruns SA, Rohde M, Prajsnar TK, Foster SJ, Schmitz I. Intracellular Staphylococcus aureus eludes selective autophagy by activating a host cell kinase. *Autophagy* 2016; **12**: 2069-2084 [PMID: 27629870 DOI: 10.1080/15548627.2016.1226732]

617 **Yin X**, Xin H, Mao S, Wu G, Guo L. The Role of Autophagy in Sepsis: Protection and Injury to Organs. *Front Physiol* 2019; **10**: 1071 [PMID: 31507440 DOI: 10.3389/fphys.2019.01071]

618 **Sydor S**, Manka P, Best J, Jafoui S, Sowa JP, Zoubek ME, Hernandez-Gea V, Cubero FJ, Kälsch J, Vetter D, Fiel MI, Hoshida Y, Bian CB, Nelson LJ, Moshage H, Faber KN, Paul A, Baba HA, Gerken G, Friedman SL, Canbay A, Bechmann LP. Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury. *Sci Rep* 2017; **7**: 8119 [PMID: 28808340 DOI: 10.1038/s41598-017-08680-w]

619 **Baulies A**, Ribas V, Núñez S, Torres S, Alarcón-Vila C, Martínez L, Suda J, Ybanez MD, Kaplowitz N, García-Ruiz C, Fernández-Checa JC. Lysosomal Cholesterol Accumulation Sensitizes To Acetaminophen Hepatotoxicity by Impairing Mitophagy. *Sci Rep* 2015; **5**: 18017 [PMID: 26657973 DOI: 10.1038/srep18017]

620 **James LP**, Alonso EM, Hynan LS, Hinson JA, Davern TJ, Lee WM, Squires RH; Pediatric Acute Liver Failure Study Group. Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. *Pediatrics* 2006; **118**: e676-e681 [PMID: 16950959 DOI: 10.1542/peds.2006-0069]

621 **Xie Y**, McGill MR, Du K, Dorko K, Kumer SC, Schmitt TM, Ding WX, Jaeschke H. Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes. *Toxicol Appl Pharmacol* 2015; **289**: 213-222 [PMID: 26431796 DOI: 10.1016/j.taap.2015.09.022]

622 **Qiu Y**, Benet LZ, Burlingame AL. Identification of the hepatic protein targets of reactive metabolites of acetaminophen *in vivo* in mice using two-dimensional gel electrophoresis and mass spectrometry. *J Biol Chem* 1998; **273**: 17940-17953 [PMID: 9651401 DOI: 10.1074/jbc.273.28.17940]

623 **McGill MR**, Lebofsky M, Norris HR, Slawson MH, Bajt ML, Xie Y, Williams CD, Wilkins DG, Rollins DE, Jaeschke H. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. *Toxicol Appl Pharmacol* 2013; **269**: 240-249 [PMID: 23571099 DOI: 10.1016/j.taap.2013.03.026]

624 **Heard KJ**, Green JL, James LP, Judge BS, Zolot L, Rhyee S, Dart RC. Acetaminophen-cysteine adducts during therapeutic dosing and following overdose. *BMC Gastroenterol* 2011; **11**: 20 [PMID: 21401949 DOI: 10.1186/1471-230X-11-20]

625 **Ni HM**, McGill MR, Chao X, Du K, Williams JA, Xie Y, Jaeschke H, Ding WX. Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice. *J Hepatol* 2016; **65**: 354-362 [PMID: 27151180 DOI: 10.1016/j.jhep.2016.04.025]

626 **Lin Z**, Wu F, Lin S, Pan X, Jin L, Lu T, Shi L, Wang Y, Xu A, Li X. Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice. *J Hepatol* 2014; **61**: 825-831 [PMID: 24882054 DOI: 10.1016/j.jhep.2014.05.033]

627 **Igusa Y**, Yamashina S, Izumi K, Inami Y, Fukada H, Komatsu M, Tanaka K, Ikejima K, Watanabe S. Loss of autophagy promotes murine acetaminophen hepatotoxicity. *J Gastroenterol* 2012; **47**: 433-443 [PMID: 22124574 DOI: 10.1007/s00535-011-0500-0]

628 **Sun Y**, Li TY, Song L, Zhang C, Li J, Lin ZZ, Lin SC, Lin SY. Liver-specific deficiency of unc-51 Like kinase 1 and 2 protects mice from acetaminophen-induced liver injury. *Hepatology* 2018; **67**: 2397-2413 [PMID: 29272037 DOI: 10.1002/hep.29759]

629 **Shan S**, Shen Z, Zhang C, Kou R, Xie K, Song F. Mitophagy protects against acetaminophen-induced acute liver injury in mice through inhibiting NLRP3 inflammasome activation. *Biochem Pharmacol* 2019; **169**: 113643 [PMID: 31542387 DOI: 10.1016/j.bcp.2019.113643]

630 **Hua D**, Ju Z, Gan X, Wang Q, Luo C, Gu J, Yu Y. Human amniotic mesenchymal stromal cells alleviate acute liver injury by inhibiting the pro-inflammatory response of liver resident macrophage through autophagy. *Ann Transl Med* 2019; **7**: 392 [PMID: 31555706 DOI: 10.21037/atm.2019.08.83]

631 **Wu Z**, Han M, Chen T, Yan W, Ning Q. Acute liver failure: mechanisms of immune-mediated liver injury. *Liver Int* 2010; **30**: 782-794 [PMID: 20492514 DOI: 10.1111/j.1478-3231.2010.02262.x]

632 **Dechêne A**, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, Schlattjan M, Saner F, Baba HA, Paul A, Dries V, Odenthal M, Gerken G, Friedman SL, Canbay A. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. *Hepatology* 2010; **52**: 1008-1016 [PMID: 20684020 DOI: 10.1002/hep.23754]

633 **Yin C**, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. *J Clin Invest* 2013; **123**: 1902-1910 [PMID: 23635788 DOI: 10.1172/JCI66369]

634 **Shen K**, Chang W, Gao X, Wang H, Niu W, Song L, Qin X. Depletion of activated hepatic stellate cell correlates with severe liver damage and abnormal liver regeneration in acetaminophen-induced liver injury. *Acta Biochim Biophys Sin (Shanghai)* 2011; **43**: 307-315 [PMID: 21335335 DOI: 10.1093/abbs/gmr005]

635 **He Y**, Jin L, Wang J, Yan Z, Chen T, Zhao Y. Mechanisms of fibrosis in acute liver failure. *Liver Int* 2015; **35**: 1877-1885 [PMID: 25388426 DOI: 10.1111/liv.12731]

636 **Langer DA**, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, Katusic ZS, Gores GJ, Shah VH. Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. *Hepatology* 2008; **47**: 1983-1993 [PMID: 18459124 DOI: 10.1002/hep.22285]

637 **Jin L**, Gao H, Wang J, Yang S, Wang J, Liu J, Yang Y, Yan T, Chen T, Zhao Y, He Y. Role and regulation of autophagy and apoptosis by nitric oxide in hepatic stellate cells during acute liver failure. *Liver Int* 2017; **37**: 1651-1659 [PMID: 28508586 DOI: 10.1111/liv.13476]

638 **Amir M**, Zhao E, Fontana L, Rosenberg H, Tanaka K, Gao G, Czaja MJ. Inhibition of hepatocyte autophagy increases tumor necrosis factor-dependent liver injury by promoting caspase-8 activation. *Cell Death Differ* 2013; **20**: 878-887 [PMID: 23519075 DOI: 10.1038/cdd.2013.21]

639 **Zhong Z**, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins G, Ali SR, McGeough MD, Ellisman MH, Seki E, Gustafsson AB, Hoffman HM, Diaz-Meco MT, Moscat J, Karin M. NF-κB Restricts Inflammasome Activation *via* Elimination of Damaged Mitochondria. *Cell* 2016; **164**: 896-910 [PMID: 26919428 DOI: 10.1016/j.cell.2015.12.057]

640 **Han J**, Bae J, Choi CY, Choi SP, Kang HS, Jo EK, Park J, Lee YS, Moon HS, Park CG, Lee MS, Chun T. Autophagy induced by AXL receptor tyrosine kinase alleviates acute liver injury *via* inhibition of NLRP3 inflammasome activation in mice. *Autophagy* 2016; **12**: 2326-2343 [PMID: 27780404 DOI: 10.1080/15548627.2016.1235124]

641 **Wang Q**, Wei S, Zhou S, Qiu J, Shi C, Liu R, Zhou H, Lu L. Hyperglycemia aggravates acute liver injury by promoting liver-resident macrophage NLRP3 inflammasome activation *via* the inhibition of AMPK/mTOR-mediated autophagy induction. *Immunol Cell Biol* 2020; **98**: 54-66 [PMID: 31625631 DOI: 10.1111/imcb.12297]

642 **Zhou S**, Gu J, Liu R, Wei S, Wang Q, Shen H, Dai Y, Zhou H, Zhang F, Lu L. Spermine Alleviates Acute Liver Injury by Inhibiting Liver-Resident Macrophage Pro-Inflammatory Response Through ATG5-Dependent Autophagy. *Front Immunol* 2018; **9**: 948 [PMID: 29770139 DOI: 10.3389/fimmu.2018.00948]

643 **Kim JS**, Wang JH, Biel TG, Kim DS, Flores-Toro JA, Vijayvargiya R, Zendejas I, Behrns KE. Carbamazepine suppresses calpain-mediated autophagy impairment after ischemia/reperfusion in mouse livers. *Toxicol Appl Pharmacol* 2013; **273**: 600-610 [PMID: 24126417 DOI: 10.1016/j.taap.2013.10.006]

644 **Biel TG**, Lee S, Flores-Toro JA, Dean JW, Go KL, Lee MH, Law BK, Law ME, Dunn WA Jr, Zendejas I, Behrns KE, Kim JS. Sirtuin 1 suppresses mitochondrial dysfunction of ischemic mouse livers in a mitofusin 2-dependent manner. *Cell Death Differ* 2016; **23**: 279-290 [PMID: 26184910 DOI: 10.1038/cdd.2015.96]

645 **Evankovich J**, Zhang R, Cardinal JS, Zhang L, Chen J, Huang H, Beer-Stolz D, Billiar TR, Rosengart MR, Tsung A. Calcium/calmodulin-dependent protein kinase IV limits organ damage in hepatic ischemia-reperfusion injury through induction of autophagy. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G189-G198 [PMID: 22575222 DOI: 10.1152/ajpgi.00051.2012]

646 **Kim JS**, Nitta T, Mohuczy D, O'Malley KA, Moldawer LL, Dunn WA Jr, Behrns KE. Impaired autophagy: A mechanism of mitochondrial dysfunction in anoxic rat hepatocytes. *Hepatology* 2008; **47**: 1725-1736 [PMID: 18311843 DOI: 10.1002/hep.22187]

647 **Fang H**, Liu A, Dahmen U, Dirsch O. Dual role of chloroquine in liver ischemia reperfusion injury: reduction of liver damage in early phase, but aggravation in late phase. *Cell Death Dis* 2013; **4**: e694 [PMID: 23807223 DOI: 10.1038/cddis.2013.225]

648 **Eng CH**, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. *Sci Signal* 2010; **3**: ra31 [PMID: 20424262 DOI: 10.1126/scisignal.2000911]

649 **Cheong H**, Lindsten T, Wu J, Lu C, Thompson CB. Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. *Proc Natl Acad Sci U S A* 2011; **108**: 11121-11126 [PMID: 21690395 DOI: 10.1073/pnas.1107969108]

650 **Polletta L**, Vernucci E, Carnevale I, Arcangeli T, Rotili D, Palmerio S, Steegborn C, Nowak T, Schutkowski M, Pellegrini L, Sansone L, Villanova L, Runci A, Pucci B, Morgante E, Fini M, Mai A, Russo MA, Tafani M. SIRT5 regulation of ammonia-induced autophagy and mitophagy. *Autophagy* 2015; **11**: 253-270 [PMID: 25700560 DOI: 10.1080/15548627.2015.1009778]

651 **Soria LR**, Allegri G, Melck D, Pastore N, Annunziata P, Paris D, Polishchuk E, Nusco E, Thöny B, Motta A, Häberle J, Ballabio A, Brunetti-Pierri N. Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia. *Proc Natl Acad Sci U S A* 2018; **115**: 391-396 [PMID: 29279371 DOI: 10.1073/pnas.1714670115]

652 **Sridhar S**, Botbol Y, Macian F, Cuervo AM. Autophagy and disease: always two sides to a problem. *J Pathol* 2012; **226**: 255-273 [PMID: 21990109 DOI: 10.1002/path.3025]

653 **Golbabapour S**, Bagheri-Lankarani K, Ghavami S, Geramizadeh B. Autoimmune Hepatitis and Stellate Cells: An Insight into the Role of Autophagy. *Curr Med Chem* 2020; **27**: 6073-6095 [PMID: 30947648 DOI: 10.2174/0929867326666190402120231]

654 **Feng Q**, Yao J, Zhou G, Xia W, Lyu J, Li X, Zhao T, Zhang G, Zhao N, Yang J. Quantitative Proteomic Analysis Reveals That Arctigenin Alleviates Concanavalin A-Induced Hepatitis Through Suppressing Immune System and Regulating Autophagy. *Front Immunol* 2018; **9**: 1881 [PMID: 30177931 DOI: 10.3389/fimmu.2018.01881]

655 **Fan X**, Men R, Wang H, Shen M, Wang T, Ye T, Luo X, Yang L. Methylprednisolone Decreases Mitochondria-Mediated Apoptosis and Autophagy Dysfunction in Hepatocytes of Experimental Autoimmune Hepatitis Model *via* the Akt/mTOR Signaling. *Front Pharmacol* 2019; **10**: 1189 [PMID: 31680966 DOI: 10.3389/fphar.2019.01189]

656 **Fan X**, Men R, Huang C, Shen M, Wang T, Ghnewa Y, Ma Y, Ye T, Yang L. Critical roles of conventional dendritic cells in autoimmune hepatitis *via* autophagy regulation. *Cell Death Dis* 2020; **11**: 23 [PMID: 31932577 DOI: 10.1038/s41419-019-2217-6]

657 **Szekerczés T**, Gógl A, Illyés I, Mandl J, Borka K, Kiss A, Schaff Z, Lendvai G, Werling K. Autophagy, Mitophagy and MicroRNA Expression in Chronic Hepatitis C and Autoimmune Hepatitis. *Pathol Oncol Res* 2020; **26**: 2143-2151 [PMID: 32124227 DOI: 10.1007/s12253-020-00799-y]

658 **Kwak BJ**, Choi HJ, Kim OH, Kim KH, You YK, Lee TY, Ahn J, Kim SJ. The Role of Phospho-c-Jun N-Terminal Kinase Expression on hepatocyte Necrosis and Autophagy in the Cholestatic Liver. *J Surg Res* 2019; **241**: 254-263 [PMID: 31035140 DOI: 10.1016/j.jss.2019.03.034]

659 **Huang YH**, Yang YL, Huang FC, Tiao MM, Lin YC, Tsai MH, Wang FS. MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice. *Exp Biol Med (Maywood)* 2018; **243**: 13-21 [PMID: 29105510 DOI: 10.1177/1535370217741500]

660 **Kim S**, Han SY, Yu KS, Han D, Ahn HJ, Jo JE, Kim JH, Shin J, Park HW. Impaired autophagy promotes bile acid-induced hepatic injury and accumulation of ubiquitinated proteins. *Biochem Biophys Res Commun* 2018; **495**: 1541-1547 [PMID: 29198703 DOI: 10.1016/j.bbrc.2017.11.202]

661 **Khambu B**, Li T, Yan S, Yu C, Chen X, Goheen M, Li Y, Lin J, Cummings OW, Lee YA, Friedman S, Dong Z, Feng GS, Wu S, Yin XM. Hepatic Autophagy Deficiency Compromises Farnesoid X Receptor Functionality and Causes Cholestatic Injury. *Hepatology* 2019; **69**: 2196-2213 [PMID: 30520052 DOI: 10.1002/hep.30407]

662 **Gao L**, Lv G, Guo X, Jing Y, Han Z, Zhang S, Sun K, Li R, Yang Y, Wei L. Activation of autophagy protects against cholestasis-induced hepatic injury. *Cell Biosci* 2014; **4**: 47 [PMID: 25922659 DOI: 10.1186/2045-3701-4-47]

663 **Woolbright BL**, Jaeschke H. Novel insight into mechanisms of cholestatic liver injury. *World J Gastroenterol* 2012; **18**: 4985-4993 [PMID: 23049206 DOI: 10.3748/wjg.v18.i36.4985]

664 **Sasaki M**, Miyakoshi M, Sato Y, Nakanuma Y. Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis. *J Hepatol* 2010; **53**: 318-325 [PMID: 20570384 DOI: 10.1016/j.jhep.2010.03.008]

665 **Sasaki M**, Nakanuma Y. Novel approach to bile duct damage in primary biliary cirrhosis: participation of cellular senescence and autophagy. *Int J Hepatol* 2012; **2012**: 452143 [PMID: 21994884 DOI: 10.1155/2012/452143]

666 **Manley S**, Ni HM, Kong B, Apte U, Guo G, Ding WX. Suppression of autophagic flux by bile acids in hepatocytes. *Toxicol Sci* 2014; **137**: 478-490 [PMID: 24189133 DOI: 10.1093/toxsci/kft246]

667 **Sasaki M**, Miyakoshi M, Sato Y, Nakanuma Y. Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. *Liver Int* 2013; **33**: 312-320 [PMID: 23231002 DOI: 10.1111/liv.12049]

668 **Sasaki M**, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. *Lab Invest* 2010; **90**: 835-843 [PMID: 20212459 DOI: 10.1038/labinvest.2010.56]

669 **van de Graaf S**, Beuers U. Autophagy - another piece of the puzzle towards understanding primary biliary cirrhosis? *Liver Int* 2014; **34**: 481-483 [PMID: 24612169 DOI: 10.1111/liv.12357]

670 **Nakanuma Y**, Sasaki M, Harada K. Autophagy and senescence in fibrosing cholangiopathies. *J Hepatol* 2015; **62**: 934-945 [PMID: 25435435 DOI: 10.1016/j.jhep.2014.11.027]

671 **Sasaki M**, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy may precede cellular senescence of bile ductular cells in ductular reaction in primary biliary cirrhosis. *Dig Dis Sci* 2012; **57**: 660-666 [PMID: 21989821 DOI: 10.1007/s10620-011-1929-y]

672 **Sasaki M**, Nakanuma Y. Biliary epithelial apoptosis, autophagy, and senescence in primary biliary cirrhosis. *Hepat Res Treat* 2010; **2010**: 205128 [PMID: 21152179 DOI: 10.1155/2010/205128]

673 **Young AR**, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, Tavaré S, Arakawa S, Shimizu S, Watt FM, Narita M. Autophagy mediates the mitotic senescence transition. *Genes Dev* 2009; **23**: 798-803 [PMID: 19279323 DOI: 10.1101/gad.519709]

674 **Sasaki M**, Ikeda H, Haga H, Manabe T, Nakanuma Y. Frequent cellular senescence in small bile ducts in primary biliary cirrhosis: a possible role in bile duct loss. *J Pathol* 2005; **205**: 451-459 [PMID: 15685690 DOI: 10.1002/path.1729]

675 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.**; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. *J Hepatol* 2017; **67**: 145-172 [PMID: 28427765 DOI: 10.1016/j.jhep.2017.03.022]

676 **Lindor KD**, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2019; **69**: 394-419 [PMID: 30070375 DOI: 10.1002/hep.30145]

677 **Gossard AA**, Lindor KD. Current and promising therapy for primary biliary cholangitis. *Expert Opin Pharmacother* 2019; **20**: 1161-1167 [PMID: 30931642 DOI: 10.1080/14656566.2019.1601701]

678 **Sasaki M**, Nakanuma Y. Bile Acids and Deregulated Cholangiocyte Autophagy in Primary Biliary Cholangitis. *Dig Dis* 2017; **35**: 210-216 [PMID: 28249264 DOI: 10.1159/000450913]

679 **Mueller M**, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, Marschall HU, Trauner M. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. *J Hepatol* 2015; **62**: 1398-1404 [PMID: 25617503 DOI: 10.1016/j.jhep.2014.12.034]

680 **Panzitt K**, Jungwirth E, Krones E, Lee JM, Pollheimer M, Thallinger GG, Kolb-Lenz D, Xiao R, Thorell A, Trauner M, Fickert P, Marschall HU, Moore DD, Wagner M. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. *J Hepatol* 2020; **72**: 1122-1131 [PMID: 32001325 DOI: 10.1016/j.jhep.2020.01.014]

681 **Wagner M**, Zollner G, Trauner M. Nuclear receptors in liver disease. *Hepatology* 2011; **53**: 1023-1034 [PMID: 21319202 DOI: 10.1002/hep.24148]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest relevant to this article and no financial support.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** July 9, 2020

**First decision:** October 6, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Pan Q, Tavernarakis N **S-Editor:** Gao CC **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 A simplified scheme of the macroautophagy pathways in the liver.** Initiation starts with activation of the unc-51-like kinase 1 complex (ULK1, Atg1 in yeast) followed by beclin 1(Atg6 in yeast) and a subsequent cascade of Atg proteins leading to autophagosome formation where LC3 (Atg8 in yeast) is implicated. LC3 is further processed to form initially LC3-I and then LC3-II. Fusion of the autophagosomes with lysosomes form the autolysosome where acid proteases (among which cathepsins are important) and lipases degrade proteins and lipids. Initiation of autophagy is controlled by two metabolic sensors the mammalian target of rapamycin complex 1 (mTORC1) and the AMP-activated protein kinase (AMPK). mTORC1 negatively regulates autophagy inhibiting ULK1. AMPK suppresses mTORC1 activity. The long-term regulation of autophagy is carried out by transcription factor EB (TFEB), the main regulator of lysosomal biogenesis and autophagy. Under nutrient-rich conditions, mTORC1 phosphorylates TFEB and retains TFEB in the cytosol. Red arrows: Inhibition. Green arrows: Positive regulation. For details see Ref.[21,29,31]. mTORC1: Mammalian target of rapamycin complex 1; TFEB: Transcription factor EB; ULK1: Unc-51-like kinase 1 complex.



**Figure 2 Implications of autophagy in critical cellular functions in the liver**. For details see text.

**Table 1 Overview of autophagy abnormalities in liver disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Disease** | **Abnormalities of autophagy** | **Results** | **Ref.** |
| Obesity | ⭣Autophagy; Hepatocytes: ⭣Mitophagy, ⭣Lipophagy; HSCs: ⭣Autophagy | ⭡ER stress🡒⭡Lipids⭡Insuline resistance🡒 Anti-fibrotic | Liu *et al*[203], Lavallard *et al*[204], Gual *et al*[205], Tremblay *et al*[206] |
| NAFLD | ⭣Lipophagy; ⭣CMA | Lipotoxicity, ⭡Lipogenic enzymes | Madrigal-Matute *et al*[30], Zhou *et al*[234], Niso-Santano *et al*[235], Singh *et al*[236] |
| NASH | Hepatocytes: ⭣Autophagy, ⭣Mitophagy; Kupffer cells: ⭣Autophagy; LSECs: ⭣Autophagy | ⭡Mallory-Denk bodies, ⭡Inflammasome activation; ⭡Cathepsins B,D, ⭡M1 polarization, ⭣M2 polarization; ⭡Inflammation, fibrosis | Xu *et al*[272], Noureddin *et al*[277], Zhang *et al*[285], Dey *et al*[287] |
| Alcoholic liver disease | Acute ETOH administration: ⭡Autophagy, ⭡Mitophagy, ⭡Lipophagy, ⭡Proteophagy; Chronic ETOH administration: ⭡ Autophagy (low dose), ⭣Autophagy (high dose); Kupffer cells: ⭣Autophagy, ⭡Autophagy; HSCs: ⭣Autophagy, ⭡Autophagy | Protection, protection, protection, 🡒Clearance of Mallory-Denk bodies; 🡒Protection, 🡒Mitochondrial damage, Cell death; Liver damage, protection; Reduced fibrosis, increased fibrosis | Chao *et al*[308], Komatsu *et al*[311], Yan *et al*[314], Harada *et al*[318] |
| HBV | ⭡Autophagy, ⭣Lysosomal acidification, ⭡Mitophagy | ⭡Virus replication, ⭣HBV degradation | Li *et al*[356], Tang *et al*[357], Luo *et al*[372], Wang *et al*[383] |
| HCV | ⭡Autophagy, ⭣Lipophagy, ⭡Mitophagy; ⭡CMA | ⭡Virus replication, steatosis, ⭡Virus replication, ⭣Apoptosis, persitent infection, ⭡Virus replication | Ferraris *et al*[387], Paul *et al*[395], Jassey *et al*[404], Ren *et al*[406] |
| Fibrosis-Cirrhosis | Hepatocytes: ⭣Autophagy, ⭣Lipophagy; Kupffer cells: ⭣Mitophagy, or, ⭡Mitophagy; HSCs: ⭣Mitophagy, ⭣Lipophagy, or, ⭡Lipophagy, ⭡Mitophagy; LSECs: ⭡⭣Autophagy; Ductular reaction: ⭡Autophagy | ⭡Fibrosis, ⭡Lipotoxicity, ⭣TGFb, ⭣Fibrosis; ⭡TGFb, ⭡Fibrosis; Pro-inflammatory anti-fibrotic: 🡒Pro-fibrotic, 🡒Pro-fibrotic, ⭡Fibrosis, ⭡Fibrosis | Zhang *et al*[437], Singh *et al*[438], Li *et al*[448], Sun *et al*[463] |
| HCC, “Double edge sword”  | Induction stage: ⭡CMA, ⭡Autophagy; Late stages: ⭡Autophagy, or, ⭣Autophagy, ⭡Mitophagy, ⭡Lipophagy | Anti-oncogenic: ⭣YAP1, ⭣proliferation, ⭡Apoptosis🡒Anti-oncogenic, ⭣Tumor suppressors; ⭡Tumor progression, ⭣⭡Progression⭡⭣Progression | Wang *et al*[558], Zhao *et al*[559], Prieto-Domínguez *et al*[560]; Niture *et al*[544], Yang *et al*[547]; Lin *et al*[549], Chen *et al*[550], Chen *et al*[551] |
| Cholangiocarcinoma | ⭡Autophagy | ⭡Tumor progression | Marciniak *et al*[580], Teckman *et al*[581] |
| A1 antitrypsin deficiency | ⭣Autophagy |  | Yamamura *et al*[590], Pastore *et al*[592] |
| Fibrinogen storage disease | ⭣Autophagy |  | Hu *et al*[609] |
| Wilson’S disease | ⭣Autophagy |  | Oami *et al*[611] |
| Glycogen storage disease | ⭣Autophagy |  | Xing *et al*[613] |
| Sepsis | Kupffer cells: ⭡Autophagy, ⭡⭡Autophagy, ⭣Mitophagy | M2 polarization, ⭣Inflammasome activation; Kupffer cell apoptosis🡒Cytokine storm, ⭣Apoptosis of CD4+ve T cells | Ying *et al*[615], Neumann *et al*[616], Sun *et al*[628], Shan *et al*[629] |
| Acetaminophene liver damage | ⭣Autophagy, ⭣Mitophagy, ⭡Kupffer cell autophagy | ⭡APAP-Protein adducts | Sydor *et al*[618], Kim *et al*[643], Biel *et al*[644] |
| Acute liver failure | ⭡Autophagy, ⭣Autophagy, ⭣HSCs Mitophagy | HMGB1🡒HSCs activation (protective); ⭡NO,ROS🡒⭣HSCs🡒Devastation | Cheong *et al*[649], Sridhar *et al*[652] |
| Ischemia/reperfusion injury  | ⭣Autophagy |  | Kwak *et al*[658], Huang *et al*[659] |
| Hepatic encephalopathy | ⭡Autophagy (NH4) | Protection | Woolbright *et al*[663], Manley *et al*[666] |
| Autoimmune hepatitis | ⭡Autophagy, ⭣ Mitophagy | Defective maturation of dendritic cells | Sasaki *et al*[671], Sasaki *et al*[672], Young *et al*[673] |
| Biliary disease (experimental) | ⭣Autophagy | Possibly through increased bile acids | Sasaki *et al*[665], European Association for the Study of the Liver[675], Lindor *et al*[676], Panzitt *et al*[680] |
| Primary biliay cholangitis | Deregulated Autophagy | Cholangiocyte senescence | Van de Graaf *et al*[669], Sasaki *et al*[665], Sasaki *et al*[674] |

Note the double edge sword behaviour of autophagy, particularly evident in hepatocellular carcinoma. Autophagy refers to macroautophagy. HSCs: Hepatic stellate cells; LSECs: Liver sinusoidal endothelial cells; CMA: Chaperone mediated autophagy; ER: Enoplamic reticulum; ASH: Acute alcoholic hepatitis.